variant_id	variant_civic_url	gene	entrez_id	variant	summary	variant_groups	chromosome	start	stop	reference_bases	variant_bases	representative_transcript	ensembl_version	reference_build	chromosome2	start2	stop2	representative_transcript2	variant_types	hgvs_expressions
1	https://civic.genome.wustl.edu/#/events/genes/4/summary/variants/1/summary#variant	ABL1	25	BCR-ABL	The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is one of the most studied fusion genes in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). However, despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and ponatinib) have seen some success in delivering a tumor response.		22	23522397	23632600			ENST00000305877.8	75	GRCh37	9	133729451	133763063	ENST00000318560.5	transcript_fusion	
2	https://civic.genome.wustl.edu/#/events/genes/4/summary/variants/2/summary#variant	ABL1	25	BCR-ABL T334I	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Imatinib Resistance,Imatinib Resistance	9	133748283	133748283	C	T	ENST00000372348.2	75	GRCh37					missense_variant,transcript_fusion	
3	https://civic.genome.wustl.edu/#/events/genes/4/summary/variants/3/summary#variant	ABL1	25	BCR-ABL E255K	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation E255K has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Imatinib Resistance	9	133738363	133738363	G	A	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	
4	https://civic.genome.wustl.edu/#/events/genes/2/summary/variants/4/summary#variant	AKT1	207	E17K	AKT1 E17K is a recurrent mutation that has been observed in breast, colorectal, lung, and ovarian cancer. It has been convincingly shown to be an activating mutation resulting in PI3K/AKT/mTOR pathway activity. It has been suggested that this mutation decreases the cell's sensitivity to AKT1 allosteric kinase inhibitors. This, and other AKT1 mutations, are the subject of much research and development for therapeutics.		14	105246551	105246551	C	T	ENST00000407796.2	75	GRCh37					missense_variant	
5	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/5/summary#variant	ALK	238	EML4-ALK	The EML4-ALK fusion variant 1 consisting of ALK kinase domain (exons 20-29) fused to EML4 exons 1-13 is the most common EML4-ALK variant, and was discovered in non-small cell lung cancer. Multiple EML4 breakpoint shave been described with differential sensitivity to inhibitors with variant 1 showing greater sensitivity than 3a in cell lines. EML4-ALK is crizotinib sensitive; however, several mutations that confer resistance mutations have been described in case studies. In the only clinical trial for crizotinib that included determination of EML4-ALK variant type in a subset of its participants, a very high response rate was observed, although the numbers were insufficient to validate correlation of variant type to outcome. Preclinical studies with this variant have indicated sensitivity to Hsp90 inhibitors.	ALK Fusions	2	42396490	42522656			ENST00000318522.5	75	GRCh37	2	29415640	29446394	ENST00000389048.3	transcript_fusion	
6	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/6/summary#variant	ALK	238	EML4-ALK C1156Y	In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, C1156Y has been shown to confer resistance to crizotinib. Case reports indicate that secondary mutations can modulate drug sensitivity. EML4-ALK C1156Y/L1196M maintained crizotinib resistance while the lorlatinib resistant combination EML4-ALK C1156Y/L1198F re-sensitized the tumor to crizotinib treatment.	ALK Fusions,Crizotinib Resistance	2	29445258	29445258	C	T	ENST00000389048.3	75	GRCh37					missense_variant,transcript_fusion	
7	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/7/summary#variant	ALK	238	EML4-ALK L1196M	In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, L1196M has been shown to confer resistance to crizotinib. This was also true in a patient with both EML4-ALK C1156Y & L1196M.	ALK Fusions,Crizotinib Resistance	2	29443631	29443631	G	T	ENST00000389048.3	75	GRCh37					missense_variant,transcript_fusion	
8	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/8/summary#variant	ALK	238	F1174L	ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.	Crizotinib Resistance	2	29443695	29443695	G	T	ENST00000389048.3	75	GRCh37					missense_variant	
9	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/9/summary#variant	ALK	238	R1275Q	ALK R1275Q has been observed as a recurrent mutation in  neuroblastoma, non-small cell lung cancer (NSCLC), as well as other cancer types. Neuroblastoma cells with this mutation have shown sensitivity to the ALK-inhibitor TAE684. This and the geldanamycin deriviative 17-DMAG have been shown to be effective in NSCLC cell lines.		2	29432664	29432664	C	T	ENST00000389048.3	75	GRCh37					missense_variant	
10	https://civic.genome.wustl.edu/#/events/genes/3/summary/variants/10/summary#variant	ARAF	369	S214C	ARAF S214C has been found to be a recurrent oncogenic mutation in non-small cell lung cancer. It has been shown to confer sensitivity to sorafenib and trametenib in cell lines. In a case study of advanced stage lung adenocarcinoma harboring this mutation, sorafenib also acheived near-complete clinical remission. This case has brought more interest to the variant from a research and clinical perspective.		X	47426121	47426121	C	G	ENST00000377045.4	75	GRCh37					missense_variant	
11	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/11/summary#variant	BRAF	673	V600D	Patients harboring mutations in valine 600 residue of BRAF have been shown to be sensitive to dabrafenib. For more information on the V600 locus, see the V600E entry.	Other V600's	7	140453135	140453136	CA	AT	ENST00000288602.6	75	GRCh37					missense_variant	
12	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/12/summary#variant	BRAF	673	V600E	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.		7	140453136	140453136	A	T	ENST00000288602.6	75	GRCh37					missense_variant	
13	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/13/summary#variant	BRAF	673	V600E+V600M	A case study of a single patient harboring both a V600E and a V600M mutation, dabrafenib was shown to acheive clinical response.	Other V600's	7	140453135	140453137			ENST00000288602.6	75	GRCh37					missense_variant	
14	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/14/summary#variant	BRAF	673	V600E AMPLIFICATION	Amplification of BRAF V600E has been shown to confer resistance to MEK inhibitors. For more information on the V600 locus, see the V600E entry.		7	140434279	140624564			ENST00000288602.6	75	GRCh37					missense_variant,transcript_amplification	
17	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/17/summary#variant	BRAF	673	V600	BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutation pages on the left sidebar.	Other V600's	7	140453136	140453137			ENST00000288602.6	75	GRCh37					protein_altering_variant	
18	https://civic.genome.wustl.edu/#/events/genes/8/summary/variants/18/summary#variant	CCND1	595	AMPLIFICATION	CCND1 amplification has been implicated in poorer prognosis in non-small cell lung cancer.		11	69455855	69469242			ENST00000227507.2	75	GRCh37					transcript_amplification	
19	https://civic.genome.wustl.edu/#/events/genes/8/summary/variants/19/summary#variant	CCND1	595	EXPRESSION	CCND1 expression, and its prognositc impact, is still in dispute. Three experiments in non-small cell lung cancer have shown it to have no impact on survival, but three additional studies have shown it results in poorer prognosis. There is also some ambiguity in how the boundaries between expression and overexpression are defined.		11	69455855	69469242			ENST00000227507.2	75	GRCh37					N/A	
20	https://civic.genome.wustl.edu/#/events/genes/8/summary/variants/20/summary#variant	CCND1	595	OVEREXPRESSION	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.		11	69455855	69469242			ENST00000227507.2	75	GRCh37					N/A	
21	https://civic.genome.wustl.edu/#/events/genes/9/summary/variants/21/summary#variant	CCND2	894	OVEREXPRESSION	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.		12	4382938	4414516			ENST00000261254.3	75	GRCh37					N/A	
22	https://civic.genome.wustl.edu/#/events/genes/9/summary/variants/22/summary#variant	CCND2	894	PROMOTER DEMETHYLATION	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.		12	4381437	4382937			ENST00000261254.3	75	GRCh37					N/A	
23	https://civic.genome.wustl.edu/#/events/genes/10/summary/variants/23/summary#variant	CCND3	896	LOSS	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are deregulated are widely variable, and range from genomic amplification to promoter methylation changes. Cyclin D3 loss has been reported in T-cell acute lymphoblastic leukemia (T-ALL), a seemingly unique trend when compared to the amplifcations and overexpressions of the other cyclin D's. Treating cyclin D3 knockout mice with the targeted therapeutic palbociclib significantly increased the median survival of a Notch-driven model of T-ALL.		6	41902671	41909586			ENST00000372991.4	75	GRCh37					loss_of_function_variant	
24	https://civic.genome.wustl.edu/#/events/genes/11/summary/variants/24/summary#variant	CCNE1	898	OVEREXPRESSION	Cyclin E, while currenly not as widely implicated as its counterpart, cyclin D, has been implicated in various carcinomas, including breast, gastric, stomach and colorectal. High levels of cyclin E, either by gene amplification or overexpression, are correlated with later stage disease and have been shown to lead to poorer prognosis in gastic carcinoma. It has also been shown, in lung cancer specifically, that neoplastic cells with higher levels of the cyclin E/CDK2 complex are more radiosensitive than their lowly expressed counterparts.		19	30302805	30315215			ENST00000262643.3	75	GRCh37					N/A	
25	https://civic.genome.wustl.edu/#/events/genes/13/summary/variants/25/summary#variant	CDK4	1019	EXPRESSION	CDK4, along with its partner CDK6, are key players in cell cycle progression. The complex has been implicated in a number of cancer types, and is the focus of therapeutic research and development. One targeted therapy for CDK inhibition is palbociclib, which may slow the growth of advanced stage breast cancers. It has also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors to PI3K inhibitors.		12	58141510	58146304			ENST00000257904.6	75	GRCh37					N/A	
27	https://civic.genome.wustl.edu/#/events/genes/14/summary/variants/27/summary#variant	CDKN2A	1029	PROMOTER HYPERMETHYLATION	CDKN2A loss has been shown to be a significant event in a number of cancer types. One mechanism by which this can occur is by hypermethylation of the CDKN2A promoter region. While no targeted therapeutic has been engaged in clinical trials, the prognostic impact has been studied by a number of meta-analyses. The prognostic impact of promoter hypermethylation has been relatively ambiguous. Many studies have shown significant p-values suggesting poorer prognostic outcomes for patients with hypermethylation in colorectal, liver, and younger lung cancer patients. This being said, there is still research to be done before this becomes a widely-accepted prognostic indicator.		9	21974827	21994591			ENST00000498124.1	75	GRCh37					N/A	
28	https://civic.genome.wustl.edu/#/events/genes/15/summary/variants/28/summary#variant	CEBPA	1050	N-TERMINAL FRAME SHIFT	CEBPA N-terminal frame shift mutations that result in a premature stop codon are associated with cytogenetically normal acute myeloid leukemia (CN-AML). CEBPA mutations are associated with a favorable prognosis; however, NPM1 and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations may have prognostic implications. N-terminal frame shift mutations within amino acids 1-120 have been shown to disrupt expression of the full-length 42kDa isoform while maintaining expression of a 30kDa isoform (translated from the AUG at full-length protein isoform amino acid M120). This 30kDa isoform exhibits dominant negative activity.		19	33792961	33793470			ENST00000498907.2	75	GRCh37					dominant_negative_variant,frameshift_truncation	
29	https://civic.genome.wustl.edu/#/events/genes/15/summary/variants/29/summary#variant	CEBPA	1050	MUTATION	CEBPA mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) and a favorable prognosis. However, NPM1 and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations may have prognostic implications.		19	33790840	33793470			ENST00000498907.2	75	GRCh37					loss_of_function_variant,transcript_variant	
30	https://civic.genome.wustl.edu/#/events/genes/33/summary/variants/30/summary#variant	CSF1R	1436	MEF2D-CSF1R	MEF2D-CSF1R is a fusion that has been observed in acute lymphocytic leukemia. In cell lines harboring this event, treatment with imatinib has shown notable sensitivity.		1	156446804	156470620			ENST00000348159.4	75	GRCh37	5	149433787	149441412	ENST00000286301.3	transcript_fusion	
31	https://civic.genome.wustl.edu/#/events/genes/17/summary/variants/31/summary#variant	PRKACA	5566	DNAJB1-PRKACA	This fusion has been found to be very recurrent in the rare form of adolescent liver cancer, fibrolamellar hepatocellular carcinoma. In one study, this fusion was observed in 15/15 FL-HCC cases examined and functional studies found that the fusion retained kinase activity. The presence of this fusion may be used as a diagnostic marker for this rare tumor type.		19	14628951	14629232			ENST00000254322.2	75	GRCh37	19	14202500	14218221	ENST00000308677.4	transcript_fusion	
32	https://civic.genome.wustl.edu/#/events/genes/18/summary/variants/32/summary#variant	DNMT3A	1788	R882	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.		2	25457241	25457243			ENST00000264709.3	75	GRCh37					missense_variant	
33	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/33/summary#variant	EGFR	1956	L858R	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.		7	55259514	55259515	CT	AG	ENST00000275493.2	75	GRCh37					missense_variant	
34	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/34/summary#variant	EGFR	1956	T790M	EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.	EGFR TKI Resistance,EGFR TKI Resistance	7	55249071	55249071	C	T	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.2369C>T
35	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/35/summary#variant	ERBB2	2064	D769H	ERBB2 D769H was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	HER2 Activating	17	37880261	37880261	G	C	ENST00000269571.5	75	GRCh37					missense_variant	NM_001289937.1:c.2305G>C,NP_001276866.1:p.Asp769His,ENST00000269571.5:c.2305G>C,NC_000017.104:g.37880261G>C
36	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/36/summary#variant	ERBB2	2064	D769Y	ERBB2 D769Y was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	HER2 Activating	17	37880261	37880261	G	T	ENST00000269571.5	75	GRCh37					missense_variant	
37	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/37/summary#variant	ERBB2	2064	DEL 755-759	ERBB2 in-frame deletion of 755-759 was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.		17	37880219	37880233	TTGAGGGAAAACACA		ENST00000269571.5	75	GRCh37					inframe_deletion	
38	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/38/summary#variant	ERBB2	2064	G309A	ERBB2 G309A was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	HER2 Activating	17	37868205	37868205	G	C	ENST00000269571.5	75	GRCh37					missense_variant	
39	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/39/summary#variant	ERBB2	2064	L755S	ERBB2 L755S was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was not shown to be an activating mutation, unlike many of the other variants queried. This mutation was also shown to confer resistance to the tyrosine kinase inhibitor lapatinib in MCF10A cell lines.		17	37880220	37880220	T	C	ENST00000269571.5	75	GRCh37					missense_variant	
40	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/40/summary#variant	ERBB2	2064	L755W	ERBB2 L755W was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.		17	37880220	37880220	T	G	ENST00000269571.5	75	GRCh37					missense_variant	
41	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/41/summary#variant	ERBB2	2064	P780INS	ERBB2 P780 insertion was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 activating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	HER2 Activating	17	37881011	37881012		GGCTCCCCA	ENST00000269571.5	75	GRCh37					inframe_insertion	
42	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/42/summary#variant	ERBB2	2064	R678Q	ERBB2 R678Q was shown to have NO functional effect in tissue culture assay (Bose et al 2013). This conclusion was confirmed by a second, independent lab.		17	37879658	37879658	G	A	ENST00000269571.5	75	GRCh37					missense_variant	
43	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/43/summary#variant	ERBB2	2064	R896C	ERBB2 R896C was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	HER2 Activating	17	37881616	37881616	C	T	ENST00000269571.5	75	GRCh37					missense_variant	
44	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/44/summary#variant	ERBB2	2064	V777L	ERBB2 V777L was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	HER2 Activating	17	37881000	37881000	G	T	ENST00000269571.5	75	GRCh37					missense_variant	
45	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/45/summary#variant	ERBB2	2064	V842I	ERBB2 V842I was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	HER2 Activating	17	37881332	37881332	G	A	ENST00000269571.5	75	GRCh37					missense_variant	
46	https://civic.genome.wustl.edu/#/events/genes/21/summary/variants/46/summary#variant	ESR1	2099	L536Q	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y536Q is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	ESR1 Ligand-Binding Domain,ESR1 Ligand-Binding Domain	6	152419920	152419921	TC	AG	ENST00000440973.1	75	GRCh37					missense_variant	
47	https://civic.genome.wustl.edu/#/events/genes/21/summary/variants/47/summary#variant	ESR1	2099	D538G	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. D538G is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	ESR1 Ligand-Binding Domain,ESR1 Ligand-Binding Domain	6	152419926	152419926	A	G	ENST00000206249.3	75	GRCh37					missense_variant	
48	https://civic.genome.wustl.edu/#/events/genes/21/summary/variants/48/summary#variant	ESR1	2099	Y537C	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537C is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	ESR1 Ligand-Binding Domain,ESR1 Ligand-Binding Domain	6	152419923	152419923	A	G	ENST00000206249.3	75	GRCh37					missense_variant	
49	https://civic.genome.wustl.edu/#/events/genes/21/summary/variants/49/summary#variant	ESR1	2099	Y537N	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537N is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	ESR1 Ligand-Binding Domain,ESR1 Ligand-Binding Domain	6	152419922	152419922	T	A	ENST00000206249.3	75	GRCh37					missense_variant	
50	https://civic.genome.wustl.edu/#/events/genes/21/summary/variants/50/summary#variant	ESR1	2099	Y537S	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537S is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	ESR1 Ligand-Binding Domain,ESR1 Ligand-Binding Domain	6	152419923	152419923	A	C	ENST00000206249.3	75	GRCh37					missense_variant	
52	https://civic.genome.wustl.edu/#/events/genes/22/summary/variants/52/summary#variant	FGFR2	2263	FGFR2-MGEA5	In a clinical sequencing program for advanced stage cancers, Wu et al (2013, Cancer Discovery) has idenified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. Cell lines harboring these fusions were shown to respond to pazopanib. Additionally, tumor size reduction was achieved by both ponatinib and pazopanib treatments administered separately in a single patient with intrahepatic cholangiocarcinoma and this fusion. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.	FGFR fusions	10	123243212	123357917			ENST00000457416.2	75	GRCh37	10	103544209	103552700	ENST00000361464.3	transcript_fusion	
53	https://civic.genome.wustl.edu/#/events/genes/23/summary/variants/53/summary#variant	FGFR3	2261	FGFR3-BAIAP2L1	In a clinical sequencing program for advanced stage cancers, Wu et al (2013, Cancer Discovery) has identified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. These fusions were shown to respond to pazopanib. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.	FGFR fusions	4	1795039	1810599			ENST00000340107.4	75	GRCh37	7	97991744	97920963	ENST00000005260.8	transcript_fusion	
54	https://civic.genome.wustl.edu/#/events/genes/22/summary/variants/54/summary#variant	FGFR2	2263	FGFR2-TACC3	In a clinical sequencing program for advanced stage cancers, Wu et al has identified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. These fusions were shown to respond to pazopanib. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.	FGFR fusions	4	123243212	123357598			ENST00000358487.5	75	GRCh37	4	1723266	1741505	ENST00000313288.4	transcript_fusion	
55	https://civic.genome.wustl.edu/#/events/genes/24/summary/variants/55/summary#variant	FLT3	2322	ITD	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.		13	28608219	28608351			ENST00000241453.7	75	GRCh37					inframe_insertion	
56	https://civic.genome.wustl.edu/#/events/genes/24/summary/variants/56/summary#variant	FLT3	2322	TKD MUTATION	FLT3 tyrosine kinase domain mutations (FLT3-TKD) are much less common than FLT3-ITD (internal tandem duplication) mutations and may not confer the same prognostic impact. Although the majority of mutations are point mutations effecting D835 (most frequently D835Y), a small proportion involve an in-frame deletion of I836. These mutations are within the activation loop of the second tyrosine kinase domain of FLT3 and thought to result in constitutive activation of the receptor.		13	28592642	28592642	C	A	ENST00000241453.7	75	GRCh37					nonsynonymous_variant	
57	https://civic.genome.wustl.edu/#/events/genes/25/summary/variants/57/summary#variant	GATA2	2624	EXPRESSION	GATA2 misregulation has been observed in a number of hematologic malignancies, as well as non-small cell lung cancer. Treatment of over-active GATA2 pathways using the proteasome inhibitor bortezomib has shown dramatic tumor regression in lung cancer.		3	128198270	128212028			ENST00000341105.2	75	GRCh37					N/A	
58	https://civic.genome.wustl.edu/#/events/genes/26/summary/variants/58/summary#variant	IDH1	3417	R132	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes, IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.		2	209113111	209113113			ENST00000415913.1	75	GRCh37					protein_altering_variant	
59	https://civic.genome.wustl.edu/#/events/genes/26/summary/variants/59/summary#variant	IDH1	3417	R132C	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.		2	209113113	209113113	G	A	ENST00000415913.1	75	GRCh37					missense_variant	
62	https://civic.genome.wustl.edu/#/events/genes/27/summary/variants/62/summary#variant	IDH2	3418	R140	IDH2 mutations have been observed in a number of hematologic malignancies. In acute myeloid leukemia, the R140 mutants show mixed results affecting overall survival as compared to their wild-type counterparts. In myelodysplastic syndromes, however, no prognostic link was discovered between IDH2 mutation status and overall survival.		15	90631934	90631934	C		ENST00000330062.3	75	GRCh37					protein_altering_variant	
63	https://civic.genome.wustl.edu/#/events/genes/27/summary/variants/63/summary#variant	IDH2	3418	R172K	IDH2 mutations have been observed in a number of hematologic malignancies. In acute myeloid leukemia, the R172K mutation has been linked with poorer prognosis and worse overall survival than IDH2 wild-type patients. However, in myelodisplastic syndromes, studies did not find a prognostic association between this variant and patient outcomes.		15	90631838	90631838	C	T	ENST00000330062.3	75	GRCh37					missense_variant	
64	https://civic.genome.wustl.edu/#/events/genes/28/summary/variants/64/summary#variant	JAK2	3717	V617F	JAK2 V617F is a highly recurrent mutation in myeloproliferative diseases, occuring in around half of all MPD's. While less associated with cancer, when it is seen, it is more likely to be in myeloid leukemias than lymphoid leukemias. The V617F mutation is an activating mutation, resulting in increased kinase activity. The mutation seems to be restricted to hematologic malignancies. Treatment of JAK mutant diseases with ruxolitinib has seen some clinical success.		9	5073770	5073770	G	T	ENST00000381652.3	75	GRCh37					gain_of_function_variant,missense_variant	
65	https://civic.genome.wustl.edu/#/events/genes/29/summary/variants/65/summary#variant	KIT	3815	D816V	KIT D816V is a mutation observed in acute myeloid leukemia (AML). This variant has been linked to poorer prognosis and worse outcome in AML patients.	KIT Exon 17	4	55599321	55599321	A	T	ENST00000288135.5	75	GRCh37					missense_variant	
66	https://civic.genome.wustl.edu/#/events/genes/29/summary/variants/66/summary#variant	KIT	3815	EXON 11 MUTATION	c-KIT mutations in exon 11 lie within the juxtamembrane domain, and are very recurrent in gastrointestinal stromal tumors, often bearing a poorer prognosis than other KIT mutations. Cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year. Small cohorts of melanoma patients harboring exon 11 KIT mutations have shown response to imatinib and sunitinib.	KIT Exon 11,KIT Exon 11,KIT Exon 11,KIT Exon 11,KIT Exon 11,KIT Exon 11	4	55593582	55593708			ENST00000288135.5	75	GRCh37					coding_sequence_variant	
67	https://civic.genome.wustl.edu/#/events/genes/29/summary/variants/67/summary#variant	KIT	3815	INTERNAL DUPLICATION	c-KIT internal duplications have been observed in exon 11, within the juxtamembrane domain. In a case study of an anal melanoma patient harboring this event, imatinib confered marked response. Also, cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year.	KIT Exon 11	4	55593582	55593708			ENST00000288135.5	75	GRCh37					inframe_insertion	
69	https://civic.genome.wustl.edu/#/events/genes/29/summary/variants/69/summary#variant	KIT	3815	EXON 14 MUTATION	c-KIT exon 14 mutations lie within the tyrosine kinase domain of the protein. While relatively rare in primary gastrointestinal tumors, they are notably more prevalent in refractory disease, suggesting a role in imatinib resistance. Unlike mutations in other KIT exons, exon 14 mutations seem relatively rare in melanoma.		4	55595501	55595651			ENST00000288135.5	75	GRCh37					exon_variant	
72	https://civic.genome.wustl.edu/#/events/genes/29/summary/variants/72/summary#variant	KIT	3815	L576P	KIT L576P is an exon 11 mutation that lies within the juxtamembrane domain. It is one of the most recurrent KIT mutations in melanoma, and both in vitro and in vivo studies have shown sensitivity to imatinib.	KIT Exon 11,KIT Exon 11,KIT Exon 11	4	55593661	55593661	T	C	ENST00000288135.5	75	GRCh37					missense_variant	
73	https://civic.genome.wustl.edu/#/events/genes/29/summary/variants/73/summary#variant	KIT	3815	V654A	KIT V654A is an exon 13 mutation that lies within the tyrosine kinase 1 domain of the protein. It has been shown to be an activating mutation by in vitro studies. This mutation is associated with imatinib resistance in melanoma patients. However, second generation TKI's such as sunitinib and midostaurin (PKC 412) have seen success in acheiving tumor response.	KIT Exon 11,KIT Exon 11	4	55594258	55594258	T	C	ENST00000288135.5	75	GRCh37					missense_variant	
75	https://civic.genome.wustl.edu/#/events/genes/30/summary/variants/75/summary#variant	KRAS	3845	EXON 2 MUTATION	Exon 2 mutations have been associated with reduced response rates or resistance to EGFR inhibitors in non-small cell lung and colorectal cancer. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS.		12	25398208	25398329			ENST00000256078.4	75	GRCh37					missense_variant,exon_variant	
76	https://civic.genome.wustl.edu/#/events/genes/30/summary/variants/76/summary#variant	KRAS	3845	G12	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.		12	25398284	25398285			ENST00000256078.4	75	GRCh37					protein_altering_variant	
77	https://civic.genome.wustl.edu/#/events/genes/30/summary/variants/77/summary#variant	KRAS	3845	G12/G13	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.		12	25398280	25398285			ENST00000256078.4	75	GRCh37					protein_altering_variant	
78	https://civic.genome.wustl.edu/#/events/genes/30/summary/variants/78/summary#variant	KRAS	3845	G12C	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	EGFR TKI Resistance	12	25398285	25398285	C	A	ENST00000256078.4	75	GRCh37					missense_variant	
79	https://civic.genome.wustl.edu/#/events/genes/30/summary/variants/79/summary#variant	KRAS	3845	G12D	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.	EGFR TKI Resistance	12	25398284	25398284	C	T	ENST00000256078.4	75	GRCh37					missense_variant	
80	https://civic.genome.wustl.edu/#/events/genes/30/summary/variants/80/summary#variant	KRAS	3845	G13	While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.		12	25398281	25398282			ENST00000256078.4	75	GRCh37					inframe_insertion,missense_variant	
81	https://civic.genome.wustl.edu/#/events/genes/30/summary/variants/81/summary#variant	KRAS	3845	G13D	While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.		12	25398281	25398281	C	T	ENST00000256078.4	75	GRCh37					missense_variant	
82	https://civic.genome.wustl.edu/#/events/genes/31/summary/variants/82/summary#variant	MAP2K1	5604	P124S	MAP2K1 P124S is a recurrent mutation in melanoma, and is seen in bladder and colon cancer to a lesser degree. The P124S mutation has been shown to contribute to AZD6244 resistance in melanoma cell lines, but considerably less so than its Q56P counterpart.		15	66729162	66729162	C	T	ENST00000307102.5	75	GRCh37					missense_variant	
83	https://civic.genome.wustl.edu/#/events/genes/31/summary/variants/83/summary#variant	MAP2K1	5604	Q56P	MAP2K1 Q56P is a recurrent mutation in melanoma and gastric cancer. This mutation has been shown to confer considerable resistance to AZD6244 treatment of melanoma cell lines.		15	66727451	66727451	A	C	ENST00000307102.5	75	GRCh37					missense_variant	
85	https://civic.genome.wustl.edu/#/events/genes/34/summary/variants/85/summary#variant	MGMT	4255	PROMOTER METHYLATION	MGMT promoter methylation has been observed to impact tumor progression in glioblastoma multiforme. In patients exhibiting promoter methylation, the akylating agent carmustine has shown efficacy. In patients lacking methylation, combining carmustine with the MGMT inhibitor O(6)-benzylguanine may be effective, but more experiments are required. Clinical trials have also shown selective sensitivity of promoter methylation-positive patients to temozolomide, making a case for wider methylation screening in GBM patients.		10	131264495	131265656			ENST00000306010.7	75	GRCh37					N/A	
86	https://civic.genome.wustl.edu/#/events/genes/35/summary/variants/86/summary#variant	NPM1	4869	EXON 12 MUTATION	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	NPM1 Exon 12	5	170837531	170837569			ENST00000517671.1	75	GRCh37					exon_variant	
87	https://civic.genome.wustl.edu/#/events/genes/35/summary/variants/87/summary#variant	NPM1	4869	W288FS	NPM1 W288fs (aka NPM1-A) is located in exon 12 of NPM1 and is the most common NPM1 mutation identified in acute myeloid leukemia. This mutation results in cytoplasmic localization of NPM1 (NPM1c) which is associated with a good response to induction therapy. Although it is the most extensively studied NPM1 exon 12mutation, it is generally grouped with other exon 12 mutations for patient analysis (see NPM1 Exon 12 variants for more information).	NPM1 Exon 12,NPM1 Exon 12,NPM1 Exon 12,NPM1 Exon 12	5	170837547	170837548		TCAG	ENST00000517671.1	75	GRCh37					frameshift_elongation	
92	https://civic.genome.wustl.edu/#/events/genes/36/summary/variants/92/summary#variant	NRAS	4893	G12	While the NRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated.		1	115258747	115258748			ENST00000369535.4	75	GRCh37					missense_variant	
93	https://civic.genome.wustl.edu/#/events/genes/36/summary/variants/93/summary#variant	NRAS	4893	G13D	While the NRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated.		1	115258744	115258744	C	T	ENST00000369535.4	75	GRCh37					missense_variant	
94	https://civic.genome.wustl.edu/#/events/genes/36/summary/variants/94/summary#variant	NRAS	4893	Q61	NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. Two melanoma patients, each harboring mutations at this locus (Q61L and Q61R), responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.		1	115256528	115256530			ENST00000369535.4	75	GRCh37					missense_variant	
95	https://civic.genome.wustl.edu/#/events/genes/36/summary/variants/95/summary#variant	NRAS	4893	Q61L	NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.		1	115256529	115256529	T	A	ENST00000369535.4	75	GRCh37					missense_variant	
96	https://civic.genome.wustl.edu/#/events/genes/36/summary/variants/96/summary#variant	NRAS	4893	Q61R	NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.		1	115256529	115256529	T	C	ENST00000369535.4	75	GRCh37					missense_variant	
98	https://civic.genome.wustl.edu/#/events/genes/38/summary/variants/98/summary#variant	PDGFRA	5156	D842I	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Imatinib Resistance	4	55152092	55152093	GA	AT	ENST00000257290.5	75	GRCh37					missense_variant	
99	https://civic.genome.wustl.edu/#/events/genes/38/summary/variants/99/summary#variant	PDGFRA	5156	D842V	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Imatinib Resistance,Imatinib Resistance,Imatinib Resistance,Imatinib Resistance	4	55152093	55152093	A	T	ENST00000257290.5	75	GRCh37					missense_variant	
100	https://civic.genome.wustl.edu/#/events/genes/38/summary/variants/100/summary#variant	PDGFRA	5156	D842Y	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Imatinib Resistance	4	55152092	55152092	G	T	ENST00000257290.5	75	GRCh37					missense_variant	
101	https://civic.genome.wustl.edu/#/events/genes/38/summary/variants/101/summary#variant	PDGFRA	5156	I843DEL	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Imatinib Resistance	4	55152095	55152097	ATC		ENST00000257290.5	75	GRCh37					inframe_deletion	
102	https://civic.genome.wustl.edu/#/events/genes/38/summary/variants/102/summary#variant	PDGFRA	5156	DI842-843VM	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. The DI842-843VM variant is the result of a double point mutation. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Imatinib Resistance	4	55152093	55152097	ACATC	TCATG	ENST00000257290.5	75	GRCh37					missense_variant	
103	https://civic.genome.wustl.edu/#/events/genes/37/summary/variants/103/summary#variant	PIK3CA	5290	E542K	PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with other PIK3CA variants or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.		3	178936082	178936082	G	A	ENST00000263967.3	75	GRCh37					missense_variant	
104	https://civic.genome.wustl.edu/#/events/genes/37/summary/variants/104/summary#variant	PIK3CA	5290	E545K	PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.		3	178936091	178936091	G	A	ENST00000263967.3	75	GRCh37					missense_variant	
105	https://civic.genome.wustl.edu/#/events/genes/37/summary/variants/105/summary#variant	PIK3CA	5290	EXON 21 MUTATION	PIK3CA Exon 21 Mutations (e.g., H1047R; often referred to as Exon 20 mutations if counting only coding exons) are among the most recurrent mutations in cancer, especially breast cancer. Of PIK3CA mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between Exon 21 and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.		3	178951882	178952495			ENST00000263967.3	75	GRCh37					exon_variant	
106	https://civic.genome.wustl.edu/#/events/genes/37/summary/variants/106/summary#variant	PIK3CA	5290	EXON 10 MUTATION	PIK3CA Exon 10 Mutations (e.g. E545K/E542K; often referred to as Exon 9 mutations if counting only coding exons) are the second most recurrent PIK3CA mutations in breast cancer, and highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that exon 10 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.		3	178935998	178936122			ENST00000263967.3	75	GRCh37					exon_variant	
107	https://civic.genome.wustl.edu/#/events/genes/37/summary/variants/107/summary#variant	PIK3CA	5290	H1047R	PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.		3	178952085	178952085	A	G	ENST00000263967.3	75	GRCh37					missense_variant	
108	https://civic.genome.wustl.edu/#/events/genes/39/summary/variants/108/summary#variant	PML	5371	PML-RARA	The PML-RARA fusion is seen as a diagnostic event in acute promyelocytic leukemia (APL). Both in vitro and in vivo studies have shown sensitivity to ATRA in APL patients harboring the PML-RARa fusion. Recent interest has been shown in combining ATRA and arsenic trioxide for treating these patients, and early results seem promising.		15	74287058	74325755			ENST00000268058.3	75	GRCh37	17	38504568	38513048	ENST00000254066.5	transcript_fusion	
110	https://civic.genome.wustl.edu/#/events/genes/41/summary/variants/110/summary#variant	PTEN	5728	R233*	PTEN R233* has been shown to be a loss of function mutation, and PTEN loss has been the subject of considerable research in breast cancer. PTEN loss may sensitize cells to PI3K-mTOR inhibition. While still being debated, there is data to support that PTEN loss is both associated with poorer prognosis, and no change in prognosis.	PTEN Loss-of-Function,PTEN Loss-of-Function	10	89717672	89717672	C	T	ENST00000371953.3	75	GRCh37					loss_of_function_variant,stop_gained	NM_000314.6:c.697C>T,NP_000305.3:p.Arg233Ter,ENST00000371953.3:c.697C>T
112	https://civic.genome.wustl.edu/#/events/genes/42/summary/variants/112/summary#variant	RET	5979	C634W	RET C634W has been implicated as an alternate mechanism of activating RET in medullary thyroid cancer. While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the C634W mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib.	Motesanib Resistance	10	43609950	43609950	C	G	ENST00000355710.3	75	GRCh37					missense_variant	
113	https://civic.genome.wustl.edu/#/events/genes/42/summary/variants/113/summary#variant	RET	5979	M918T	RET M819T is the most common somatically acquired mutation in medullary thyroid cancer (MTC). While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the M918T mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib. It has also been suggested that RET M819T leads to more aggressive MTC with a poorer prognosis.	Motesanib Resistance	10	43617416	43617416	T	C	ENST00000355710.3	75	GRCh37					missense_variant	
114	https://civic.genome.wustl.edu/#/events/genes/44/summary/variants/114/summary#variant	SF3B1	23451	K666N	SF3B1 K666N is a variant found in myelodysplastic syndromes, chronic leukemias, and more recently, breast cancer. This somatic mutation has been linked to better overall outcome and event-free survival in MDS patients.	HEAT domain mutation	2	198267359	198267359	C	A	ENST00000335508.6	75	GRCh37					missense_variant	
116	https://civic.genome.wustl.edu/#/events/genes/45/summary/variants/116/summary#variant	TP53	7157	R175H	While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant.		17	7578406	7578406	C	T	ENST00000269305.4	75	GRCh37					missense_variant	
117	https://civic.genome.wustl.edu/#/events/genes/45/summary/variants/117/summary#variant	TP53	7157	R248Q	While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.		17	7577538	7577538	C	T	ENST00000269305.4	75	GRCh37					missense_variant	
118	https://civic.genome.wustl.edu/#/events/genes/45/summary/variants/118/summary#variant	TP53	7157	R248W	While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.		17	7577539	7577539	G	A	ENST00000269305.4	75	GRCh37					missense_variant	
119	https://civic.genome.wustl.edu/#/events/genes/45/summary/variants/119/summary#variant	TP53	7157	R249	This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R249 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.		17	7577535	7577535	C	G	ENST00000269305.4	75	GRCh37					protein_altering_variant	
121	https://civic.genome.wustl.edu/#/events/genes/45/summary/variants/121/summary#variant	TP53	7157	R273C	While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.		17	7577121	7577121	G	A	ENST00000269305.4	75	GRCh37					missense_variant	
122	https://civic.genome.wustl.edu/#/events/genes/45/summary/variants/122/summary#variant	TP53	7157	R273H	While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.		17	7577120	7577120	C	T	ENST00000269305.4	75	GRCh37					missense_variant	
124	https://civic.genome.wustl.edu/#/events/genes/46/summary/variants/124/summary#variant	TSC1	7248	FRAMESHIFT TRUNCATION	In a small cohort study of bladder cancer, patients with TSC1 mutations showed better responses to and increased treatment duration tolerance with the mTOR inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2 wildtype cells.	TSC Loss,TSC Loss	9	135766735	135820008			ENST00000298552.3	75	GRCh37					frameshift_truncation	
125	https://civic.genome.wustl.edu/#/events/genes/46/summary/variants/125/summary#variant	TSC1	7248	LOSS-OF-FUNCTION	In a small cohort study of bladder cancer, patients with TSC1 mutations showed better responses to and increased treatment duration tolerance with the mTOR inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2 wildtype cells.	TSC Loss	9	135766735	135820008			ENST00000298552.3	75	GRCh37					loss_of_function_variant	
127	https://civic.genome.wustl.edu/#/events/genes/48/summary/variants/127/summary#variant	U2AF1	7307	Q157P/R	U2AF1 Q157P/R has been shown to be a recurrent mutation in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and lung adenocarcinomas. This mutation is less common than the S34F mutation, occurs in the second zinc finger domain of U2AF1 and has been demonstrated to alter splicing. The impact of U2AF1 mutations on overall survival in MDS has been debated, however, patients with U2AF1 mutations were shown to be at an increased risk of transformation to secondary AML. The presence of this mutation was not associated with a specific prognostic outcome in AML when compared to U2AF1 wildtype patients.		21	44514777	44514777	T	G	ENST00000291552.4	75	GRCh37					missense_variant	
128	https://civic.genome.wustl.edu/#/events/genes/48/summary/variants/128/summary#variant	U2AF1	7307	S34Y/F	U2AF1 S34Y/F has been shown to be a recurrent mutation in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and lung adenocarcinomas. This mutation is the most commonly identified variant in MDS, occurs in the first zinc finger domain of U2AF1 and has been demonstrated to alter splicing. The impact of U2AF1 mutations on overall survival in MDS has been debated, however, patients with U2AF1 mutations were shown to be at an increased risk of transformation to secondary AML. The presence of this mutation was not associated with a specific prognostic outcome in AML when compared to U2AF1 wildtype patients.		21	44524456	44524456	G	A	ENST00000291552.4	75	GRCh37					missense_variant	
129	https://civic.genome.wustl.edu/#/events/genes/49/summary/variants/129/summary#variant	WT1	7490	EXON 7 MUTATION	WT1 exon 7 mutations have been shown to be recurrent in acute myeloid leukemia. Many sources have examined the prognostic impact of these, agreeing that the mutant exon 7 cohort is correlated with worse overall survival and a number of poor prognistic outcomes. This may be the result of an overall poor response to chemotherapy from WT1 mutant tumors.		11	32417803	32417953			ENST00000332351.3	75	GRCh37					exon_variant	
130	https://civic.genome.wustl.edu/#/events/genes/49/summary/variants/130/summary#variant	WT1	7490	EXON 9 MUTATION	WT1 exon 9 mutations have been shown to be recurrent in acute myeloid leukemia, although at a less frequent rate than their exon 7 counterparts. Many sources have examined the prognostic impact of these, agreeing that the mutant exon 9 cohort is correlated with worse overall survival and a number of poor prognistic outcomes. This may be the result of an overall poor response to chemotherapy from WT1 mutant tumors.		11	32413518	32413610			ENST00000332351.3	75	GRCh37					exon_variant	
131	https://civic.genome.wustl.edu/#/events/genes/6/summary/variants/131/summary#variant	BRCA1	672	LOSS-OF-FUNCTION	BRCA1 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.	BRCA Germline Variants	17	41196312	41277387			ENST00000357654.3	75	GRCh37					loss_of_heterozygosity,loss_of_function_variant	
132	https://civic.genome.wustl.edu/#/events/genes/7/summary/variants/132/summary#variant	BRCA2	675	LOSS-OF-FUNCTION	BRCA2 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.	BRCA Germline Variants	13	32889611	32973347			ENST00000380152.3	75	GRCh37					loss_of_function_variant	
133	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/133/summary#variant	EGFR	1956	EXON 19 DELETION	Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma.		7	55242415	55242513			ENST00000275493.2	75	GRCh37					inframe_deletion	
134	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/134/summary#variant	EGFR	1956	G719S	While not as recurrent as the L858R mutation, EGFR G719S has also been shown to be an activating mutation. In lung cancer cell lines, it also confers sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib.		7	55241707	55241707	G	A	ENST00000275493.2	75	GRCh37					missense_variant	
135	https://civic.genome.wustl.edu/#/events/genes/50/summary/variants/135/summary#variant	NOTCH1	4851	D1642H	Activating mutations in NOTCH1, including D1642H, have been shown to be poor prognostic markers in lung cancer.		9	139399219	139399219	C	G	ENST00000277541.6	75	GRCh37					missense_variant	
136	https://civic.genome.wustl.edu/#/events/genes/50/summary/variants/136/summary#variant	NOTCH1	4851	R2327W	Activating mutations in NOTCH1, including R2327W, have been shown to be poor prognostic markers in lung cancer.		9	139391212	139391212	G	A	ENST00000277541.6	75	GRCh37					missense_variant	
137	https://civic.genome.wustl.edu/#/events/genes/50/summary/variants/137/summary#variant	NOTCH1	4851	V2444FS	Activating mutations in NOTCH1, including a frameshift insertion at V2444, have been shown to be poor prognostic markers in lung cancer.		9	139390861	139390861	G	TGT	ENST00000277541.6	75	GRCh37						
138	https://civic.genome.wustl.edu/#/events/genes/50/summary/variants/138/summary#variant	NOTCH1	4851	S2275FS	Activating mutations in NOTCH1, including a frameshift insertion at S2275, have been shown to be poor prognostic markers in lung cancer.		9	139391369	139391370		A	ENST00000277541.6	75	GRCh37					plus_1_frameshift_variant	
139	https://civic.genome.wustl.edu/#/events/genes/51/summary/variants/139/summary#variant	DDR2	4921	L63V	Activating mutations in DDR2, including L63V, has been shown to be sensitive to dasatinib in cell lines.		1	162724415	162724415	C	G	ENST00000367922.3	75	GRCh37					missense_variant	
140	https://civic.genome.wustl.edu/#/events/genes/51/summary/variants/140/summary#variant	DDR2	4921	L239R	Activating mutations in DDR2, including L239R, has been shown to be sensitive to dasatinib in cell lines.		1	162729630	162729630	T	G	ENST00000367922.3	75	GRCh37					missense_variant	
141	https://civic.genome.wustl.edu/#/events/genes/51/summary/variants/141/summary#variant	DDR2	4921	G253C	Activating mutations in DDR2, including G253C, has been shown to be sensitive to dasatinib in cell lines.		1	162729671	162729671	G	T	ENST00000367922.3	75	GRCh37					missense_variant	
142	https://civic.genome.wustl.edu/#/events/genes/51/summary/variants/142/summary#variant	DDR2	4921	G505S	Activating mutations in DDR2, including G505S, has been shown to be sensitive to dasatinib in cell lines.		1	162741822	162741822	G	A	ENST00000367922.3	75	GRCh37					missense_variant	
143	https://civic.genome.wustl.edu/#/events/genes/51/summary/variants/143/summary#variant	DDR2	4921	I638F	DDR2 I638F has been shown to be a loss of function mutation, but also confers sensitivity to dasatinib in cell lines.		1	162745497	162745497	A	T	ENST00000367922.3	75	GRCh37					missense_variant	
144	https://civic.genome.wustl.edu/#/events/genes/51/summary/variants/144/summary#variant	DDR2	4921	G774V	Activating mutations in DDR2, including G774V, has been shown to be sensitive to dasatinib in cell lines.		1	162748407	162748407	G	T	ENST00000367922.3	75	GRCh37					missense_variant	
145	https://civic.genome.wustl.edu/#/events/genes/51/summary/variants/145/summary#variant	DDR2	4921	S768R	Activating mutations in DDR2, including S768R, has been shown to be sensitive to dasatinib in cell lines.		1	162748390	162748390	T	A	ENST00000367922.3	75	GRCh37					missense_variant	
148	https://civic.genome.wustl.edu/#/events/genes/30/summary/variants/148/summary#variant	KRAS	3845	G12A	KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.	EGFR TKI Resistance	12	25398284	25398284	C	G	ENST00000256078.4	75	GRCh37					missense_variant	
151	https://civic.genome.wustl.edu/#/events/genes/59/summary/variants/151/summary#variant	BCL2	596	IGH-BCL2	The typically reciprocal t(14;18)(q32;q21) translocation involves rearrangement between the immunoglobulin heavy chain locus on chromosome 14 and the 3' UTR of BCL2 on chromosome 18, leading to the overexpression of BCL2. This rearrangment is observed in >80% of patients with follicular lymphoma.		14	106032614	107288051				75	GRCh37	18	60794268	60987019	ENST00000333681.4	transcript_regulatory_region_fusion	
152	https://civic.genome.wustl.edu/#/events/genes/59/summary/variants/152/summary#variant	BCL2	596	EXPRESSION			18	60790579	60987361			ENST00000398117.1	75	GRCh37					N/A	
153	https://civic.genome.wustl.edu/#/events/genes/56/summary/variants/153/summary#variant	FOXP1	27086	AMPLIFICATION	Amplication in FOXP1 has been shown to be associated with the ABC subtype of DLBCL.		3	71003844	71633140			ENST00000318789.4	75	GRCh37					transcript_amplification	
154	https://civic.genome.wustl.edu/#/events/genes/57/summary/variants/154/summary#variant	REL	5966	AMPLIFICATION			2	61108709	61149800			ENST00000295025.8	75	GRCh37					transcript_amplification	
155	https://civic.genome.wustl.edu/#/events/genes/43/summary/variants/155/summary#variant	RUNX1	861	MUTATION	RUNX1 mutations are associated with poor prognosis in patients with acute myeloid leukemia or adult T-cell acute lymphocytic leukemia. In younger (<60 years old) AML patients, allogeneic stem cell transplant at complete remission led to much better relapse-free survival than repetitive cycles of high-dose cytarabine.		21	36160098	36421641			ENST00000300305.3	75	GRCh37					loss_of_function_variant,transcript_variant	
156	https://civic.genome.wustl.edu/#/events/genes/60/summary/variants/156/summary#variant	IGF2	3481	OVEREXPRESSION			11	2150348	2170833			ENST00000300632.5	75	GRCh37					N/A	
157	https://civic.genome.wustl.edu/#/events/genes/55/summary/variants/157/summary#variant	TET2	54790	MUTATION			4	106067450	106200973			ENST00000513237.1	75	GRCh37					loss_of_function_variant,gene_variant	
158	https://civic.genome.wustl.edu/#/events/genes/61/summary/variants/158/summary#variant	AURKA	6790	EXPRESSION			20	54944446	54967393			ENST00000395913.3	75	GRCh37					N/A	
159	https://civic.genome.wustl.edu/#/events/genes/58/summary/variants/159/summary#variant	VHL	7428	LOSS-OF-FUNCTION			3	10182692	10193904			ENST00000256474.2	75	GRCh37					loss_of_function_variant	
160	https://civic.genome.wustl.edu/#/events/genes/58/summary/variants/160/summary#variant	VHL	7428	MUTATION			3	10182692	10193904			ENST00000256474.2	75	GRCh37					loss_of_function_variant,gene_variant	
161	https://civic.genome.wustl.edu/#/events/genes/62/summary/variants/161/summary#variant	PBRM1	55193	MUTATION			3	52581857	52719852			ENST00000394830.3	75	GRCh37					transcription_variant,loss_of_function_variant	
163	https://civic.genome.wustl.edu/#/events/genes/63/summary/variants/163/summary#variant	EZH2	2146	MUTATION			7	148504477	148581370			ENST00000320356.2	75	GRCh37						
164	https://civic.genome.wustl.edu/#/events/genes/53/summary/variants/164/summary#variant	FLI1	2313	EWSR1-FLI1 Type 1	Although multiple fusion transcripts have been described, type 1 consists of EWSR1 exon 7 fused to FLI1 exon 6, the most common arrangement in Ewings Sarcoma.		22	29664007	29683123			ENST00000397938.2	75	GRCh37	11	128675261	128683162	ENST00000527786.2	transcript_fusion	
165	https://civic.genome.wustl.edu/#/events/genes/63/summary/variants/165/summary#variant	EZH2	2146	Y646	Mutations of Y646 are associated with a diagnosis of Germinal Center B type DLBCL and Follicular non-Hodgkin Lymphoma. In vitro experimental findings suggest that this may be due to reduced methyltransferase activity of EZH2 on protein H3K27 (Morin et al., 2010).		7	148508726	148508728			ENST00000320356.2	75	GRCh37					protein_altering_variant	
167	https://civic.genome.wustl.edu/#/events/genes/64/summary/variants/167/summary#variant	KMT2D	8085	LOSS-OF-FUNCTION			12	49412758	49449107			ENST00000301067.7	75	GRCh37					loss_of_function_variant	
168	https://civic.genome.wustl.edu/#/events/genes/65/summary/variants/168/summary#variant	BTK	695	C481S			X	100611165	100611165	A	T	ENST00000308731.7	75	GRCh37					missense_variant	
169	https://civic.genome.wustl.edu/#/events/genes/2/summary/variants/169/summary#variant	AKT1	207	Q79K			14	105243048	105243048	G	T	ENST00000407796.2	75	GRCh37					missense_variant	
170	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/170/summary#variant	ALK	238	EML4-ALK AMPLIFICATION			2	42396490	42528380			ENST00000318522.5	75	GRCh37	2	29415640	29446394	ENST00000389048.3	transcript_fusion,transcript_amplification	
171	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/171/summary#variant	ALK	238	ALK FUSION G1202R	ALK fusion with G1202R mutation in the ALK kinase domain was first identified in a lung adenocarcinoma patient who had progressed after 10 months of responding to crizotinib. Further characterization of this variant verified crizotinib resistance and additionally demonstrated resistance to multiple next generation ALK inhibitors including ceritinib, alectinib and brigatinib. Experiments using the HSP90 inhibitor  17-AAG have indicated potential sensitivity of EML4-ALK G1202R to this drug, suggesting this variant may be an HSP90 client protein.		2	29443613	29443613	C	T	ENST00000389048.3	75	GRCh37					missense_variant,transcript_fusion	
172	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/172/summary#variant	ALK	238	EML4-ALK S1206Y		Crizotinib Resistance	2	29443600	29443600	G	T	ENST00000389048.3	75	GRCh37					missense_variant,transcript_fusion	
173	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/173/summary#variant	ALK	238	EML4-ALK T1151INST	The ALK fusion variant with insertion of T at amino acid 1151 was found in an ALK rearranged lung adenocarcinoma which had progressed after responding to crizotinib treatment. The mutation was absent in tumor sample taken before crizotinib treatment. Characterization of the variant using cell lines expressing EML4-ALK with 1151 T insert found the variant to be highly crizotinib resistant, and other work demonstrated resistance to next generation inhibitor alectinib, while resistance to tool compound TAE684 indicates potential resistance to the next generation ALK inhibitor ceritinib which is derived from TAE684. Other experiments suggest theraputic potential for HSP90 inhibitors, as EML4-ALK T1151 Tins sensitivity to 17-AAG has been observed.		2	29445271	29445272		CGT	ENST00000389048.3	75	GRCh37					inframe_insertion,transcript_fusion	
174	https://civic.genome.wustl.edu/#/events/genes/66/summary/variants/174/summary#variant	APC	324	MUTATION			5	112043218	112181936			ENST00000457016.1	75	GRCh37						
175	https://civic.genome.wustl.edu/#/events/genes/67/summary/variants/175/summary#variant	AR	367	F877L			X	66943549	66943549	T	C	ENST00000374690.3	75	GRCh37					missense_variant	
176	https://civic.genome.wustl.edu/#/events/genes/67/summary/variants/176/summary#variant	AR	367	W742			X	66937370	66937372			ENST00000374690.3	75	GRCh37					missense_variant	
177	https://civic.genome.wustl.edu/#/events/genes/68/summary/variants/177/summary#variant	ASXL1	171023	MUTATION	ASXL1 mutations are most frequently observed in the absence of FLT3-ITD and NPM1 mutations in acute myeloid leukemia (AML) patients and seem to be enriched in older patients (>60 years). These mutations are associated with poor prognosis with respect to both survival and compete remission rates.		20	30946155	31027122			ENST00000375687.4	75	GRCh37					protein_altering_variant	
178	https://civic.genome.wustl.edu/#/events/genes/69/summary/variants/178/summary#variant	ATM	472	MUTATION			11	108093559	108239826			ENST00000278616.4	75	GRCh37					transcription_variant,loss_of_function_variant	
179	https://civic.genome.wustl.edu/#/events/genes/69/summary/variants/179/summary#variant	ATM	472	UNDEREXPRESSION			11	108093559	108239826			ENST00000278616.4	75	GRCh37					N/A	
180	https://civic.genome.wustl.edu/#/events/genes/61/summary/variants/180/summary#variant	AURKA	6790	AMPLIFICATION			20	54944446	54967393			ENST00000395913.3	75	GRCh37					transcript_amplification	
181	https://civic.genome.wustl.edu/#/events/genes/61/summary/variants/181/summary#variant	AURKA	6790	OVEREXPRESSION			20	54944446	54967393			ENST00000395913.3	75	GRCh37					N/A	
182	https://civic.genome.wustl.edu/#/events/genes/70/summary/variants/182/summary#variant	BAP1	8314	EXPRESSION			3	52435029	52444366			ENST00000460680.1	75	GRCh37					N/A	
183	https://civic.genome.wustl.edu/#/events/genes/70/summary/variants/183/summary#variant	BAP1	8314	MUTATION			3	52435029	52444366			ENST00000460680.1	75	GRCh37					loss_of_function_variant,protein_altering_variant	
184	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/184/summary#variant	BRAF	673	AKAP9-BRAF		BRAF Fusions	7	91570181	91625114			ENST00000356239.3	75	GRCh37	7	140434279	140487384	ENST00000288602.6	transcript_fusion	
185	https://civic.genome.wustl.edu/#/events/genes/6/summary/variants/185/summary#variant	BRCA1	672	MUTATION			17	41196312	41277387			ENST00000357654.3	75	GRCh37					loss_of_function_variant,gene_variant	
186	https://civic.genome.wustl.edu/#/events/genes/7/summary/variants/186/summary#variant	BRCA2	675	MUTATION			13	32889611	32973347			ENST00000380152.3	75	GRCh37					loss_of_function_variant,gene_variant	
187	https://civic.genome.wustl.edu/#/events/genes/11/summary/variants/187/summary#variant	CCNE1	898	AMPLIFICATION			19	30302805	30315215			ENST00000262643.3	75	GRCh37					transcript_amplification	
189	https://civic.genome.wustl.edu/#/events/genes/18/summary/variants/189/summary#variant	DNMT3A	1788	MUTATION	DNMT3A mutations occur in a variety of myeloid malignancies. These mutations are associated with adverse prognosis in acute myeloid leukemia (AML), particularly in the context of NPM1 and FLT3-ITD mutations, which often co-occur. Early results indicate AML patients with DNMT3A mutations may respond better to decitabine than those with wild-type. Shorter survival has been indicated in patients with T-cell acute lymphoblastic leukemia and myelodysplastic syndrome, however, larger cohorts are required to verify this finding. DNMT3A mutations have been suggested as a pre-leukemic lesion and found in older individuals with clonal hematopoiesis but no overt malignancy.		2	25455845	25565459			ENST00000264709.3	75	GRCh37					transcript_variant	
190	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/190/summary#variant	EGFR	1956	AMPLIFICATION			7	55086794	55279321			ENST00000275493.2	75	GRCh37					transcript_amplification	
191	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/191/summary#variant	EGFR	1956	COPY NUMBER VARIATION			7	55086794	55279321			ENST00000275493.2	75	GRCh37					copy_number_change	
193	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/193/summary#variant	EGFR	1956	OVEREXPRESSION			7	55086794	55279321			ENST00000275493.2	75	GRCh37					N/A	
194	https://civic.genome.wustl.edu/#/events/genes/71/summary/variants/194/summary#variant	ERG	2078	EWSR1-ERG	EWSR1-ERG is found in 5% of patients with Ewing Sarcoma and considered to be diagnostic of this disease, a small tumor more often found in bone, but less frequently in soft tissue. To better identify EWSR1-ERG in patients, conventional cytogenetics methods were analyzed: FISH and RT-PCR. Ultimately concluding that more than one method is needed to accurately diagnose patients due to the strengths and weaknesses of each individual method.		22	29664007	29683123			ENST00000397938.2	75	GRCh37	21	39751949	39755845	ENST00000398907.1	transcript_fusion	
195	https://civic.genome.wustl.edu/#/events/genes/71/summary/variants/195/summary#variant	ERG	2078	TMPRSS2-ERG	TMPRSS2 fusions are prevalent in Prostate Cancer. TMPRSS2 fusion with ETS family members such as ERG are among the most common. Fusion of TMPRSS2 with ERG may result in overexpression of ERG driven by the TMPRSS2 androgen-responsive promoter elements. Due to the high prevalence of this fusion, it may have diagnostic utility for prostate cancer, especially ERG expression positive prostate cancer.		21	42879877	42879992			ENST00000398585.3	75	GRCh37	21	39751949	39817544	ENST00000398910.1	transcript_fusion	
196	https://civic.genome.wustl.edu/#/events/genes/23/summary/variants/196/summary#variant	FGFR3	2261	Y375C			4	1806099	1806099	A	G	ENST00000340107.4	75	GRCh37					missense_variant	
197	https://civic.genome.wustl.edu/#/events/genes/53/summary/variants/197/summary#variant	FLI1	2313	EWSR1-FLI1			22	29664007	29683123			ENST00000397938.2	75	GRCh37	11	128651853	128683162	ENST00000527786.2	transcript_fusion	
198	https://civic.genome.wustl.edu/#/events/genes/72/summary/variants/198/summary#variant	FOXL2	668	C134W	The variant C134W on the FOXL2 gene was revealed to have a high frequency (95-97%) in the adult form of granulosa cell tumors that comprises 5% of ovarian cancers. Due to the mutation's high frequency, future therapeutics might target for this single apparent mechanism. However, the consequence of this mutation remain unknown.		3	138665163	138665163	G	C	ENST00000330315.3	75	GRCh37					missense_variant	
199	https://civic.genome.wustl.edu/#/events/genes/27/summary/variants/199/summary#variant	IDH2	3418	R172			15	90631837	90631839			ENST00000330062.3	75	GRCh37					protein_altering_variant	
200	https://civic.genome.wustl.edu/#/events/genes/73/summary/variants/200/summary#variant	IKZF1	10320	DELETION			7	50344378	50472799			ENST00000331340.3	75	GRCh37					transcript_ablation	
201	https://civic.genome.wustl.edu/#/events/genes/29/summary/variants/201/summary#variant	KIT	3815	M541L			4	55593464	55593464	A	C	ENST00000288135.5	75	GRCh37					missense_variant	
202	https://civic.genome.wustl.edu/#/events/genes/29/summary/variants/202/summary#variant	KIT	3815	V560DEL			4	55593612	55593614	GTT		ENST00000288135.5	75	GRCh37					inframe_deletion,amino_acid_deletion	
203	https://civic.genome.wustl.edu/#/events/genes/30/summary/variants/203/summary#variant	KRAS	3845	Q61			12	25380275	25380277			ENST00000256078.4	75	GRCh37					protein_altering_variant	
204	https://civic.genome.wustl.edu/#/events/genes/74/summary/variants/204/summary#variant	NCOA3	8202	AMPLIFICATION			20	46130646	46285621			ENST00000372004.3	75	GRCh37					transcript_amplification	
205	https://civic.genome.wustl.edu/#/events/genes/74/summary/variants/205/summary#variant	NCOA3	8202	OVEREXPRESSION			20	46130646	46285621			ENST00000372004.3	75	GRCh37					N/A	
206	https://civic.genome.wustl.edu/#/events/genes/50/summary/variants/206/summary#variant	NOTCH1	4851	MUTATION			9	139388896	139440314			ENST00000277541.6	75	GRCh37					protein_altering_variant	
207	https://civic.genome.wustl.edu/#/events/genes/50/summary/variants/207/summary#variant	NOTCH1	4851	P2514FS	This mutation disrupts the C-terminal PEST domain that in normal conditions promotes degradation,  resulting in accumulation of an active NOTCH1 isoform sustaining deregulated signaling.		9	139390649	139390650	AG		ENST00000277541.6	75	GRCh37					frameshift_truncation	
208	https://civic.genome.wustl.edu/#/events/genes/36/summary/variants/208/summary#variant	NRAS	4893	MUTATION			1	115247090	115259515			ENST00000369535.4	75	GRCh37					gain_of_function_variant,transcript_variant	
209	https://civic.genome.wustl.edu/#/events/genes/75/summary/variants/209/summary#variant	PAX8	7849	PAX8-PPARG	PAX8-PPAR gamma is a oncogene caused by a translocation between 2q13 and 3p25 resulting in an in-frame fusion between the two genes. It has been observed in Follicular Thyroid Cancer (FTC) and is one of two known fusion products involving PPAR gamma in FTC indicating this region may be a breakpoint hotspot. Studies have indicated that the fusion product increases cell viability and proliferation and decreases apoptosis.		2	114036521	113992971			ENST00000429538.3	75	GRCh37	3	12329400	12475810	ENST00000397015.2	transcript_fusion	
210	https://civic.genome.wustl.edu/#/events/genes/76/summary/variants/210/summary#variant	PGR	5241	EXPRESSION			11	100900355	101001255			ENST00000325455.5	75	GRCh37					N/A	
212	https://civic.genome.wustl.edu/#/events/genes/37/summary/variants/212/summary#variant	PIK3CA	5290	AMPLIFICATION			3	178866311	178957881			ENST00000263967.3	75	GRCh37					transcript_amplification	
213	https://civic.genome.wustl.edu/#/events/genes/41/summary/variants/213/summary#variant	PTEN	5728	DELETION			10	89622870	89731687			ENST00000371953.3	75	GRCh37					transcript_ablation	
214	https://civic.genome.wustl.edu/#/events/genes/41/summary/variants/214/summary#variant	PTEN	5728	LOSS			10	89622870	89731687			ENST00000371953.3	75	GRCh37					loss_of_function_variant	
215	https://civic.genome.wustl.edu/#/events/genes/44/summary/variants/215/summary#variant	SF3B1	23451	MUTATION			2	198254508	198299815			ENST00000335508.6	75	GRCh37					protein_altering_variant	
216	https://civic.genome.wustl.edu/#/events/genes/77/summary/variants/216/summary#variant	SMAD4	4089	MUTATION			18	48556583	48611409			ENST00000342988.3	75	GRCh37					loss_of_function_variant,transcript_variant	
217	https://civic.genome.wustl.edu/#/events/genes/78/summary/variants/217/summary#variant	SMARCA4	6597	MUTATION			19	11071598	11172958			ENST00000358026.2	75	GRCh37					loss_of_function_variant,gene_variant	
218	https://civic.genome.wustl.edu/#/events/genes/78/summary/variants/218/summary#variant	SMARCA4	6597	INACTIVATING MUTATION			19	11071598	11172958			ENST00000358026.2	75	GRCh37					loss_of_function_variant	
219	https://civic.genome.wustl.edu/#/events/genes/79/summary/variants/219/summary#variant	TERT	7015	AMPLIFICATION			5	1253282	1295162			ENST00000310581.5	75	GRCh37					transcript_amplification	
220	https://civic.genome.wustl.edu/#/events/genes/79/summary/variants/220/summary#variant	TERT	7015	PROMOTER MUTATION			5	1295161	1295373			ENST00000310581.5	75	GRCh37					regulatory_region_variant	
221	https://civic.genome.wustl.edu/#/events/genes/45/summary/variants/221/summary#variant	TP53	7157	DELETERIOUS MUTATION			17	7571720	7590856			ENST00000269305.4	75	GRCh37						
222	https://civic.genome.wustl.edu/#/events/genes/45/summary/variants/222/summary#variant	TP53	7157	MUTATION			17	7571720	7590856			ENST00000269305.4	75	GRCh37					protein_altering_variant	
223	https://civic.genome.wustl.edu/#/events/genes/45/summary/variants/223/summary#variant	TP53	7157	TRUNCATING MUTATION			17	7573998	7579714			ENST00000269305.4	75	GRCh37					frameshift_truncation	
224	https://civic.genome.wustl.edu/#/events/genes/80/summary/variants/224/summary#variant	TTF1	7270	AMPLIFICATION			9	135251008	135282209			ENST00000334270.2	75	GRCh37					transcript_amplification	
230	https://civic.genome.wustl.edu/#/events/genes/8950/summary/variants/230/summary#variant	CHEK2	11200	LOSS-OF-FUNCTION			22	29083732	29137832			ENST00000328354.6	75	GRCh37					loss_of_function_variant	
236	https://civic.genome.wustl.edu/#/events/genes/12112/summary/variants/236/summary#variant	CDK12	51755	LOSS-OF-FUNCTION			17	37618292	37691399			ENST00000447079.4	75	GRCh37					loss_of_function_variant	
238	https://civic.genome.wustl.edu/#/events/genes/9189/summary/variants/238/summary#variant	NT5C2	22978	R367Q			10	104852955	104852955	C	T	ENST00000343289.5	75	GRCh37					missense_variant	
239	https://civic.genome.wustl.edu/#/events/genes/9189/summary/variants/239/summary#variant	NT5C2	22978	K359Q			10	104852980	104852980	T	G	ENST00000343289.5	75	GRCh37					missense_variant	
240	https://civic.genome.wustl.edu/#/events/genes/9189/summary/variants/240/summary#variant	NT5C2	22978	D407A			10	104850745	104850745	T	G	ENST00000343289.5	75	GRCh37					missense_variant	
241	https://civic.genome.wustl.edu/#/events/genes/4/summary/variants/241/summary#variant	ABL1	25	BCR-ABL F317L	BCR-ABL F317L, like the similar BCR-ABL T315I mutation, is becoming a common clinical marker for resistance to front-line therapies in CML. It has been shown to confer resistance to dasatinib, but responds well to ponatinib and other second generation inhibitors.	Imatinib Resistance	9	133748288	133748288	T	C	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	
242	https://civic.genome.wustl.edu/#/events/genes/45/summary/variants/242/summary#variant	TP53	7157	DNA BINDING DOMAIN MUTATION			17	7577149	7578443			ENST00000269305.4	75	GRCh37						
243	https://civic.genome.wustl.edu/#/events/genes/69/summary/variants/243/summary#variant	ATM	472	V2288FS*1	A frameshift mutation predicted to cause truncation before the C-terminal phosphoinositide 3-kinase (PI3K) catalytic domain.		11	108196840	108196841	TC	-	ENST00000278616.4	75	GRCh37					frameshift_truncation	
244	https://civic.genome.wustl.edu/#/events/genes/69/summary/variants/244/summary#variant	ATM	472	N2875H	A missense mutation within the C-terminal phosphoinositide 3-kinase (PI3K) catalytic domain		11	108218044	108218044	A	C	ENST00000278616.4	75	GRCh37					missense_variant	
245	https://civic.genome.wustl.edu/#/events/genes/3870/summary/variants/245/summary#variant	NF2	4771	Y177FS			22	30051593	30051594		T	ENST00000338641.4	75	GRCh37					frameshift_elongation	
247	https://civic.genome.wustl.edu/#/events/genes/38/summary/variants/247/summary#variant	PDGFRA	5156	V561A			4	55141036	55141036	T	C	ENST00000257290.5	75	GRCh37					missense_variant	
248	https://civic.genome.wustl.edu/#/events/genes/79/summary/variants/248/summary#variant	TERT	7015	C228T			5	1295228	1295228	G	A	ENST00000310581.5	75	GRCh37					regulatory_region_variant	
249	https://civic.genome.wustl.edu/#/events/genes/6144/summary/variants/249/summary#variant	XRCC1	7515	R194W			19	44057574	44057574	G	A	ENST00000262887.5	75	GRCh37					missense_variant	
250	https://civic.genome.wustl.edu/#/events/genes/2473/summary/variants/250/summary#variant	GSTP1	2950	DELETION			11	67351066	67354131			ENST00000398606.3	75	GRCh37					transcript_ablation	
251	https://civic.genome.wustl.edu/#/events/genes/14842/summary/variants/251/summary#variant	BIRC7	79444	AMPLIFICATION			20	61867235	61871859			ENST00000217169.3	75	GRCh37					transcript_amplification	
252	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/252/summary#variant	EGFR	1956	EXON 4 DELETION			7	55214299	55214433			ENST00000275493.2	75	GRCh37					exon_loss_variant	
253	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/253/summary#variant	EGFR	1956	3' UTR MUTATION															3_prime_UTR_variant	
254	https://civic.genome.wustl.edu/#/events/genes/30/summary/variants/254/summary#variant	KRAS	3845	RS61764370	Germline variant in the 3' UTR of KRAS that predicts resistance to platinum-based therapy.		12	25360224	25360224	A	C	ENST00000311936.3	75	GRCh37					3_prime_UTR_variant	
255	https://civic.genome.wustl.edu/#/events/genes/1741/summary/variants/255/summary#variant	ERCC5	2073	RS751402			13	103498198	103498199	A	G	ENST00000355739.4	75	GRCh37					5_prime_UTR_variant,SNP	
256	https://civic.genome.wustl.edu/#/events/genes/29/summary/variants/256/summary#variant	KIT	3815	3' UTR MUTATION			4	55604724	55606881			ENST00000288135.5	75	GRCh37					3_prime_UTR_variant	
257	https://civic.genome.wustl.edu/#/events/genes/63/summary/variants/257/summary#variant	EZH2	2146	INTRON 6 MUTATION			7	148524359	148525831			ENST00000320356.2	75	GRCh37					intron_variant	
258	https://civic.genome.wustl.edu/#/events/genes/3672/summary/variants/258/summary#variant	MTHFR	4524	A222V			1	11856378	11856378	G	A	ENST00000376592.1	75	GRCh37					missense_variant	
259	https://civic.genome.wustl.edu/#/events/genes/2473/summary/variants/259/summary#variant	GSTP1	2950	I105V			11	67352689	67352689	A	G	ENST00000398606.3	75	GRCh37					missense_variant	
260	https://civic.genome.wustl.edu/#/events/genes/7451/summary/variants/260/summary#variant	ABCG2	9429	Q141K			4	89052323	89052323	G	T	ENST00000237612.3	75	GRCh37					missense_variant	
261	https://civic.genome.wustl.edu/#/events/genes/6144/summary/variants/261/summary#variant	XRCC1	7515	Q399R			19	44055726	44055726	T	C	ENST00000262887.5	75	GRCh37					missense_variant	
262	https://civic.genome.wustl.edu/#/events/genes/4244/summary/variants/262/summary#variant	ABCB1	5243	S893T			7	87160618	87160618	A	T	ENST00000265724.3	75	GRCh37					missense_variant	
263	https://civic.genome.wustl.edu/#/events/genes/4244/summary/variants/263/summary#variant	ABCB1	5243	I1145I			7	87138645	87138645	A	G	ENST00000265724.3	75	GRCh37					synonymous_variant	
264	https://civic.genome.wustl.edu/#/events/genes/1736/summary/variants/264/summary#variant	ERCC2	2068	K751Q			19	45854919	45854919	T	G	ENST00000391945.4	75	GRCh37					missense_variant	
265	https://civic.genome.wustl.edu/#/events/genes/5971/summary/variants/265/summary#variant	TYMS	7298	5' TANDEM REPEAT			18	657604	657742			ENST00000323274.10	75	GRCh37					5_prime_UTR_variant,short_tandem_repeat_variation	
266	https://civic.genome.wustl.edu/#/events/genes/12146/summary/variants/266/summary#variant	LRP1B	53353	EXON 1222 DELETION			2	141665446	141777671			ENST00000389484.3	75	GRCh37					exon_loss_variant	
267	https://civic.genome.wustl.edu/#/events/genes/1885/summary/variants/267/summary#variant	FGFR1	2260	AMPLIFICATION	FGFR1 amplifications are the most common aberrations of the FGFR family in cancer. One study reports FGFR1 aberrations in 3.5% of 4,853 patients of which most are FGFR1 amplifications (Helsten et. al.). Preclinically, FGFR1 amplifications have also been shown to confer sensitivity to FGFR1 inhibitors (Weiss et. al.). Clinical studies are currently ongoing (e.g. NCT01004224).		8	38268656	38325363			ENST00000425967.3	75	GRCh37					transcript_amplification	
268	https://civic.genome.wustl.edu/#/events/genes/1885/summary/variants/268/summary#variant	FGFR1	2260	EXPRESSION	FGFR1 high expression has been reported in 11.8% (178 patients) of oral squamous cell carcinoma patients, and was enriched in early stages (Freier et. al.). Another study reports FGFR1 expression in 35% of primary HNSSC (353 patients) (Gke et. al.). In both studies, FGFR1 gene amplification and expression do not correlate well with about 35% of samples with FGFR1 amplification overexpressing FGFR1 (Gke et. al.). FGFR1 expression also correlated with sensitivity to FGFR1 inhibitors in preclinical models of lung cancer (Wynes et. al.), HNSSC (Gke et. al.) and urothelial carcinoma (Lamont et. al.).		8	38268656	38325363			ENST00000425967.3	75	GRCh37					N/A	
269	https://civic.genome.wustl.edu/#/events/genes/4941/summary/variants/269/summary#variant	ROS1	6098	REARRANGEMENT	ROS1 is a receptor tyrosine kinase that frequently forms gene fusions in several cancer types. Approximately 2% of NSCLC patients harbor a ROS1 gene fusion. Several fusion partners have been described with a constant ROS1-breakpoint, maintaining the kinase domain (Solomon B, 2015). Following case-studies and retrospective analyses, an expansion cohort of a phase-1 study showed clinical benefit of crizotinib in ROS1 rearranged NSCLC. The benefit was independent of the type of ROS1-rearrangement (Shaw et. al.,2014).		6	117609463	117747018			ENST00000368508.3	75	GRCh37					transcript_fusion	
270	https://civic.genome.wustl.edu/#/events/genes/52/summary/variants/270/summary#variant	MET	4233	AMPLIFICATION			7	116312459	116436396			ENST00000318493.6	75	GRCh37					transcript_amplification	
271	https://civic.genome.wustl.edu/#/events/genes/524/summary/variants/271/summary#variant	ATR	545	I774FS	Single A insertion or deletion in the 10 A mononucleotide run in exon 10 of ATR results in a frameshift of codon I774. In patients with endometrial cancer, this mutation has only been observed in patients with microsatellite instability.		3	142274740	142274740	A		ENST00000350721.4	75	GRCh37					frameshift_truncation	
272	https://civic.genome.wustl.edu/#/events/genes/14/summary/variants/272/summary#variant	CDKN2A	1029	p16 EXPRESSION	CDKN2A (p16) expression is a surrogate marker of HPV infection in oropharyngeal squamous cell carcinoma. CDKN2A and p53 are inactivated through HPV proteins E6 and E7 and therefore not altered in expression level in HPV-associated carcinomas. However, there is no perfect overlap between p16 expression and HPV status with some 10-12.5% of HPV-negative tumors expressing p16. (Seiwert, T JCO, 2014). p16 positivity is a well-established positive prognostic factor in squamous cell cancer of the head and neck in the primary and, as increasing evidence suggests, recurrent/metastatic disease settings. Predictive information from HPV status have not been established to date. A lack of benefit from EGFR-inhibitors has been proposed by some studies. Other studies were not able to reproduce this finding.		9	21968055	21974865			ENST00000498124.1	75	GRCh37					N/A	
273	https://civic.genome.wustl.edu/#/events/genes/42/summary/variants/273/summary#variant	RET	5979	KIF5B-RET	In a study by Takeuchi et. al. a fusion screen was performed in 1529 lung cancer samples. 14 adenocarcinomas with KIF5B-RET and CCDC6-RET fusions were identified. (Takeuchi K et. al., Nature Medicine 18, 378381 (2012) doi:10.1038/nm.2658)		10	32306071	32345359			ENST00000302418.4	75	GRCh37	10	43609928	43625799	ENST00000355710.3	transcript_fusion	
274	https://civic.genome.wustl.edu/#/events/genes/2747/summary/variants/274/summary#variant	HRAS	3265	G13D			11	534285	534285	C	T	ENST00000451590.1	75	GRCh37					missense_variant	
275	https://civic.genome.wustl.edu/#/events/genes/2747/summary/variants/275/summary#variant	HRAS	3265	MUTATION			11	533873	534289			ENST00000451590.1	75	GRCh37						
276	https://civic.genome.wustl.edu/#/events/genes/11335/summary/variants/276/summary#variant	CD274	29126	EXPRESSION			9	5450525	5470547			ENST00000381577.3	75	GRCh37					N/A	
277	https://civic.genome.wustl.edu/#/events/genes/2073/summary/variants/277/summary#variant	MTOR	2475	MUTATION			1	11166592	11322564			ENST00000361445.4	75	GRCh37					protein_altering_variant	
278	https://civic.genome.wustl.edu/#/events/genes/254/summary/variants/278/summary#variant	AKT2	208	EXPRESSION			19	40736224	40791302			ENST00000392038.2	75	GRCh37					N/A	
279	https://civic.genome.wustl.edu/#/events/genes/3870/summary/variants/279/summary#variant	NF2	4771	K159FS*16			22	30050673	30050675			ENST00000338641.4	75	GRCh37					frameshift_truncation	
281	https://civic.genome.wustl.edu/#/events/genes/12903/summary/variants/281/summary#variant	FBXW7	55294	MUTATION			4	153245446	153332714			ENST00000281708.4	75	GRCh37						
282	https://civic.genome.wustl.edu/#/events/genes/77/summary/variants/282/summary#variant	SMAD4	4089	UNDEREXPRESSION			18	48556583	48611409			ENST00000342988.3	75	GRCh37					N/A	
283	https://civic.genome.wustl.edu/#/events/genes/2073/summary/variants/283/summary#variant	MTOR	2475	H1968Y			1	11188519	11188519	G	A	ENST00000361445.4	75	GRCh37					gain_of_function_variant,missense_variant	ENST00000361445.4:c.5902C>T
284	https://civic.genome.wustl.edu/#/events/genes/2073/summary/variants/284/summary#variant	MTOR	2475	P2213S			1	11184580	11184580	G	A	ENST00000361445.4	75	GRCh37					gain_of_function_variant,missense_variant	
285	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/285/summary#variant	BRAF	673	AGK-BRAF		BRAF Fusions	7	141250989	141255367			ENST00000355413.4	75	GRCh37	7	140434279	140494267	ENST00000288602.6	transcript_fusion	
286	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/286/summary#variant	BRAF	673	PAPSS1-BRAF		BRAF Fusions	4	108603171	108641608			ENST00000265174.4	75	GRCh37	7	140434279	140487384	ENST00000288602.6	gene_fusion,transcript_fusion	
287	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/287/summary#variant	BRAF	673	TRIM24-BRAF		BRAF Fusions	7	138145079	138239711			ENST00000343526.4	75	GRCh37	7	140434279	140487384	ENST00000288602.6	transcript_fusion	
288	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/288/summary#variant	BRAF	673	L597R		Other V600's	7	140453145	140453145	A	C	ENST00000288602.6	75	GRCh37					missense_variant	
289	https://civic.genome.wustl.edu/#/events/genes/1733/summary/variants/289/summary#variant	ERBB3	2065	OVEREXPRESSION			12	56473645	56497289			ENST00000267101.3	75	GRCh37					N/A	
290	https://civic.genome.wustl.edu/#/events/genes/3976/summary/variants/290/summary#variant	NT5E	4907	OVEREXPRESSION			6	86159809	86205496			ENST00000257770.3	75	GRCh37					N/A	
291	https://civic.genome.wustl.edu/#/events/genes/63/summary/variants/291/summary#variant	EZH2	2146	OVEREXPRESSION			7	148504477	148581370			ENST00000320356.2	75	GRCh37					N/A	
292	https://civic.genome.wustl.edu/#/events/genes/3742/summary/variants/292/summary#variant	MYD88	4615	OVEREXPRESSION			3	38179969	38184510			ENST00000417037.2	75	GRCh37					N/A	
294	https://civic.genome.wustl.edu/#/events/genes/37/summary/variants/294/summary#variant	PIK3CA	5290	P471L			3	178928226	178928226	C	T	ENST00000263967.3	75	GRCh37					missense_variant	
295	https://civic.genome.wustl.edu/#/events/genes/42/summary/variants/295/summary#variant	RET	5979	EXPRESSION			10	43572475	43625799			ENST00000355710.3	75	GRCh37					N/A	
296	https://civic.genome.wustl.edu/#/events/genes/4875/summary/variants/296/summary#variant	RIT1	6016	OVEREXPRESSION			1	155870065	155880706			ENST00000368322.3	75	GRCh37					N/A	
297	https://civic.genome.wustl.edu/#/events/genes/4875/summary/variants/297/summary#variant	RIT1	6016	MUTATION			1	155870065	155880706			ENST00000368322.3	75	GRCh37					transcript_variant	
298	https://civic.genome.wustl.edu/#/events/genes/3741/summary/variants/298/summary#variant	MYCN	4613	AMPLIFICATION			2	16080686	16087129			ENST00000281043.3	75	GRCh37					transcript_amplification	
299	https://civic.genome.wustl.edu/#/events/genes/5365/summary/variants/299/summary#variant	SMO	6608	D473H			7	128849189	128849189	G	C	ENST00000249373.3	75	GRCh37					missense_variant	
300	https://civic.genome.wustl.edu/#/events/genes/5365/summary/variants/300/summary#variant	SMO	6608	MUTATION			7	128828713	128853386			ENST00000249373.3	75	GRCh37						
301	https://civic.genome.wustl.edu/#/events/genes/4645/summary/variants/301/summary#variant	PTCH1	5727	MUTATION			9	98205262	98270943			ENST00000331920.6	75	GRCh37						
302	https://civic.genome.wustl.edu/#/events/genes/4645/summary/variants/302/summary#variant	PTCH1	5727	LOH			9	98205262	98270943			ENST00000331920.6	75	GRCh37					loss_of_heterozygosity	
303	https://civic.genome.wustl.edu/#/events/genes/5534/summary/variants/303/summary#variant	STK11	6794	EXON 1-2 MUTATION			19	1205740	1218499			ENST00000326873.7	75	GRCh37					exon_variant	
304	https://civic.genome.wustl.edu/#/events/genes/5534/summary/variants/304/summary#variant	STK11	6794	UNDEREXPRESSION			19	1205740	1228428			ENST00000326873.7	75	GRCh37					N/A	
305	https://civic.genome.wustl.edu/#/events/genes/5572/summary/variants/305/summary#variant	SYK	6850	OVEREXPRESSION			9	93564069	93660831			ENST00000375754.4	75	GRCh37					N/A	
306	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/306/summary#variant	ERBB2	2064	AMPLIFICATION	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.		17	37856333	37884915			ENST00000269571.5	75	GRCh37					transcript_amplification	
307	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/307/summary#variant	ALK	238	EML4-ALK L1152R			2	29445270	29445270	A	C	ENST00000389048.3	75	GRCh37					missense_variant,transcript_fusion	
308	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/308/summary#variant	ALK	238	EML4-ALK G1269A	The EML4-ALK G1269A mutation has been identified in non-small cell lung cancer patients resistant to crizotinib. Cell line data from multiple groups have shown this mutation enhances resistance to crizotinib treatment in vitro.		2	29432682	29432682	C	G	ENST00000389048.3	75	GRCh37					missense_variant,transcript_fusion	
309	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/309/summary#variant	EGFR	1956	AUTOCRINE ACTIVATION			7	55086794	55279321			ENST00000275493.2	75	GRCh37						
310	https://civic.genome.wustl.edu/#/events/genes/1734/summary/variants/310/summary#variant	ERBB4	2066	MUTATION	ERBB4 mutations have been identified in melanoma, lung adenocarcinoma and medulloblastoma. In-vitro studies suggest that melanoma cell lines harboring an ERBB4 mutation are sensitive to ERBB4 inhibition with lapatinib.		2	212295697	212578308			ENST00000342788.4	75	GRCh37					gain_of_function_variant,transcript_variant	
311	https://civic.genome.wustl.edu/#/events/genes/37/summary/variants/311/summary#variant	PIK3CA	5290	MUTATION			3	178866311	178957881			ENST00000263967.3	75	GRCh37					gain_of_function_variant,transcript_variant	
312	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/312/summary#variant	EGFR	1956	VIII	The EGFRvIII variant is an oncogenic mutation that has been reported in several cancers including glioblastoma multiforme, breast, lung, head and neck, ovarian and prostate. In high-grade gliomas, EGFRvIII has been reported in about 30% of cases with EGFR amplification. The EGFRvIII mutation leads to deletion of the receptor ectodomain exons 2-7. The presence of this variant has been linked with clinical response to EGFR TKI. (Arteaga and Engelmann, 2014)		7	55087058	55223523			ENST00000275493.2	75	GRCh37						
313	https://civic.genome.wustl.edu/#/events/genes/41/summary/variants/313/summary#variant	PTEN	5728	EXPRESSION			10	89622870	89731687			ENST00000371953.3	75	GRCh37					N/A	
314	https://civic.genome.wustl.edu/#/events/genes/2593/summary/variants/314/summary#variant	NRG1	3084	EXPRESSION			8	31497942	32622294			ENST00000523534.1	75	GRCh37					N/A	
315	https://civic.genome.wustl.edu/#/events/genes/389/summary/variants/315/summary#variant	AREG	374	EXPRESSION			4	75310851	75320726			ENST00000395748.3	75	GRCh37					N/A	
316	https://civic.genome.wustl.edu/#/events/genes/5742/summary/variants/316/summary#variant	TGFA	7039	EXPRESSION			2	70674412	70781147			ENST00000295400.6	75	GRCh37					N/A	
317	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/317/summary#variant	EGFR	1956	G724S			7	55241722	55241722	G	A	ENST00000275493.2	75	GRCh37					missense_variant	
318	https://civic.genome.wustl.edu/#/events/genes/1737/summary/variants/318/summary#variant	EREG	2069	EXPRESSION			4	75230860	75254468			ENST00000244869.2	75	GRCh37					N/A	
319	https://civic.genome.wustl.edu/#/events/genes/1627/summary/variants/319/summary#variant	EFNA2	1943	EXPRESSION			19	1286153	1301430			ENST00000215368.2	75	GRCh37					N/A	
320	https://civic.genome.wustl.edu/#/events/genes/4532/summary/variants/320/summary#variant	MAPK1	5594	E322K			2	22127164	22127164	C	T	ENST00000215832.6	75	GRCh37					gain_of_function_variant,missense_variant	ENST00000215832.6:c.964G>A
321	https://civic.genome.wustl.edu/#/events/genes/4532/summary/variants/321/summary#variant	MAPK1	5594	AMPLIFICATION			22	22108789	22221919			ENST00000215832.6	75	GRCh37					transcript_amplification	
322	https://civic.genome.wustl.edu/#/events/genes/30/summary/variants/322/summary#variant	KRAS	3845	A146V			12	25378561	25378561	G	A	ENST00000256078.4	75	GRCh37					missense_variant	
323	https://civic.genome.wustl.edu/#/events/genes/52/summary/variants/323/summary#variant	MET	4233	MUTATION			7	116312459	116436396			ENST00000318493.6	75	GRCh37					transcription_variant,gain_of_function_variant	
324	https://civic.genome.wustl.edu/#/events/genes/52/summary/variants/324/summary#variant	MET	4233	EXON 14 SKIPPING MUTATION	Exon 14 mutations have been observed in ~3% of patients with NSCLC (28/933 reported by Awad et al J Clin Onc 2016), confirmed to cause exon skipping when available, and associated with concurrent MET amplification. Responses to the c-MET inhibitor crizotinib have been reported in preclinical models and in individual case reports as well as a small-scale clinical trial (17 patients treated, Drilon et al., 2016 (suppl; abstr 108; ASCO ID 167889-176)). Larger studies are needed but enrollment of patients with MET exon 14 skipping mutation in trials with MET inhibitors or off-label treatment is encouraged (Paik et al., 2015 (suppl; abstr 8021)).		7	116411903	116412043			ENST00000318493.6	75	GRCh37					exon_loss_variant	
325	https://civic.genome.wustl.edu/#/events/genes/23/summary/variants/325/summary#variant	FGFR3	2261	EXPRESSION			4	1795039	1810599			ENST00000440486.2	75	GRCh37					N/A	
326	https://civic.genome.wustl.edu/#/events/genes/9705/summary/variants/326/summary#variant	CBLC	23624	EXPRESSION			19	45281126	45303891			ENST00000270279.3	75	GRCh37					N/A	
327	https://civic.genome.wustl.edu/#/events/genes/4692/summary/variants/327/summary#variant	PTPRD	5789	MUTATION			9	8314246	10033790			ENST00000381196.4	75	GRCh37					loss_of_function_variant,transcript_variant	
328	https://civic.genome.wustl.edu/#/events/genes/1428/summary/variants/328/summary#variant	DEFA1	1667	EXPRESSION			8	6835172	6837602			ENST00000382692.2	75	GRCh37					N/A	
329	https://civic.genome.wustl.edu/#/events/genes/1735/summary/variants/329/summary#variant	ERCC1	2067	EXPRESSION			19	45916692	45926824			ENST00000013807.5	75	GRCh37					N/A	
330	https://civic.genome.wustl.edu/#/events/genes/50/summary/variants/330/summary#variant	NOTCH1	4851	AMPLIFICATION			9	139388896	139440314			ENST00000277541.6	75	GRCh37					transcript_amplification	
331	https://civic.genome.wustl.edu/#/events/genes/6104/summary/variants/331/summary#variant	WEE1	7465	POLYMORPHISM															intron_variant,polymorphic_sequence_variant	
332	https://civic.genome.wustl.edu/#/events/genes/1950/summary/variants/332/summary#variant	FNTB	2342	RS11623866			14	65453063	65453063	G	C	ENST00000246166.2	75	GRCh37					regulatory_region_variant	
333	https://civic.genome.wustl.edu/#/events/genes/8878/summary/variants/333/summary#variant	PTPRT	11122	PROMOTER HYPERMETHYLATION															N/A	
334	https://civic.genome.wustl.edu/#/events/genes/6071/summary/variants/334/summary#variant	VEGFA	7422	UNDEREXPRESSION			6	43738444	43752346			ENST00000372055.4	75	GRCh37					N/A	
335	https://civic.genome.wustl.edu/#/events/genes/1510/summary/variants/335/summary#variant	DNMT1	1786	EXPRESSION			19	10244022	10305811			ENST00000340748.4	75	GRCh37					N/A	
336	https://civic.genome.wustl.edu/#/events/genes/30/summary/variants/336/summary#variant	KRAS	3845	MUTATION			12	25362365	25403737			ENST00000256078.4	75	GRCh37					protein_altering_variant	
337	https://civic.genome.wustl.edu/#/events/genes/10573/summary/variants/337/summary#variant	PDCD4	27250	EXPRESSION	A new study, a retrospective analysis of 77 patients, has implicated PDCD4 expression in the sensitivity to paclitaxel. However, this finding came from a large proteome screen and has not yet been replicated in independent patient sets.		10	112631596	112659763			ENST00000393104.2	75	GRCh37					N/A	
338	https://civic.genome.wustl.edu/#/events/genes/34/summary/variants/338/summary#variant	MGMT	4255	RS16906252			10	131265545	131265545	C	T	ENST00000306010.7	75	GRCh37					synonymous_variant	
339	https://civic.genome.wustl.edu/#/events/genes/5737/summary/variants/339/summary#variant	TFF3	7033	EXPRESSION			21	43731777	43735761			ENST00000518498.1	75	GRCh37					N/A	
340	https://civic.genome.wustl.edu/#/events/genes/9171/summary/variants/340/summary#variant	DKK1	22943	NUCLEAR EXPRESSION			10	54074056	54077417			ENST00000373970.3	75	GRCh37					N/A	
341	https://civic.genome.wustl.edu/#/events/genes/855/summary/variants/341/summary#variant	CD44	960	ISOFORM EXPRESSION			11	35160728	35251574			ENST00000428726.2	75	GRCh37					N/A	
342	https://civic.genome.wustl.edu/#/events/genes/1634/summary/variants/342/summary#variant	EGF	1950	EXPRESSION			4	110834047	110933422			ENST00000265171.5	75	GRCh37					N/A	
343	https://civic.genome.wustl.edu/#/events/genes/3465/summary/variants/343/summary#variant	MDM2	4193	EXPRESSION			12	69201956	69239214			ENST00000462284.1	75	GRCh37					N/A	
344	https://civic.genome.wustl.edu/#/events/genes/2657/summary/variants/344/summary#variant	HMOX1	3162	EXPRESSION			22	35776828	35790207			ENST00000216117.8	75	GRCh37					N/A	
345	https://civic.genome.wustl.edu/#/events/genes/7041/summary/variants/345/summary#variant	SPHK1	8877	OVEREXPRESSION			17	74380731	74383936			ENST00000323374.4	75	GRCh37					N/A	
346	https://civic.genome.wustl.edu/#/events/genes/761/summary/variants/346/summary#variant	CASP8	841	EXPRESSION			2	202122759	202152434			ENST00000358485.4	75	GRCh37					N/A	
347	https://civic.genome.wustl.edu/#/events/genes/5971/summary/variants/347/summary#variant	TYMS	7298	EXPRESSION			18	657604	673578			ENST00000323274.10	75	GRCh37					N/A	
348	https://civic.genome.wustl.edu/#/events/genes/13276/summary/variants/348/summary#variant	PBK	55872	OVEREXPRESSION			8	27667137	27695612			ENST00000301905.4	75	GRCh37					N/A	
349	https://civic.genome.wustl.edu/#/events/genes/78/summary/variants/349/summary#variant	SMARCA4	6597	UNDEREXPRESSION			19	11071598	11172958			ENST00000358026.2	75	GRCh37					N/A	
350	https://civic.genome.wustl.edu/#/events/genes/10024/summary/variants/350/summary#variant	SETBP1	26040	EXON 4 MUTATION			18	42531877	42531918			ENST00000282030.5	75	GRCh37					exon_variant	
351	https://civic.genome.wustl.edu/#/events/genes/10024/summary/variants/351/summary#variant	SETBP1	26040	G870S			18	42531913	42531913	G	A	ENST00000282030.5	75	GRCh37					missense_variant	
352	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/352/summary#variant	ALK	238	EML4-ALK C1156YL1198F	EML4-ALK C1156Y alone is resistant to crizotinib in non-small cell lung cancer (NSCLC) which has been shown to be modulated (both increased sensitivity and resistance) by additional ALK mutations. A case report showed that an NSCLC harboring EML4-ALK C1156YL1198F was resistant to lorlatinib but this second mutation re-sensitized this tumor to crizotinib.		2	29443625	29445258			ENST00000389048.3	75	GRCh37					missense_variant,transcript_fusion	
354	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/354/summary#variant	EGFR	1956	EXPRESSION			7	55086794	55279321			ENST00000275493.2	75	GRCh37					N/A	
355	https://civic.genome.wustl.edu/#/events/genes/913/summary/variants/355/summary#variant	CDKN1A	1026	EXPRESSION			6	36646487	36655108			ENST00000405375.1	75	GRCh37					N/A	
356	https://civic.genome.wustl.edu/#/events/genes/259/summary/variants/356/summary#variant	ALCAM	214	EXPRESSION			3	105085753	105295744			ENST00000306107.5	75	GRCh37					N/A	
357	https://civic.genome.wustl.edu/#/events/genes/3255/summary/variants/357/summary#variant	STMN1	3925	EXPRESSION			1	26211931	26232957			ENST00000426559.2	75	GRCh37					N/A	
358	https://civic.genome.wustl.edu/#/events/genes/12121/summary/variants/358/summary#variant	RSF1	51773	AMPLIFICATION			11	77371041	77532063			ENST00000308488.6	75	GRCh37					transcript_amplification	
359	https://civic.genome.wustl.edu/#/events/genes/67/summary/variants/359/summary#variant	AR	367	OVEREXPRESSION			X	66764465	66950461			ENST00000374690.3	75	GRCh37					N/A	
360	https://civic.genome.wustl.edu/#/events/genes/914/summary/variants/360/summary#variant	CDKN1B	1027	CYTOPLASMIC MISLOCALIZATION			12	12870058	12875305			ENST00000228872.4	75	GRCh37					N/A	
361	https://civic.genome.wustl.edu/#/events/genes/1733/summary/variants/361/summary#variant	ERBB3	2065	EXPRESSION			12	56473645	56497289			ENST00000267101.3	75	GRCh37					N/A	
362	https://civic.genome.wustl.edu/#/events/genes/67/summary/variants/362/summary#variant	AR	367	SPLICE VARIANT 7			X	66764662	66915917			ENST00000504326.1	75	GRCh37						
363	https://civic.genome.wustl.edu/#/events/genes/6023/summary/variants/363/summary#variant	UGT1A	7361	EXPRESSION			2	234526291	234681956			ENST00000373450.4	75	GRCh37					N/A	
364	https://civic.genome.wustl.edu/#/events/genes/1734/summary/variants/364/summary#variant	ERBB4	2066	NUCLEAR TRANSLOCATION			2	212240446	213403565			ENST00000342788.4	75	GRCh37					N/A	
365	https://civic.genome.wustl.edu/#/events/genes/1734/summary/variants/365/summary#variant	ERBB4	2066	EXPRESSION			2	212240446	213403565			ENST00000342788.4	75	GRCh37					N/A	
366	https://civic.genome.wustl.edu/#/events/genes/16872/summary/variants/366/summary#variant	SLFN11	91607	EXPRESSION			17	33677324	33700639			ENST00000394566.1	75	GRCh37					N/A	
367	https://civic.genome.wustl.edu/#/events/genes/4753/summary/variants/367/summary#variant	RAC1	5879	P29S			7	6426892	6426892	C	T	ENST00000356142.4	75	GRCh37					missense_variant	
368	https://civic.genome.wustl.edu/#/events/genes/355/summary/variants/368/summary#variant	BIRC5	332	NUCLEAR EXPRESSION			17	76210267	76221717			ENST00000301633.4	75	GRCh37					N/A	
369	https://civic.genome.wustl.edu/#/events/genes/45/summary/variants/369/summary#variant	TP53	7157	WILD TYPE			17	7571720	7590856			ENST00000269305.4	75	GRCh37					wild_type	
370	https://civic.genome.wustl.edu/#/events/genes/3586/summary/variants/370/summary#variant	MRE11	4361	LOSS			11	94152895	94227074			ENST00000323929.3	75	GRCh37					loss_of_function_variant	
371	https://civic.genome.wustl.edu/#/events/genes/5845/summary/variants/371/summary#variant	TOP1	7150	AMPLIFICATION			20	39657458	39753127			ENST00000361337.2	75	GRCh37					transcript_amplification	
372	https://civic.genome.wustl.edu/#/events/genes/914/summary/variants/372/summary#variant	CDKN1B	1027	EXPRESSION			12	12870058	12875305			ENST00000228872.4	75	GRCh37					N/A	
373	https://civic.genome.wustl.edu/#/events/genes/8407/summary/variants/373/summary#variant	AGR2	10551	EXPRESSION			7	16831435	16844704			ENST00000419304.2	75	GRCh37					N/A	
374	https://civic.genome.wustl.edu/#/events/genes/17016/summary/variants/374/summary#variant	NAPRT	93100	PROMOTER HYPERMETHYLATION															N/A	
375	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/375/summary#variant	EGFR	1956	EXON 18 OVEREXPRESSION			7	55237999	55238735			ENST00000344576.2	75	GRCh37					exon_variant	
376	https://civic.genome.wustl.edu/#/events/genes/5649/summary/variants/376/summary#variant	ZEB1	6935	EXPRESSION			10	31608101	31818741			ENST00000361642.5	75	GRCh37					N/A	
377	https://civic.genome.wustl.edu/#/events/genes/5777/summary/variants/377/summary#variant	TIMP1	7076	OVEREXPRESSION			X	47441712	47446188			ENST00000218388.4	75	GRCh37					N/A	
378	https://civic.genome.wustl.edu/#/events/genes/8908/summary/variants/378/summary#variant	PTP4A3	11156	OVEREXPRESSION			8	142402093	142441394			ENST00000521578.1	75	GRCh37					N/A	
379	https://civic.genome.wustl.edu/#/events/genes/5971/summary/variants/379/summary#variant	TYMS	7298	AMPLIFICATION			18	657604	673578			ENST00000323274.10	75	GRCh37					transcript_amplification	
380	https://civic.genome.wustl.edu/#/events/genes/2899/summary/variants/380/summary#variant	IGF1R	3480	EXPRESSION			15	99192200	99507759			ENST00000268035.6	75	GRCh37					N/A	
381	https://civic.genome.wustl.edu/#/events/genes/1721/summary/variants/381/summary#variant	EPHB4	2050	EXPRESSION			7	100400187	100425121			ENST00000358173.3	75	GRCh37					N/A	
382	https://civic.genome.wustl.edu/#/events/genes/5971/summary/variants/382/summary#variant	TYMS	7298	UNDEREXPRESSION			18	657604	673578			ENST00000323274.10	75	GRCh37					N/A	
383	https://civic.genome.wustl.edu/#/events/genes/5848/summary/variants/383/summary#variant	TOP2A	7153	EXPRESSION			17	38544768	38574202			ENST00000423485.1	75	GRCh37					N/A	
384	https://civic.genome.wustl.edu/#/events/genes/5845/summary/variants/384/summary#variant	TOP1	7150	EXPRESSION			20	39657458	39753127			ENST00000361337.2	75	GRCh37					N/A	
385	https://civic.genome.wustl.edu/#/events/genes/4503/summary/variants/385/summary#variant	PRKAA2	5563	T172 PHOSPHORYLATION			1	57159476	57159478			ENST00000371244.4	75	GRCh37					N/A	
386	https://civic.genome.wustl.edu/#/events/genes/2778/summary/variants/386/summary#variant	HSPA5	3309	EXPRESSION			9	127997132	128003609			ENST00000324460.6	75	GRCh37					N/A	
387	https://civic.genome.wustl.edu/#/events/genes/1655/summary/variants/387/summary#variant	EIF4EBP1	1978	PHOSPHORYLATION			8	37888200	37914663			ENST00000338825.4	75	GRCh37					N/A	
388	https://civic.genome.wustl.edu/#/events/genes/29/summary/variants/388/summary#variant	KIT	3815	MUTATION			4	55524085	55606881			ENST00000288135.5	75	GRCh37					gain_of_function_variant,transcript_variant	
389	https://civic.genome.wustl.edu/#/events/genes/8262/summary/variants/389/summary#variant	TUBB3	10381	EXPRESSION			16	89989687	90002505			ENST00000315491.7	75	GRCh37					N/A	
390	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/390/summary#variant	EGFR	1956	Y1092 PHOSPHORYLATION	Although referred to as Y1068 in the literature, based on the recognition peptide described, this tyrosine occurs at Y1039 (ENST00000454757.2 v75) or Y1092 (ENST00000275493.2 v75).		7	55272951	55272953			ENST00000275493.2	75	GRCh37					N/A	
391	https://civic.genome.wustl.edu/#/events/genes/2899/summary/variants/391/summary#variant	IGF1R	3480	NUCLEAR EXPRESSION			15	99192200	99507759			ENST00000268035.6	75	GRCh37					N/A	
392	https://civic.genome.wustl.edu/#/events/genes/7009/summary/variants/392/summary#variant	CFLAR	8837	EXPRESSION			2	201980827	202041410			ENST00000309955.3	75	GRCh37					N/A	
393	https://civic.genome.wustl.edu/#/events/genes/7014/summary/variants/393/summary#variant	PROM1	8842	EXPRESSION			4	15969857	16085324			ENST00000510224.1	75	GRCh37					N/A	
394	https://civic.genome.wustl.edu/#/events/genes/11587/summary/variants/394/summary#variant	FOXP3	50943	EXPRESSION			X	49106897	49121288			ENST00000376207.4	75	GRCh37					N/A	
395	https://civic.genome.wustl.edu/#/events/genes/5013/summary/variants/395/summary#variant	RPS6	6194	PHOSPHORYLATION			9	19376309	19376323			ENST00000380394.4	75	GRCh37					N/A	
396	https://civic.genome.wustl.edu/#/events/genes/3090/summary/variants/396/summary#variant	JAK1	3716	OVEREXPRESSION			1	65298912	65432187			ENST00000342505.4	75	GRCh37					N/A	
397	https://civic.genome.wustl.edu/#/events/genes/6/summary/variants/397/summary#variant	BRCA1	672	EXPRESSION			17	41196312	41277387			ENST00000357654.3	75	GRCh37					N/A	
398	https://civic.genome.wustl.edu/#/events/genes/1567/summary/variants/398/summary#variant	DUSP6	1848	EXPRESSION			12	89741009	89747048			ENST00000279488.7	75	GRCh37					N/A	
399	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/399/summary#variant	BRAF	673	MUTATION			7	140453136	140481403			ENST00000288602.6	75	GRCh37					gain_of_function_variant,gene_variant	
400	https://civic.genome.wustl.edu/#/events/genes/2784/summary/variants/400/summary#variant	HSPB1	3315	EXPRESSION			7	75931861	75933612			ENST00000248553.6	75	GRCh37					N/A	
401	https://civic.genome.wustl.edu/#/events/genes/1463/summary/variants/401/summary#variant	NQO1	1728	EXPRESSION			16	69743304	69760854			ENST00000320623.5	75	GRCh37					N/A	
402	https://civic.genome.wustl.edu/#/events/genes/1463/summary/variants/402/summary#variant	NQO1	1728	P187S			16	69745145	69745145	G	A	ENST00000320623.5	75	GRCh37					missense_variant	
403	https://civic.genome.wustl.edu/#/events/genes/6/summary/variants/403/summary#variant	BRCA1	672	UNDEREXPRESSION			17	41196312	41277387			ENST00000357654.3	75	GRCh37					N/A	
404	https://civic.genome.wustl.edu/#/events/genes/4244/summary/variants/404/summary#variant	ABCB1	5243	EXPRESSION			7	87133175	87342564			ENST00000265724.3	75	GRCh37					N/A	
405	https://civic.genome.wustl.edu/#/events/genes/6329/summary/variants/405/summary#variant	CXCR4	7852	EXPRESSION			2	136871919	136873813			ENST00000409817.1	75	GRCh37					N/A	
406	https://civic.genome.wustl.edu/#/events/genes/11261/summary/variants/406/summary#variant	MAGEH1	28986	EXPRESSION			X	55478538	55479998			ENST00000342972.1	75	GRCh37					N/A	
407	https://civic.genome.wustl.edu/#/events/genes/6906/summary/variants/407/summary#variant	ABCC3	8714	AMPLIFICATION			17	48712218	48769613			ENST00000285238.8	75	GRCh37					transcript_amplification	
408	https://civic.genome.wustl.edu/#/events/genes/16656/summary/variants/408/summary#variant	ABCC10	89845	EXPRESSION			6	43395292	43418168			ENST00000372530.4	75	GRCh37					N/A	
409	https://civic.genome.wustl.edu/#/events/genes/446/summary/variants/409/summary#variant	ASNS	440	AMPLIFICATION			7	97481430	97501854			ENST00000175506.4	75	GRCh37					transcript_amplification	
410	https://civic.genome.wustl.edu/#/events/genes/927/summary/variants/410/summary#variant	CDX2	1045	EXPRESSION			13	28536274	28545276			ENST00000381020.7	75	GRCh37					N/A	
411	https://civic.genome.wustl.edu/#/events/genes/5516/summary/variants/411/summary#variant	STAT3	6774	SH2 DOMAIN MUTATION			17	40465342	40475372			ENST00000264657.5	75	GRCh37						
412	https://civic.genome.wustl.edu/#/events/genes/4419/summary/variants/412/summary#variant	POU5F1	5460	EXPRESSION			6	31132120	31138470			ENST00000259915.8	75	GRCh37					N/A	
413	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/413/summary#variant	ERBB2	2064	KINASE DOMAIN MUTATION			17	37879863	37882870			ENST00000269571.5	75	GRCh37					protein_altering_variant	
414	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/414/summary#variant	ERBB2	2064	M774INSAYVM	Mutations in the HER2 kinase domain occur at a 2-4% frequency in lung adenocarcinomas, the majority of which are in exon 20 as in-frame duplications or insertions in a small 8 codon region (774-781 or 775-782). These are analogous to the exon 20 alterations found in EGFR TK domain. The M774 insertion, M774insAYVM, represents 62.5% of all HER2 kinase domain mutations identified (when combined with the A775insYVMA mutations as they translate to the identical amino acid sequence changes). As demonstrated in mouse models (Perrera et al., PNAS 2009) and subsequent clinical trials in human lung adenocarcinoma with these insertions, HER2 YVMA mutants predict response to several targeted HER2 agonists such as afatinib, trastuzumab, neratinib and TDM-1 (trastuzumab emtansine) as monotherapy or combined with specific chemotherapies.		17	37880993	37880994		GCTTACGTGATG	ENST00000269571.5	75	GRCh37					inframe_insertion	
415	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/415/summary#variant	EGFR	1956	C797S			7	55249091	55249091	T	A	ENST00000275493.2	75	GRCh37					missense_variant	
416	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/416/summary#variant	ERBB2	2064	SERUM LEVELS			17	37856333	37884915			ENST00000269571.5	75	GRCh37					N/A	
417	https://civic.genome.wustl.edu/#/events/genes/5761/summary/variants/417/summary#variant	THBS2	7058	UNDEREXPRESSION			6	169615875	169654139			ENST00000366787.3	75	GRCh37					N/A	
419	https://civic.genome.wustl.edu/#/events/genes/3983/summary/variants/419/summary#variant	NTRK1	4914	NTRK1 FUSIONS			1	156844175	156851434			ENST00000524377.1	75	GRCh37					transcript_fusion	
420	https://civic.genome.wustl.edu/#/events/genes/26/summary/variants/420/summary#variant	IDH1	3417	R132H	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.		2	209113112	209113112	C	T	ENST00000415913.1	75	GRCh37					missense_variant	
421	https://civic.genome.wustl.edu/#/events/genes/79/summary/variants/421/summary#variant	TERT	7015	RS2736100			5	1286516	1286516	C	A	ENST00000310581.5	75	GRCh37					coding_transcript_intron_variant,polymorphic_sequence_variant	
422	https://civic.genome.wustl.edu/#/events/genes/8553/summary/variants/422/summary#variant	STAG2	10735	UNDEREXPRESSION			X	123095568	123236506			ENST00000371157.3	75	GRCh37					N/A	
423	https://civic.genome.wustl.edu/#/events/genes/2622/summary/variants/423/summary#variant	HLA-DRA	3122	EXPRESSION			6	32407619	32412823			ENST00000395388.2	75	GRCh37					N/A	
424	https://civic.genome.wustl.edu/#/events/genes/3742/summary/variants/424/summary#variant	MYD88	4615	L265P			3	38182641	38182641	T	C	ENST00000396334.3	75	GRCh37					gain_of_function_variant,missense_variant	
425	https://civic.genome.wustl.edu/#/events/genes/30/summary/variants/425/summary#variant	KRAS	3845	G12V			12	25398284	25398284	C	A	ENST00000256078.4	75	GRCh37					missense_variant	
426	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/426/summary#variant	BRAF	673	WILD TYPE			7	140434279	140624564			ENST00000288602.6	75	GRCh37					wild_type	
427	https://civic.genome.wustl.edu/#/events/genes/36/summary/variants/427/summary#variant	NRAS	4893	Q61K			1	115256530	115256530	G	T	ENST00000369535.4	75	GRCh37					missense_variant	
428	https://civic.genome.wustl.edu/#/events/genes/3586/summary/variants/428/summary#variant	MRE11	4361	FRAMESHIFT MUTATION			11	94152895	94227074			ENST00000323929.3	75	GRCh37					frameshift_variant	
429	https://civic.genome.wustl.edu/#/events/genes/29/summary/variants/429/summary#variant	KIT	3815	EXPRESSION			4	55524085	55606881			ENST00000288135.5	75	GRCh37					N/A	
431	https://civic.genome.wustl.edu/#/events/genes/776/summary/variants/431/summary#variant	CBFB	865	CBFB-MYH11	CBFB-MYH11 is the result of inv(16)(p13q22) or t(16;16)(p13;q22) and is sufficient for the diagnosis of acute myeloid leukemia (in the correct setting) according to WHO criteria, even when blast counts are <20% (Vardiman et al, Blood 2008). This fusion is typically associated with favorable prognosis relative to other AML subtypes (including cytogenetically normal); however, the impact of additional mutations in the context of this fusion is incompletely understood. AMLs with this fusion are often grouped with other rearrangements affecting genes encoding core binding factor subunits, referred to as CBF AMLs.		16	67063148	67116211			ENST00000412916.2	75	GRCh37	16	15797029	15820911	ENST00000396324.3	transcript_fusion	
432	https://civic.genome.wustl.edu/#/events/genes/3537/summary/variants/432/summary#variant	KMT2A	4297	MLL-MLLT3															transcript_fusion	
433	https://civic.genome.wustl.edu/#/events/genes/2596/summary/variants/433/summary#variant	HIF1A	3091	3' UTR Polymorphism			14	62213848	62213848	T	C	ENST00000394997.1	75	GRCh37					3_prime_UTR_variant,SNP	
434	https://civic.genome.wustl.edu/#/events/genes/2596/summary/variants/434/summary#variant	HIF1A	3091	OVEREXPRESSION			14	62162258	62214976			ENST00000394997.1	75	GRCh37					N/A	
435	https://civic.genome.wustl.edu/#/events/genes/1705/summary/variants/435/summary#variant	EPAS1	2034	OVEREXPRESSION			2	46524541	46613836			ENST00000263734.3	75	GRCh37					N/A	
436	https://civic.genome.wustl.edu/#/events/genes/58/summary/variants/436/summary#variant	VHL	7428	LOSS			3	10182692	10193904			ENST00000256474.2	75	GRCh37					loss_of_function_variant	
437	https://civic.genome.wustl.edu/#/events/genes/24/summary/variants/437/summary#variant	FLT3	2322	D835			13	28592642	28592642	C	A	ENST00000241453.7	75	GRCh37					protein_altering_variant	
438	https://civic.genome.wustl.edu/#/events/genes/4616/summary/variants/438/summary#variant	PSMB8	5696	NUCLEAR EXPRESSION			6	32808494	32812480			ENST00000374881.2	75	GRCh37					N/A	
439	https://civic.genome.wustl.edu/#/events/genes/13276/summary/variants/439/summary#variant	PBK	55872	NUCLEAR EXPRESSION			8	27667137	27695612			ENST00000301905.4	75	GRCh37					N/A	
440	https://civic.genome.wustl.edu/#/events/genes/7297/summary/variants/440/summary#variant	PTTG1	9232	OVEREXPRESSION			5	159848829	159855748			ENST00000352433.5	75	GRCh37					N/A	
441	https://civic.genome.wustl.edu/#/events/genes/3274/summary/variants/441/summary#variant	LEPR	3953	UNDEREXPRESSION			1	65886335	66107242			ENST00000349533.6	75	GRCh37					N/A	
442	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/442/summary#variant	EGFR	1956	MUTATION			7	55086794	55279321			ENST00000275493.2	75	GRCh37					inframe_variant	
443	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/443/summary#variant	EGFR	1956	G465R			7	55227926	55227926	G	A	ENST00000275493.2	75	GRCh37					missense_variant	
444	https://civic.genome.wustl.edu/#/events/genes/3852/summary/variants/444/summary#variant	NEDD9	4739	EXPRESSION			6	11185051	11382581			ENST00000504387.1	75	GRCh37					N/A	
445	https://civic.genome.wustl.edu/#/events/genes/1763/summary/variants/445/summary#variant	ETS2	2114	RS461155			21	40191638	40191638	A	G	ENST00000360214.3	75	GRCh37					synonymous_variant	
446	https://civic.genome.wustl.edu/#/events/genes/3215/summary/variants/446/summary#variant	KRT18	3875	UNDEREXPRESSION			12	53342655	53346684			ENST00000388837.2	75	GRCh37					N/A	
447	https://civic.genome.wustl.edu/#/events/genes/1883/summary/variants/447/summary#variant	FGF13	2258	CYTOPLASMIC EXPRESSION			X	137715011	138286269			ENST00000370603.3	75	GRCh37					N/A	
448	https://civic.genome.wustl.edu/#/events/genes/5500/summary/variants/448/summary#variant	SSX1	6756	SS18-SSX1		SYT-SSX fusions													transcript_fusion	
449	https://civic.genome.wustl.edu/#/events/genes/5501/summary/variants/449/summary#variant	SSX2	6757	SS18-SSX2		SYT-SSX fusions													transcript_fusion	
450	https://civic.genome.wustl.edu/#/events/genes/5503/summary/variants/450/summary#variant	SSX4	6759	SS18-SSX4		SYT-SSX fusions	18	23612363	23670589			ENST00000415083.2	75	GRCh37	X	48261524	48265521	ENST00000376884.2	transcript_fusion	
451	https://civic.genome.wustl.edu/#/events/genes/4244/summary/variants/451/summary#variant	ABCB1	5243	S893A/T	Refer to  https://www.pharmgkb.org/rsid/rs2032582  for more information.		7	87160618	87160618	A	C	ENST00000265724.3	75	GRCh37					missense_variant	
453	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/453/summary#variant	EGFR	1956	S492R			7	55228009	55228009	C	A	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.1476C>A
454	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/454/summary#variant	EGFR	1956	R451C			7	55227884	55227884	C	T	ENST00000275493.2	75	GRCh37					missense_variant	
455	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/455/summary#variant	EGFR	1956	K467T			7	55227933	55227933	A	C	ENST00000275493.2	75	GRCh37					missense_variant	
456	https://civic.genome.wustl.edu/#/events/genes/1842/summary/variants/456/summary#variant	FCGR2A	2212	H167R			1	161479745	161479745	A	G	ENST00000271450.6	75	GRCh37					missense_variant	
457	https://civic.genome.wustl.edu/#/events/genes/1844/summary/variants/457/summary#variant	FCGR3A	2214	F212V			1	161514542	161514542	A	C	ENST00000367969.3	75	GRCh37					missense_variant	
458	https://civic.genome.wustl.edu/#/events/genes/1843/summary/variants/458/summary#variant	FCGR2B	2213	I232T			1	161643798	161643798	T	C	ENST00000358671.5	75	GRCh37					missense_variant	
460	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/460/summary#variant	EGFR	1956	P753S			7	55242487	55242487	C	T	ENST00000275493.2	75	GRCh37					missense_variant	
461	https://civic.genome.wustl.edu/#/events/genes/39/summary/variants/461/summary#variant	PML	5371	B2 DOMAIN MUTATION	The B2 domain in PML is the binding site for ATRA. Point mutations in this region have been associated with ATRA resistance in patients with APL.	PML-RARa B2 Domain	15	74315213	74315219			ENST00000268058.3	75	GRCh37					missense_variant	
462	https://civic.genome.wustl.edu/#/events/genes/39/summary/variants/462/summary#variant	PML	5371	PML-RARA A216V	A216V in the B2 domain of PML is one of the variants found in a patient with ATRA-resistant APL.	PML-RARa B2 Domain	15	74315213	74315213	C	T	ENST00000268058.3	75	GRCh37					missense_variant	
463	https://civic.genome.wustl.edu/#/events/genes/39/summary/variants/463/summary#variant	PML	5371	PML-RARA L218P	L218P in the B2 domain of PML is one of the variants found in a patient with ATRA-resistant APL.	PML-RARa B2 Domain	15	74315219	74315219	T	C	ENST00000268058.3	75	GRCh37					missense_variant	
464	https://civic.genome.wustl.edu/#/events/genes/52/summary/variants/464/summary#variant	MET	4233	EXON 14 MUTATION + AMPLIFICATION			7	116312459	116436396			ENST00000318493.6	75	GRCh37					exon_loss_variant,transcript_amplification	
465	https://civic.genome.wustl.edu/#/events/genes/4941/summary/variants/465/summary#variant	ROS1	6098	CD74-ROS1 G2032R	The G2032R missense mutation has been observed in patients with crizotinib-resistant non-small cell lung cancer harboring CD74-ROS1 rearrangement. Independent in vitro studies have confirmed that this mutation confers marked resistance to crizotinib cells over CD74-ROS1 alone. Multiple groups have indicated CD74-ROS1 G2032R expressing cell lines are sensitive to both cabozantinib and foretinib individually administered in vitro. One group additionally showed this mutation conferred relative resistance to alectinib, brigatinib, ceritinib, and AZD3463 in vitro.		6	117638347	117638347	C	T	ENST00000368508.3	75	GRCh37					missense_variant,transcript_fusion	
466	https://civic.genome.wustl.edu/#/events/genes/1885/summary/variants/466/summary#variant	FGFR1	2260	ZNF198-FGFR1															transcript_fusion	
467	https://civic.genome.wustl.edu/#/events/genes/3153/summary/variants/467/summary#variant	KDR	3791	A1065T			4	55955969	55955969	C	T	ENST00000263923.4	75	GRCh37					missense_variant	
468	https://civic.genome.wustl.edu/#/events/genes/3153/summary/variants/468/summary#variant	KDR	3791	D717V			4	55968180	55968180	T	A	ENST00000263923.4	75	GRCh37					missense_variant	
469	https://civic.genome.wustl.edu/#/events/genes/47/summary/variants/469/summary#variant	TSC2	7249	Q1178*			16	2130300	2130300	C	T	ENST00000219476.3	75	GRCh37					stop_gained	
470	https://civic.genome.wustl.edu/#/events/genes/2073/summary/variants/470/summary#variant	MTOR	2475	F2108L			1	11187094	11187094	G	T	ENST00000361445.4	75	GRCh37					missense_variant	
471	https://civic.genome.wustl.edu/#/events/genes/4765/summary/variants/471/summary#variant	RAD51D	5892	R186*			17	33433425	33433425	G	A	ENST00000345365.6	75	GRCh37					stop_gained	
472	https://civic.genome.wustl.edu/#/events/genes/7024/summary/variants/472/summary#variant	ALDH1A2	8854	EXPRESSION			15	58245622	58358616			ENST00000249750.4	75	GRCh37					N/A	
473	https://civic.genome.wustl.edu/#/events/genes/7024/summary/variants/473/summary#variant	ALDH1A2	8854	UNDEREXPRESSION			15	58245622	58358616			ENST00000249750.4	75	GRCh37					N/A	
474	https://civic.genome.wustl.edu/#/events/genes/13948/summary/variants/474/summary#variant	KIAA1524	57650	EXPRESSION			3	108268716	108308299			ENST00000295746.8	75	GRCh37					N/A	
475	https://civic.genome.wustl.edu/#/events/genes/13948/summary/variants/475/summary#variant	KIAA1524	57650	UNDEREXPRESSION			3	108268716	108308299			ENST00000295746.8	75	GRCh37					N/A	
476	https://civic.genome.wustl.edu/#/events/genes/24938/summary/variants/476/summary#variant	MIR218-1	407000	EXPRESSION			4	20529898	20530007			ENST00000384999.1	75	GRCh37					N/A	
477	https://civic.genome.wustl.edu/#/events/genes/6/summary/variants/477/summary#variant	BRCA1	672	P968FS			17	41244645	41244646		GA	ENST00000471181.2	75	GRCh37					frameshift_truncation	
479	https://civic.genome.wustl.edu/#/events/genes/30/summary/variants/479/summary#variant	KRAS	3845	Q22*			12	25398255	25398255	G	A	ENST00000256078.4	75	GRCh37					stop_gained	
480	https://civic.genome.wustl.edu/#/events/genes/18/summary/variants/480/summary#variant	DNMT3A	1788	P904L			2	25457176	25457176	G	A	ENST00000264709.3	75	GRCh37					missense_variant	
481	https://civic.genome.wustl.edu/#/events/genes/13005/summary/variants/481/summary#variant	DDX43	55510	OVEREXPRESSION			6	74104471	74127292			ENST00000370336.4	75	GRCh37					N/A	
482	https://civic.genome.wustl.edu/#/events/genes/29/summary/variants/482/summary#variant	KIT	3815	RS3733542			4	55602765	55602765	G	C	ENST00000288135.5	75	GRCh37					synonymous_variant	NM_000222.2:c.2586G>C,NP_000213.1:p.Leu862=,ENST00000288135.5:c.2586G>C
483	https://civic.genome.wustl.edu/#/events/genes/11322/summary/variants/483/summary#variant	TBK1	29110	OVEREXPRESSION			12	64845660	64895888			ENST00000331710.5	75	GRCh37					N/A	
485	https://civic.genome.wustl.edu/#/events/genes/5534/summary/variants/485/summary#variant	STK11	6794	LOSS			19	1205740	1228428			ENST00000326873.7	75	GRCh37					loss_of_function_variant	
486	https://civic.genome.wustl.edu/#/events/genes/16394/summary/variants/486/summary#variant	HAVCR2	84868	OVEREXPRESSION			5	156512843	156536725			ENST00000307851.4	75	GRCh37					N/A	
487	https://civic.genome.wustl.edu/#/events/genes/3549/summary/variants/487/summary#variant	MMP2	4313	SERUM LEVELS			16	55512883	55540603			ENST00000219070.4	75	GRCh37					N/A	
488	https://civic.genome.wustl.edu/#/events/genes/3553/summary/variants/488/summary#variant	MMP9	4318	SERUM LEVELS			20	44637547	44645200			ENST00000372330.3	75	GRCh37					N/A	
490	https://civic.genome.wustl.edu/#/events/genes/8614/summary/variants/490/summary#variant	HSPH1	10808	NUCLEAR EXPRESSION			13	31710765	31736064			ENST00000320027.5	75	GRCh37					N/A	
491	https://civic.genome.wustl.edu/#/events/genes/8614/summary/variants/491/summary#variant	HSPH1	10808	T17 DELETION			13	31722621	31722637			ENST00000320027.5	75	GRCh37					short_tandem_repeat_variation	
492	https://civic.genome.wustl.edu/#/events/genes/26599/summary/variants/492/summary#variant	ECSCR	641700	EXPRESSION															N/A	
493	https://civic.genome.wustl.edu/#/events/genes/12367/summary/variants/493/summary#variant	ROBO4	54538	EXPRESSION			11	124753587	124768177			ENST00000306534.3	75	GRCh37					N/A	
494	https://civic.genome.wustl.edu/#/events/genes/4286/summary/variants/494/summary#variant	PIM1	5292	NUCLEAR EXPRESSION			6	37137979	37143202			ENST00000373509.5	75	GRCh37					N/A	
495	https://civic.genome.wustl.edu/#/events/genes/3465/summary/variants/495/summary#variant	MDM2	4193	SNP309			12	69202580	69202580	T	G	ENST00000462284.1	75	GRCh37					coding_transcript_intron_variant	
496	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/496/summary#variant	ERBB2	2064	L866M	This mutation was shown to be an activating mutation and conferred sensitivity to a combination of trastuzumab with neratinib or lapatinib in colorectal cancer patient-derived xenografts.		17	37881404	37881404	C	A	ENST00000269571.5	75	GRCh37					missense_variant	
497	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/497/summary#variant	ERBB2	2064	S310F/Y	ERBB2 S310F/Y was one of the first ERBB2 variants to be functionally classified (Greulich et al. 2012). This mutation was shown to be an activating mutation (through hyperphosphorylation) in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in murine Ba/F3 cells have been shown to be sensitive to the ERBB2 inhibitors (afatinib, lapatinib and neratinib). More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.		17	37868208	37868208	C	T	ENST00000269571.5	75	GRCh37					missense_variant	ENST00000269571.5:c.929C>T
498	https://civic.genome.wustl.edu/#/events/genes/24938/summary/variants/498/summary#variant	MIR218-1	407000	UNDEREXPRESSION			4	20529898	20530007			ENST00000384999.1	75	GRCh37					N/A	
499	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/499/summary#variant	ALK	238	ALK FUSIONS	Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer.   In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response.   Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib  a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.     ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.	ALK Fusions	2	29415640	29446394			ENST00000389048.3	75	GRCh37					transcript_fusion	
500	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/500/summary#variant	ALK	238	EML4-ALK E20;A20	EML4-ALK variant 2 consists of a fusion of the ALK kinase domain (exons 20-29) with EML4 exons 1-20. Variant 2 has cytoplasmic distribution and makes up ~10% of EML4-ALK fusions found in NSCLC,. Although the specific variant is not consistently reported, single cases demonstrating response to crizotinib treatment in NSCLC and a differentiated malignant neoplasm of unknown origin have been reported. In vitro, this variant has shown greater sensitivity to ALK inhibition with TAE684 and crizotinib than the EML4-ALK variants 1 (E13;A20), 3a (E6;A20) and 3b (E6ins33;A20). The variant was reported to be less stable in cells than other variants, and may be a client protein of Hsp90. Along these lines the variant has shown preclinical sensitivity to Hsp90 inhibition.	ALK Fusions	2	42396490	42552694			ENST00000318522.5	75	GRCh37	2	29415640	29446394	ENST00000389048.3	transcript_fusion	
501	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/501/summary#variant	ALK	238	EML4-ALK E2;A20		ALK Fusions	2	42396490	42472827			ENST00000318522.5	75	GRCh37	2	29415640	29446394	ENST00000389048.3	transcript_fusion	
502	https://civic.genome.wustl.edu/#/events/genes/3153/summary/variants/502/summary#variant	KDR	3791	R961W			4	55961059	55961059	G	A	ENST00000263923.4	75	GRCh37					missense_variant	
503	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/503/summary#variant	ALK	238	EML4-ALK E6;A20	The EML4-ALK variant 3a consists of the ALK kinase domain fused to EML4 exons 1-6, while the 3b variant has an additional 33bp of intronic EML4 sequence between EML4 and ALK regions. The two variants were found to originate from a single genomic rearrangement, and 3a/3b is found in ~ 30% of EML4-ALK positive NSCLC. Variant 3a has cytoplasmic and nuclear distribution. In vitro, these variants have shown sensitivity to ALK inhibitors TAE684 and crizotinib but less sensitive than other EML4-ALK variants. The H2228 cell line contains 3a and 3b variants and is described as having cyctostatic response to ALK inhibition as opposed to apoptotic. In a study of 31 NSCLC patients with EML4-ALK rearrangements, 4/5 patients with the 3a variant showed a partial response while 1 showed progressive disease (the only PD observed). In cells the 3a variant was reported to be more stable than other variants, less sensitive to crizotinib and not to respond to Hsp90 inhibition.	ALK Fusions	2	42396490	42491871			ENST00000318522.5	75	GRCh37	2	29415640	29446394	ENST00000389048.3	transcript_fusion	
504	https://civic.genome.wustl.edu/#/events/genes/45/summary/variants/504/summary#variant	TP53	7157	P47S			17	7579548	7579548	G	A	ENST00000269305.4	75	GRCh37					missense_variant	
505	https://civic.genome.wustl.edu/#/events/genes/2317/summary/variants/505/summary#variant	GNAQ	2776	MUTATION			9	80331003	80646374			ENST00000286548.4	75	GRCh37						
506	https://civic.genome.wustl.edu/#/events/genes/2308/summary/variants/506/summary#variant	GNA11	2767	MUTATION			19	3094408	3124002			ENST00000078429.4	75	GRCh37						
507	https://civic.genome.wustl.edu/#/events/genes/2317/summary/variants/507/summary#variant	GNAQ	2776	Q209			9	80409487	80409489			ENST00000286548.4	75	GRCh37					protein_altering_variant	
508	https://civic.genome.wustl.edu/#/events/genes/4371/summary/variants/508/summary#variant	PMS2	5395	K706FS*19			7	6022512	6022512	T		ENST00000265849.7	75	GRCh37					minus_1_frameshift_variant	NM_000535.6:c.2117delA,NP_000526.2:p.Lys706Serfs
509	https://civic.genome.wustl.edu/#/events/genes/29/summary/variants/509/summary#variant	KIT	3815	EXON 9 MUTATION	In patients with gastrointestinal stromal tumors (GIST), imatinib has improved outcomes for patients with KIT mutations. However, acquired resistance to imatinib is common. Patients harboring exon 9 KIT mutations may benefit from higher imatinib doses (800mg/daily). Similarly, imatinib-refractory tumors showed sensitivity to sunitinib treatment. Improved responses to either treatment were not observed in patients with exon 11 mutations.		4	55592023	55592216			ENST00000288135.5	75	GRCh37					exon_variant	
510	https://civic.genome.wustl.edu/#/events/genes/41/summary/variants/510/summary#variant	PTEN	5728	MUTATION			10	89622870	89731687			ENST00000371953.3	75	GRCh37					protein_altering_variant	
511	https://civic.genome.wustl.edu/#/events/genes/22/summary/variants/511/summary#variant	FGFR2	2263	MUTATION			10	123239371	123357917			ENST00000457416.2	75	GRCh37					gain_of_function_variant,transcript_variant	
512	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/512/summary#variant	ALK	238	MUTATION			2	29415640	30144432			ENST00000389048.3	75	GRCh37					gain_of_function_variant,gene_variant	
513	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/513/summary#variant	ALK	238	NPM-ALK		ALK Fusions	5	170814120	170818803			ENST00000517671.1	75	GRCh37	2	29415640	29446394	ENST00000389048.3	transcript_fusion	
514	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/514/summary#variant	ALK	238	RANBP2-ALK		ALK Fusions	2	109335937	109375004			ENST00000283195.6	75	GRCh37	2	29415640	29446394	ENST00000389048.3	transcript_fusion	
515	https://civic.genome.wustl.edu/#/events/genes/1885/summary/variants/515/summary#variant	FGFR1	2260	N546K			8	38274849	38274849	G	T	ENST00000341462.5	75	GRCh37					missense_variant	
516	https://civic.genome.wustl.edu/#/events/genes/4941/summary/variants/516/summary#variant	ROS1	6098	CD74-ROS1 L2026M	The L2026M mutation is considered a gatekeeper mutation located in the inhibitor binding pocket of ROS1 and corresponding to L1196M in ALK and T790M in EGFR. This mutation has not been reportedly observed in a patient but inferred as a variant likely to emerge in crizotinib-resistant tumors. In vitro kinase activity, structural predictions and growth inhibition assays indicate the L2026M mutation in the CD74-ROS1 fusion provides crizotinib resistance. Additional preclinical assays have indicated that crizotinib resistant cells harboring this mutation are sensitive to PF-06463922 and foretinib.		6	117638365	117638365	G	T	ENST00000368508.3	75	GRCh37					missense_variant,transcript_fusion	
517	https://civic.genome.wustl.edu/#/events/genes/4941/summary/variants/517/summary#variant	ROS1	6098	CD74-ROS1 L2155S			6	117630062	117630062	A	G	ENST00000368508.3	75	GRCh37					missense_variant,transcript_fusion	
518	https://civic.genome.wustl.edu/#/events/genes/4941/summary/variants/518/summary#variant	ROS1	6098	CD74-ROS1 G2101A			6	117631376	117631376	C	G	ENST00000368508.3	75	GRCh37					missense_variant,transcript_fusion	
519	https://civic.genome.wustl.edu/#/events/genes/24/summary/variants/519/summary#variant	FLT3	2322	MUTATION			13	28577411	28674729			ENST00000241453.7	75	GRCh37					gain_of_function_variant,transcript_variant	
520	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/520/summary#variant	ALK	238	CLTC-ALK	The t(2;17)(p23;q23) translocation results in the CLTC-ALK fusion protein, the most common ALK fusion observed in diffuse large B cell lymphoma (DLBCL). ALK-rearranged DLBCL is less responsive to CHOP chemotherapy. Preclinical work indicates that CLTC-ALK DLBCL is responsive to ALK inhibition in cell lines and mouse models, and two case studies show short response followed by progression when heavily pretreated and advanced ALK-positive DLBCL is treated with crizotinib (one case CLTC-ALK, one case an unknown ALK fusion).	ALK Fusions	17	57697219	57768072			ENST00000269122.3	75	GRCh37	2	29415640	29446394	ENST00000389048.3	transcript_fusion	
521	https://civic.genome.wustl.edu/#/events/genes/48/summary/variants/521/summary#variant	U2AF1	7307	MUTATION			21	44513066	44527697			ENST00000291552.4	75	GRCh37					protein_altering_variant	
522	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/522/summary#variant	BRAF	673	DEL 485-490			7	140477838	140477855			ENST00000288602.6	75	GRCh37					inframe_deletion	
524	https://civic.genome.wustl.edu/#/events/genes/34321/summary/variants/524/summary#variant	DUX4	100288687	DUX4 FUSIONS															transcript_fusion	
525	https://civic.genome.wustl.edu/#/events/genes/2239/summary/variants/525/summary#variant	B4GALT1	2683	EXPRESSION			9	33110635	33167354			ENST00000379731.4	75	GRCh37					N/A	
526	https://civic.genome.wustl.edu/#/events/genes/7953/summary/variants/526/summary#variant	BCL2L11	10018	DELETION POLYMORPHISM			2	111883195	111886097			ENST00000393256.3	75	GRCh37					polymorphic_sequence_variant	
527	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/527/summary#variant	ALK	238	ALK FUSION I1171	Multiple case reports indicate that the I1171T missense mutation in ALK-rearranged non-small cell lung cancer (NSCLC) confers resistance to crizotinib and alectinib but is sensitive to ceritinib treatment. These results have been validated in vitro. In vitro evidence indicates this mutation interferes with alectinib binding the active site of ALK and may explain the sensitivity to the structurally distinct ALK inhibitor ceritinib.		2	29445213	29445213	A	G	ENST00000389048.3	75	GRCh37					missense_variant,transcript_fusion	
528	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/528/summary#variant	ALK	238	EML4-ALK  V1180L	The V1180L missense mutation was identified in a mutagenesis screen to find mutations that conferred resistance to alectinib in a non-small cell lung cancer cell line. This mutation shows resistance to crizotinib and alectinib but sensitivity to TAE684, ceritinib and more mild sensitivity to brigatinib. Similar to I1171T, it resides in the ATP pocket of ALK and likely interferes with alectinib and crizotinib binding as a mechanism of resistance.		2	29443679	29443679	C	G	ENST00000389048.3	75	GRCh37					missense_variant,transcript_fusion	
529	https://civic.genome.wustl.edu/#/events/genes/9538/summary/variants/529/summary#variant	SIRT1	23411	OVEREXPRESSION			10	69644427	69678147			ENST00000212015.6	75	GRCh37					N/A	
530	https://civic.genome.wustl.edu/#/events/genes/30/summary/variants/530/summary#variant	KRAS	3845	G12R			12	25398285	25398285	C	G	ENST00000256078.4	75	GRCh37					missense_variant	
531	https://civic.genome.wustl.edu/#/events/genes/45/summary/variants/531/summary#variant	TP53	7157	P72R	This polymorphism is relatively widely studied across cancer types, but meta-analyses in breast, lung and cervical cancer cohorts have so far been inconclusive as to the significance of a patient's genotype at this locus as it relates to cancer susceptibility and prognosis.		17	7579472	7579472	G	C	ENST00000269305.4	75	GRCh37					missense_variant	
532	https://civic.genome.wustl.edu/#/events/genes/15013/summary/variants/532/summary#variant	PALB2	79728	BIALLELIC INACTIVATION			16	23614491	23652631			ENST00000261584.4	75	GRCh37					loss_of_function_variant	
533	https://civic.genome.wustl.edu/#/events/genes/77/summary/variants/533/summary#variant	SMAD4	4089	EXPRESSION			18	48556583	48611409			ENST00000342988.3	75	GRCh37					N/A	
534	https://civic.genome.wustl.edu/#/events/genes/1811/summary/variants/534/summary#variant	FANCC	2176	LOSS-OF-FUNCTION			9	97861336	98079984			ENST00000289081.3	75	GRCh37					loss_of_function_variant	
535	https://civic.genome.wustl.edu/#/events/genes/4176/summary/variants/535/summary#variant	PDGFRB	5159	EBF1-PDGFRB	EBF1-PDGFRB fusions are associated with Ph-like acute lymphoblastic leukemia lacking the BCR-ABL fusion. Case reports have shown positive responses to imatinib treatment.														transcript_fusion	
536	https://civic.genome.wustl.edu/#/events/genes/5525/summary/variants/536/summary#variant	SULT1E1	6783	SNP																
537	https://civic.genome.wustl.edu/#/events/genes/4795/summary/variants/537/summary#variant	RB1	5925	EXPRESSION			13	48877911	49056122			ENST00000267163.4	75	GRCh37					N/A	
538	https://civic.genome.wustl.edu/#/events/genes/3532/summary/variants/538/summary#variant	MLH1	4292	METHYLATION															N/A	
539	https://civic.genome.wustl.edu/#/events/genes/4685/summary/variants/539/summary#variant	PTPN11	5781	EXPRESSION			12	112856718	112947717			ENST00000351677.2	75	GRCh37					N/A	
540	https://civic.genome.wustl.edu/#/events/genes/24/summary/variants/540/summary#variant	FLT3	2322	T227M	FLT3 T227M (rs1933437) is a common polymorphism with a GMAF around .60 based on the Exome Aggregation Consortium (ExAC) data. Its role in cancer predisposition is still unknown, however it may be associated with the development of leukopenia in patients treated with sunitinib.		13	28624294	28624294	G	A	ENST00000241453.7	75	GRCh37					missense_variant,SNP	
541	https://civic.genome.wustl.edu/#/events/genes/15013/summary/variants/541/summary#variant	PALB2	79728	L531FS*30			16	23646276	23646276	A		ENST00000261584.4	75	GRCh37					minus_1_frameshift_variant,SNP	
542	https://civic.genome.wustl.edu/#/events/genes/2073/summary/variants/542/summary#variant	MTOR	2475	S2215Y			1	11184573	11184573	G	T	ENST00000361445.4	75	GRCh37					missense_variant	
543	https://civic.genome.wustl.edu/#/events/genes/2073/summary/variants/543/summary#variant	MTOR	2475	C1483Y			1	11217230	11217230	C	T	ENST00000361445.4	75	GRCh37					missense_variant	
544	https://civic.genome.wustl.edu/#/events/genes/2073/summary/variants/544/summary#variant	MTOR	2475	E1799K			1	11190804	11190804	C	T	ENST00000361445.4	75	GRCh37					missense_variant	
545	https://civic.genome.wustl.edu/#/events/genes/22/summary/variants/545/summary#variant	FGFR2	2263	N550K			10	123258034	123258034	A	T	ENST00000457416.2	75	GRCh37					gain_of_function_variant,missense_variant	
546	https://civic.genome.wustl.edu/#/events/genes/128/summary/variants/546/summary#variant	ACTA1	58	EXPRESSION			1	229566992	229569841			ENST00000366684.3	75	GRCh37					N/A	
547	https://civic.genome.wustl.edu/#/events/genes/4795/summary/variants/547/summary#variant	RB1	5925	OVEREXPRESSION			13	48877911	49056122			ENST00000267163.4	75	GRCh37					N/A	
548	https://civic.genome.wustl.edu/#/events/genes/9722/summary/variants/548/summary#variant	PPP1R15A	23645	RS557806			19	49377242	49377242	G	C	ENST00000200453.5	75	GRCh37					missense_variant,polymorphic_sequence_variant	
549	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/549/summary#variant	ALK	238	F1245C			2	29436859	29436859	A	C	ENST00000389048.3	75	GRCh37					missense_variant	
550	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/550/summary#variant	ALK	238	DEL4-11			2	29497965	29754982			ENST00000389048.3	75	GRCh37					inframe_deletion	
551	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/551/summary#variant	ALK	238	ALK FUSION F1245C	In neuroblastoma, F1245 is one of three hotspot ALK mutations found at a high frequency. In a case study, a pretreated non-small cell lung cancer (NSCLC) patient with EML4-ALK F1245C mutation responded well to ceritinib after slow disease progression during crizotinib treatment. Crizotinib resistance was attributed to the F1245C mutation, although the ALK-rearrangement was not sequenced prior to crizotinib treatment. The patient's slow onset of disease progression during crizotinib treatment mirrors preclinical findings that indicate ALK-fusion with F1245C has moderate resistance to crizotinib compared to the fusion alone.		2	29436859	29436859	A	C	ENST00000389048.3	75	GRCh37					missense_variant,transcript_fusion	
552	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/552/summary#variant	ALK	238	ALK FUSION G1269A			2	29432682	29432682	C	G	ENST00000389048.3	75	GRCh37					missense_variant,transcript_fusion	
553	https://civic.genome.wustl.edu/#/events/genes/13/summary/variants/553/summary#variant	CDK4	1019	AMPLIFICATION			12	58141510	58146304			ENST00000257904.6	75	GRCh37					transcript_amplification	
554	https://civic.genome.wustl.edu/#/events/genes/14/summary/variants/554/summary#variant	CDKN2A	1029	LOSS			9	21967752	21994623			ENST00000579755.1	75	GRCh37					loss_of_function_variant	
555	https://civic.genome.wustl.edu/#/events/genes/916/summary/variants/555/summary#variant	CDKN2B	1030	LOSS			9	22002902	22009362			ENST00000276925.6	75	GRCh37					transcript_ablation	
556	https://civic.genome.wustl.edu/#/events/genes/13/summary/variants/556/summary#variant	CDK4	1019	R24C			12	58145431	58145431	G	A	ENST00000257904.6	75	GRCh37					missense_variant	
557	https://civic.genome.wustl.edu/#/events/genes/68/summary/variants/557/summary#variant	ASXL1	171023	EXON 12 MUTATION			20	31021087	31021720			ENST00000375687.4	75	GRCh37					exon_variant	
558	https://civic.genome.wustl.edu/#/events/genes/2308/summary/variants/558/summary#variant	GNA11	2767	Q209			19	3118942	3118942			ENST00000078429.4	75	GRCh37					missense_variant	
559	https://civic.genome.wustl.edu/#/events/genes/732/summary/variants/559/summary#variant	CALR	811	EXON 9 FRAMESHIFT	Exon 9 insertions and deletions have become part of the WHO diagnostic criteria for essential thrombocythemia (ET) and primary myelofibrosis (PMF) (Arber et al, 2016). These mutations are typically heterozygous and in the absence of JAK2 and MPL mutations. Approximately 80% of observed mutations are type 1 (p.L367fs*46), the result of a 52bp deletion, or type 2 (p.K385fs*47), the result of a 5-bp TTGTC insertion, and studies have suggested phenotypic and prognostic differences between them. In PMF patients, CALR exon 9 mutations have been associated with improved median survival.		19	13054527	13054727			ENST00000316448.5	75	GRCh37					exon_variant	
560	https://civic.genome.wustl.edu/#/events/genes/1239/summary/variants/560/summary#variant	CSF3R	1441	MUTATION			1	36932096	36933444			ENST00000373106.1	75	GRCh37					protein_altering_variant	
562	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/562/summary#variant	EGFR	1956	S768I			7	55249005	55249005	G	T	ENST00000275493.2	75	GRCh37					missense_variant	
563	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/563/summary#variant	BRAF	673	V600K		Other V600's	7	140453136	140453137	AC	TT	ENST00000288602.6	75	GRCh37					missense_variant	ENST00000288602.6:c.1798_1799delinsAA
564	https://civic.genome.wustl.edu/#/events/genes/77/summary/variants/564/summary#variant	SMAD4	4089	LOSS			18	48556583	48611409			ENST00000342988.3	75	GRCh37					loss_of_function_variant	
565	https://civic.genome.wustl.edu/#/events/genes/44/summary/variants/565/summary#variant	SF3B1	23451	K700E		HEAT domain mutation	2	198266834	198266834	T	C	ENST00000335508.6	75	GRCh37					missense_variant	
566	https://civic.genome.wustl.edu/#/events/genes/4546/summary/variants/566/summary#variant	MAP2K7	5609	E116K			19	7975157	7975157	G	A	ENST00000397979.3	75	GRCh37					missense_variant	
567	https://civic.genome.wustl.edu/#/events/genes/38/summary/variants/567/summary#variant	PDGFRA	5156	PDGFRA FUSIONS															transcript_fusion	
568	https://civic.genome.wustl.edu/#/events/genes/4176/summary/variants/568/summary#variant	PDGFRB	5159	PDGFRB FUSIONS															transcript_fusion	
569	https://civic.genome.wustl.edu/#/events/genes/1885/summary/variants/569/summary#variant	FGFR1	2260	FGFR1 FUSIONS															transcript_fusion	
570	https://civic.genome.wustl.edu/#/events/genes/27/summary/variants/570/summary#variant	IDH2	3418	MUTATION			15	90626277	90645736			ENST00000330062.3	75	GRCh37					protein_altering_variant	
571	https://civic.genome.wustl.edu/#/events/genes/28/summary/variants/571/summary#variant	JAK2	3717	PCM1-JAK2										GRCh37					transcript_fusion	
572	https://civic.genome.wustl.edu/#/events/genes/2073/summary/variants/572/summary#variant	MTOR	2475	E2014K + E2419K			1	11174420	11187857			ENST00000361445.4	75	GRCh37					missense_variant	
573	https://civic.genome.wustl.edu/#/events/genes/20480/summary/variants/573/summary#variant	RICTOR	253260	AMPLIFICATION			5	38938021	39074510			ENST00000357387.3	75	GRCh37					transcript_amplification	
574	https://civic.genome.wustl.edu/#/events/genes/38/summary/variants/574/summary#variant	PDGFRA	5156	FIP1L1-PDGFRA	Prospective trials of patients with hypereosinophilic syndrome harboring the FIP1L1-PDGFRA fusion identified marked response to imatinib treatment (Gotlib and Cool, Leukemia 2008). Imatinib is FDA approved for the treatment of &quot;adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFR fusion kinase&quot; (NDA021588).		4	54243812	54294350			ENST00000337488.6	75	GRCh37	4	55141008	55164414	ENST00000257290.5	transcript_fusion	
576	https://civic.genome.wustl.edu/#/events/genes/4941/summary/variants/576/summary#variant	ROS1	6098	TFG-ROS1			3	100428269	100447702			ENST00000240851.4	75	GRCh37	6	117609463	117642557	ENST00000368508.3	transcript_fusion	
577	https://civic.genome.wustl.edu/#/events/genes/38/summary/variants/577/summary#variant	PDGFRA	5156	FIP1L1-PDGFRA T674I	A case study of relapsed myeloproliferative hypereosinophilic syndrome suggests that a T674I mutation in the PDGFRA split kinase domain of FIP1L1-PDGFRA fusions may confer resistance to imatinib.		4	55144547	55144547	C	T	ENST00000257290.5	75	GRCh37					missense_variant,transcript_fusion	
578	https://civic.genome.wustl.edu/#/events/genes/355/summary/variants/578/summary#variant	BIRC5	332	OVEREXPRESSION			17	76210267	76221717			ENST00000301633.4	75	GRCh37					N/A	
579	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/579/summary#variant	BRAF	673	D594A		Kinase Dead BRAF Mutation	7	140453154	140453154	T	G	ENST00000288602.6	75	GRCh37					missense_variant	ENST00000288602.6:c.1781A>C
580	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/580/summary#variant	BRAF	673	D594V		Kinase Dead BRAF Mutation	7	140453154	140453154	T	A	ENST00000288602.6	75	GRCh37					missense_variant	
581	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/581/summary#variant	BRAF	673	K483M	The K483M variant is a kinase dead loss-of-function variant in the catalytic site of BRAF. This engineered variant is often used as a control when evaluating other BRAF variants.	Kinase Dead BRAF Mutation	7	140477859	140477860	TT	CA	ENST00000288602.6	75	GRCh37					loss_of_function_variant,missense_variant	
582	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/582/summary#variant	BRAF	673	L597S			7	140453145	140453146	AG	GA	ENST00000288602.6	75	GRCh37					missense_variant	
583	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/583/summary#variant	BRAF	673	L597Q			7	140453145	140453145	A	T	ENST00000288602.6	75	GRCh37					missense_variant	
584	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/584/summary#variant	BRAF	673	K601E			7	140453134	140453134	T	C	ENST00000288602.6	75	GRCh37					missense_variant	
585	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/585/summary#variant	BRAF	673	L597V			7	140453146	140453146	G	C	ENST00000288602.6	75	GRCh37					missense_variant	
586	https://civic.genome.wustl.edu/#/events/genes/29/summary/variants/586/summary#variant	KIT	3815	AMPLIFICATION			4	55524085	55606881			ENST00000288135.5	75	GRCh37					transcript_amplification	
587	https://civic.genome.wustl.edu/#/events/genes/3867/summary/variants/587/summary#variant	NF1	4763	MUTATION			17	29421945	29704695			ENST00000358273.4	75	GRCh37					loss_of_function_variant,protein_altering_variant	
588	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/588/summary#variant	ALK	238	HIP1-ALK I1171N			2	29445213	29445213	A	T	ENST00000389048.3	75	GRCh37					missense_variant,transcript_fusion	
589	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/589/summary#variant	ALK	238	EML4-ALK I1171S			2	29445213	29445213	A	C	ENST00000389048.3	75	GRCh37					missense_variant,transcript_fusion	
590	https://civic.genome.wustl.edu/#/events/genes/353/summary/variants/590/summary#variant	BIRC3	330	TRUNCATING MUTATION			11	102201730	102207833			ENST00000263464.3	75	GRCh37					frameshift_variant	
591	https://civic.genome.wustl.edu/#/events/genes/4767/summary/variants/591/summary#variant	RAF1	5894	AMPLIFICATION			3	12625100	12705725			ENST00000251849.4	75	GRCh37					transcript_amplification	
592	https://civic.genome.wustl.edu/#/events/genes/30/summary/variants/592/summary#variant	KRAS	3845	AMPLIFICATION			12	25362365	25403737			ENST00000256078.4	75	GRCh37					transcript_amplification	
594	https://civic.genome.wustl.edu/#/events/genes/15/summary/variants/594/summary#variant	CEBPA	1050	BIALLELIC INACTIVATION			19	33790840	33793470			ENST00000498907.2	75	GRCh37					loss_of_function_variant	
595	https://civic.genome.wustl.edu/#/events/genes/5210/summary/variants/595/summary#variant	SRSF2	6427	MUTATION			17	74732402	74733113			ENST00000392485.2	75	GRCh37						
596	https://civic.genome.wustl.edu/#/events/genes/36/summary/variants/596/summary#variant	NRAS	4893	G12/G13			1	115258744	115258748			ENST00000369535.4	75	GRCh37					protein_altering_variant	
597	https://civic.genome.wustl.edu/#/events/genes/42/summary/variants/597/summary#variant	RET	5979	OVEREXPRESSION			10	43572475	43625799			ENST00000355710.3	75	GRCh37					N/A	
599	https://civic.genome.wustl.edu/#/events/genes/1285/summary/variants/599/summary#variant	CTLA4	1493	CTLA4-CD28	A survey of 115 T-cell lymphoma samples of diverse subtypes identified this fusion in 26 of 45 cases of angioimmunoblastic T-cell lymphomas (58%), nine of 39 peripheral T-cell lymphomas, not otherwise specified (23%), and nine of 31 extranodal NK/T cell lymphomas (29%).		2	204732509	204736210			ENST00000302823.3	75	GRCh37	2	204599507	204603635	ENST00000324106.8	transcript_fusion	
600	https://civic.genome.wustl.edu/#/events/genes/67/summary/variants/600/summary#variant	AR	367	MUTATION			X	66764465	66950461			ENST00000374690.3	75	GRCh37					transcript_variant	
601	https://civic.genome.wustl.edu/#/events/genes/50/summary/variants/601/summary#variant	NOTCH1	4851	LOSS-OF-FUNCTION			9	139388896	139440314			ENST00000277541.6	75	GRCh37					loss_of_function_variant	
602	https://civic.genome.wustl.edu/#/events/genes/12/summary/variants/602/summary#variant	CDK6	1021	OVEREXPRESSION			7	92234235	92463231			ENST00000265734.4	75	GRCh37					N/A	
603	https://civic.genome.wustl.edu/#/events/genes/24/summary/variants/603/summary#variant	FLT3	2322	OVEREXPRESSION			13	28577411	28674729			ENST00000241453.7	75	GRCh37					N/A	
604	https://civic.genome.wustl.edu/#/events/genes/2317/summary/variants/604/summary#variant	GNAQ	2776	Q209P			9	80409488	80409488	T	G	ENST00000286548.4	75	GRCh37					missense_variant	
605	https://civic.genome.wustl.edu/#/events/genes/41/summary/variants/605/summary#variant	PTEN	5728	V317FS			10	89720799	89720802	TACT	-	ENST00000371953.3	75	GRCh37					frameshift_variant	ENST00000371953.3:c.950_953delTACT
606	https://civic.genome.wustl.edu/#/events/genes/4795/summary/variants/606/summary#variant	RB1	5925	LOSS-OF-FUNCTION			13	48877911	49056122			ENST00000267163.4	75	GRCh37					loss_of_function_variant	
607	https://civic.genome.wustl.edu/#/events/genes/21/summary/variants/607/summary#variant	ESR1	2099	OVEREXPRESSION			6	152128686	152424406			ENST00000206249.3	75	GRCh37					N/A	
608	https://civic.genome.wustl.edu/#/events/genes/1/summary/variants/608/summary#variant	ALK	238	EML4-ALK C1156YL1196M			2	29443631	29445258			ENST00000389048.3	75	GRCh37					missense_variant,transcript_fusion	
609	https://civic.genome.wustl.edu/#/events/genes/2073/summary/variants/609/summary#variant	MTOR	2475	M2327I			1	11177096	11177096	C	A	ENST00000361445.4	75	GRCh37					missense_variant	
610	https://civic.genome.wustl.edu/#/events/genes/2073/summary/variants/610/summary#variant	MTOR	2475	A2034V			1	11187796	11187796	G	A	ENST00000361445.4	75	GRCh37					missense_variant	
611	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/611/summary#variant	BRAF	673	D594G			7	140453154	140453154	T	C	ENST00000288602.6	75	GRCh37					missense_variant	
612	https://civic.genome.wustl.edu/#/events/genes/24/summary/variants/612/summary#variant	FLT3	2322	D835H			13	28592642	28592642	C	G	ENST00000241453.7	75	GRCh37					missense_variant	
613	https://civic.genome.wustl.edu/#/events/genes/24/summary/variants/613/summary#variant	FLT3	2322	D835H/Y			13	28592642	28592642	C	G/A	ENST00000241453.7	75	GRCh37					missense_variant	
614	https://civic.genome.wustl.edu/#/events/genes/3090/summary/variants/614/summary#variant	JAK1	3716	Q503*			1	65321333	65321333	G	A	ENST00000342505.4	75	GRCh37					stop_gained	
615	https://civic.genome.wustl.edu/#/events/genes/28/summary/variants/615/summary#variant	JAK2	3717	Exon 12 splice site insertion			9	5070053	5070054		G	ENST00000381652.3	75	GRCh37						
616	https://civic.genome.wustl.edu/#/events/genes/537/summary/variants/616/summary#variant	B2M	567	S14FS			15	45003786	45003789	TCTT		ENST00000558401.1	75	GRCh37					frameshift_truncation	
617	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/617/summary#variant	BRAF	673	PPFIBP2-BRAF		BRAF Fusions	11	7535001	7586998			ENST00000299492.4	75	GRCh37	7	140434279	140481493	ENST00000288602.6	transcript_fusion	
618	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/618/summary#variant	BRAF	673	KIAA1549-BRAF		BRAF Fusions	7	138545885	138666064			ENST00000440172.1	75	GRCh37	7	140434279	140487384	ENST00000288602.6	transcript_fusion	
619	https://civic.genome.wustl.edu/#/events/genes/4659/summary/variants/619/summary#variant	PTGS2	5743	OVEREXPRESSION			1	186640923	186649559			ENST00000367468.5	75	GRCh37					N/A	
621	https://civic.genome.wustl.edu/#/events/genes/52/summary/variants/621/summary#variant	MET	4233	OVEREXPRESSION			7	116312459	116436396			ENST00000318493.6	75	GRCh37					N/A	
623	https://civic.genome.wustl.edu/#/events/genes/9935/summary/variants/623/summary#variant	POT1	25913	MUTATION			7	124462440	124570035			ENST00000357628.3	75	GRCh37					loss_of_function_variant,protein_altering_variant	
624	https://civic.genome.wustl.edu/#/events/genes/3529/summary/variants/624/summary#variant	MKI67	4288	EXPRESSION			10	129894923	129924649			ENST00000368654.3	75	GRCh37					N/A	
625	https://civic.genome.wustl.edu/#/events/genes/4760/summary/variants/625/summary#variant	RAD23B	5887	EXPRESSION			9	110045560	110094475			ENST00000358015.3	75	GRCh37					N/A	
626	https://civic.genome.wustl.edu/#/events/genes/42/summary/variants/626/summary#variant	RET	5979	CCDC6-RET															transcript_fusion	
627	https://civic.genome.wustl.edu/#/events/genes/31/summary/variants/627/summary#variant	MAP2K1	5604	C121S			15	66729154	66729154	G	C	ENST00000307102.5	75	GRCh37					missense_variant	
628	https://civic.genome.wustl.edu/#/events/genes/23/summary/variants/628/summary#variant	FGFR3	2261	S249C			4	1803568	1803568	C	G	ENST00000340107.4	75	GRCh37					missense_variant	
629	https://civic.genome.wustl.edu/#/events/genes/22/summary/variants/629/summary#variant	FGFR2	2263	AMPLIFICATION			10	123239371	123357917			ENST00000457416.2	75	GRCh37					transcript_amplification	
630	https://civic.genome.wustl.edu/#/events/genes/1873/summary/variants/630/summary#variant	FGF3	2248	AMPLIFICATION			11	69624992	69633792			ENST00000334134.2	75	GRCh37					transcript_amplification	
631	https://civic.genome.wustl.edu/#/events/genes/58/summary/variants/631/summary#variant	VHL	7428	R200W (c.598C>T)			3	10191605	10191605	C	T	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.598C>T,NP_000542.1:p.Arg200Trp,ENST00000256474.2:c.598C>T
632	https://civic.genome.wustl.edu/#/events/genes/4795/summary/variants/632/summary#variant	RB1	5925	PHOSPHORYLATION			13	48877911	49056122			ENST00000267163.4	75	GRCh37					N/A	
633	https://civic.genome.wustl.edu/#/events/genes/4289/summary/variants/633/summary#variant	PIK3R1	5295	MUTATION			5	67511548	67597649			ENST00000521381.1	75	GRCh37					gain_of_function_variant,missense_variant	
634	https://civic.genome.wustl.edu/#/events/genes/5534/summary/variants/634/summary#variant	STK11	6794	D194E			19	1220489	1220489	C	A	ENST00000326873.7	75	GRCh37					loss_of_heterozygosity,missense_variant	
635	https://civic.genome.wustl.edu/#/events/genes/254/summary/variants/635/summary#variant	AKT2	208	AMPLIFICATION			19	40736224	40791302			ENST00000392038.2	75	GRCh37					transcript_amplification	
636	https://civic.genome.wustl.edu/#/events/genes/41/summary/variants/636/summary#variant	PTEN	5728	R130*			10	89692904	89692904	C	T	ENST00000371953.3	75	GRCh37					stop_gained	NM_000314.6:c.388C>T,NP_000305.3:p.Arg130Ter,ENST00000371953.3:c.388C>T
637	https://civic.genome.wustl.edu/#/events/genes/12903/summary/variants/637/summary#variant	FBXW7	55294	LOSS-OF-FUNCTION			4	153242410	153457253			ENST00000281708.4	75	GRCh37					loss_of_function_variant	
638	https://civic.genome.wustl.edu/#/events/genes/4795/summary/variants/638/summary#variant	RB1	5925	M695FS*26			13	49033946	49033947		A	ENST00000267163.4	75	GRCh37					frameshift_truncation	
639	https://civic.genome.wustl.edu/#/events/genes/3094/summary/variants/639/summary#variant	JUN	3725	OVEREXPRESSION			1	59246465	59249785			ENST00000371222.2	75	GRCh37					N/A	
640	https://civic.genome.wustl.edu/#/events/genes/1955/summary/variants/640/summary#variant	FOS	2353	OVEREXPRESSION			14	75745477	75748933			ENST00000303562.4	75	GRCh37					N/A	
641	https://civic.genome.wustl.edu/#/events/genes/14/summary/variants/641/summary#variant	CDKN2A	1029	RS3814960			9	21975017	21975017	C	T	ENST00000498124.1	75	GRCh37					5_prime_UTR_exon_variant	
642	https://civic.genome.wustl.edu/#/events/genes/3465/summary/variants/642/summary#variant	MDM2	4193	RS34886328			12	69234988	69234988	A		ENST00000462284.1	75	GRCh37					3_prime_UTR_truncation	
643	https://civic.genome.wustl.edu/#/events/genes/779/summary/variants/643/summary#variant	CBLB	868	RS2305035			3	105439026	105439026	G	A	ENST00000264122.4	75	GRCh37					synonymous_variant,polymorphic_sequence_variant	
644	https://civic.genome.wustl.edu/#/events/genes/593/summary/variants/644/summary#variant	PRDM1	639	MUTATION			6	106534195	106557813			ENST00000369096.4	75	GRCh37					loss_of_function_variant,transcript_variant	
645	https://civic.genome.wustl.edu/#/events/genes/26/summary/variants/645/summary#variant	IDH1	3417	MUTATION			2	209101803	209116275			ENST00000415913.1	75	GRCh37					transcript_variant	
646	https://civic.genome.wustl.edu/#/events/genes/77/summary/variants/646/summary#variant	SMAD4	4089	DELETION			18	48556583	48611409			ENST00000342988.3	75	GRCh37					transcript_ablation	
647	https://civic.genome.wustl.edu/#/events/genes/12146/summary/variants/647/summary#variant	LRP1B	53353	DELETION			2	140988992	142889270			ENST00000389484.3	75	GRCh37					transcript_ablation	
648	https://civic.genome.wustl.edu/#/events/genes/525/summary/variants/648/summary#variant	ATRX	546	UNDEREXPRESSION			X	76760356	77041702			ENST00000373344.5	75	GRCh37					N/A	
649	https://civic.genome.wustl.edu/#/events/genes/52/summary/variants/649/summary#variant	MET	4233	D1228N			7	116423407	116423407	G	A	ENST00000397752.3	75	GRCh37					missense_variant	
650	https://civic.genome.wustl.edu/#/events/genes/761/summary/variants/650/summary#variant	CASP8	841	D302H			2	202149589	202149589	G	C	ENST00000264275.5	75	GRCh37					missense_variant,polymorphic_sequence_variant	
651	https://civic.genome.wustl.edu/#/events/genes/533/summary/variants/651/summary#variant	AXL	558	EXPRESSION			19	41725108	41767671			ENST00000301178.4	75	GRCh37					N/A	
652	https://civic.genome.wustl.edu/#/events/genes/2186/summary/variants/652/summary#variant	GAS6	2621	EXPRESSION			13	114523524	114567046			ENST00000357389.3	75	GRCh37					N/A	
653	https://civic.genome.wustl.edu/#/events/genes/1767/summary/variants/653/summary#variant	ETV4	2118	OVEREXPRESSION			17	41605212	41623800			ENST00000319349.5	75	GRCh37					N/A	
654	https://civic.genome.wustl.edu/#/events/genes/8552/summary/variants/654/summary#variant	STAG3	10734	UNDEREXPRESSION			7	99775186	99812003			ENST00000426455.1	75	GRCh37					N/A	
655	https://civic.genome.wustl.edu/#/events/genes/31/summary/variants/655/summary#variant	MAP2K1	5604	Q56_V60 DELETION			15	66727449	66727463	CCAGAAGCAGAAGGT		ENST00000307102.5	75	GRCh37						
656	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/656/summary#variant	BRAF	673	BRAF-CUL1		BRAF Fusions	7	140434279	140487384			ENST00000288602.6	75	GRCh37	7	148395737	148457588	ENST00000602748.1	transcript_fusion	
657	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/657/summary#variant	BRAF	673	ZKSCAN1-BRAF		BRAF Fusions	7	99613222	99627575			ENST00000426572.1	75	GRCh37	7	140434279	140482957	ENST00000288602.6	transcript_fusion	
658	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/658/summary#variant	BRAF	673	L505H			7	140477794	140477794	A	T	ENST00000288602.6	75	GRCh37					missense_variant	ENST00000288602.6:c.1514T>A
659	https://civic.genome.wustl.edu/#/events/genes/3870/summary/variants/659/summary#variant	NF2	4771	MUTATION			22	29999547	30094587			ENST00000338641.4	75	GRCh37					transcript_variant	
660	https://civic.genome.wustl.edu/#/events/genes/2596/summary/variants/660/summary#variant	HIF1A	3091	EXPRESSION			14	62164340	62214489			ENST00000539097.1	75	GRCh37					N/A	
661	https://civic.genome.wustl.edu/#/events/genes/7/summary/variants/661/summary#variant	BRCA2	675	D3095E			13	32968854	32968854	C	A	ENST00000544455.1	75	GRCh37					missense_variant	
662	https://civic.genome.wustl.edu/#/events/genes/3532/summary/variants/662/summary#variant	MLH1	4292	EXPRESSION			3	37034823	37092409			ENST00000231790.2	75	GRCh37					N/A	
663	https://civic.genome.wustl.edu/#/events/genes/12555/summary/variants/663/summary#variant	BCOR	54880	MUTATION			X	39910501	40036582			ENST00000342274.4	75	GRCh37					transcript_variant	
664	https://civic.genome.wustl.edu/#/events/genes/888/summary/variants/664/summary#variant	CDH1	999	MUTATION			16	68771128	68869451			ENST00000261769.5	75	GRCh37					transcription_variant	
665	https://civic.genome.wustl.edu/#/events/genes/399/summary/variants/665/summary#variant	RHOA	387	MUTATION			3	49412898	49405977			ENST00000418115.1	75	GRCh37					transcription_variant,gain_of_function_variant	
666	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/666/summary#variant	ERBB2	2064	MUTATION			17	37868196	37881332			ENST00000269571.5	75	GRCh37					missense_variant	
667	https://civic.genome.wustl.edu/#/events/genes/3485/summary/variants/667/summary#variant	MEN1	4221	FRAMESHIFT TRUNCATION			11	64572092	64572092	C		ENST00000337652.1	75	GRCh37					frameshift_truncation	
668	https://civic.genome.wustl.edu/#/events/genes/14089/summary/variants/668/summary#variant	KMT2C	58508	MUTATION			7	151832010	152133090			ENST00000262189.6	75	GRCh37					transcription_variant,loss_of_function_variant	
669	https://civic.genome.wustl.edu/#/events/genes/8553/summary/variants/669/summary#variant	STAG2	10735	MUTATION			X	123176418	123217308			ENST00000218089.9	75	GRCh37					missense_variant,splice_site_variant,frameshift_variant,stop_gained	
670	https://civic.genome.wustl.edu/#/events/genes/3738/summary/variants/670/summary#variant	MYCL	4610	EXPRESSION			1	40361098	40367685			ENST00000397332.2	75	GRCh37					N/A	
671	https://civic.genome.wustl.edu/#/events/genes/2591/summary/variants/671/summary#variant	HGF	3082	EXPRESSION			7	81328322	81399514			ENST00000222390.5	75	GRCh37					N/A	
672	https://civic.genome.wustl.edu/#/events/genes/5418/summary/variants/672/summary#variant	SOX10	6663	LOSS			22	38368307	38380544			ENST00000396884.2	75	GRCh37					loss_of_function_variant	
673	https://civic.genome.wustl.edu/#/events/genes/1872/summary/variants/673/summary#variant	FGF2	2247	EXPRESSION			4	123747863	123819391			ENST00000264498.3	75	GRCh37					N/A	
674	https://civic.genome.wustl.edu/#/events/genes/1646/summary/variants/674/summary#variant	EIF1AX	1964	MUTATION			X	20156713	20159754			ENST00000379607.5	75	GRCh37					transcript_variant	
683	https://civic.genome.wustl.edu/#/events/genes/75/summary/variants/683/summary#variant	PAX8	7849	EXPRESSION			2	113973574	114036527			ENST00000429538.3	75	GRCh37					N/A	
691	https://civic.genome.wustl.edu/#/events/genes/12271/summary/variants/691/summary#variant	ERRFI1	54206	E384*			1	8073509	8073509	C	A	ENST00000377482.5	75	GRCh37					loss_of_function_variant,stop_gained	
692	https://civic.genome.wustl.edu/#/events/genes/21/summary/variants/692/summary#variant	ESR1	2099	S463P			6	152415537	152415537	T	C	ENST00000440973.1	75	GRCh37					missense_variant	
693	https://civic.genome.wustl.edu/#/events/genes/5225/summary/variants/693/summary#variant	SGK1	6446	OVEREXPRESSION			6	134490384	134639196			ENST00000367858.5	75	GRCh37					N/A	
694	https://civic.genome.wustl.edu/#/events/genes/5/summary/variants/694/summary#variant	BRAF	673	G596C			7	140453149	140453149	C	A	ENST00000288602.6	75	GRCh37					missense_variant	
695	https://civic.genome.wustl.edu/#/events/genes/5356/summary/variants/695/summary#variant	SMARCB1	6598	UNDEREXPRESSION			22	24129150	24176703			ENST00000344921.6	75	GRCh37					N/A	
696	https://civic.genome.wustl.edu/#/events/genes/5356/summary/variants/696/summary#variant	SMARCB1	6598	DELETION			22	24129150	24176703			ENST00000344921.6	75	GRCh37					transcript_ablation	
697	https://civic.genome.wustl.edu/#/events/genes/3870/summary/variants/697/summary#variant	NF2	4771	LOSS			22	29999547	30094587			ENST00000338641.4	75	GRCh37					loss_of_function_variant	
698	https://civic.genome.wustl.edu/#/events/genes/3867/summary/variants/698/summary#variant	NF1	4763	LOSS			17	29421945	29704695			ENST00000358273.4	75	GRCh37					loss_of_function_variant	
699	https://civic.genome.wustl.edu/#/events/genes/7954/summary/variants/699/summary#variant	SH2B3	10019	RS3184504			12	111884608	111884608	T	C	ENST00000341259.2	75	GRCh37					missense_variant,polymorphic_sequence_variant	
700	https://civic.genome.wustl.edu/#/events/genes/7502/summary/variants/700/summary#variant	KIF23	9493	EXPRESSION			15	69706688	69740756			ENST00000260363.4	75	GRCh37					N/A	
701	https://civic.genome.wustl.edu/#/events/genes/1733/summary/variants/701/summary#variant	ERBB3	2065	V104M			12	56478854	56478854	G	A	ENST00000267101.3	75	GRCh37					missense_variant	
702	https://civic.genome.wustl.edu/#/events/genes/1733/summary/variants/702/summary#variant	ERBB3	2065	R103G			12	56478851	56478851	C	G	ENST00000267101.3	75	GRCh37					missense_variant	
703	https://civic.genome.wustl.edu/#/events/genes/1733/summary/variants/703/summary#variant	ERBB3	2065	G284R			12	56481922	56481922	G	A	ENST00000267101.3	75	GRCh37					missense_variant	
705	https://civic.genome.wustl.edu/#/events/genes/1411/summary/variants/705/summary#variant	GADD45A	1647	1506T>C																
706	https://civic.genome.wustl.edu/#/events/genes/54/summary/variants/706/summary#variant	EWSR1	2130	EWSR1-FLI1	In approximately 90% of Ewing sarcoma/primitive neuroectodermal tumor (ES/PNET) a translocation t(11;22)(q24; q12) is identified, fusing the 5 exons (containing the transactivatin domain, at least exon 1-7) of EWSR1, with the 3 exons (from exon 9, coding the DNA binding domain) of FLI1.		22	29664307	29688158			ENST00000414183.2	75	GRCh37	11	128638013	128683162	ENST00000527786.2	transcript_fusion	
707	https://civic.genome.wustl.edu/#/events/genes/5813/summary/variants/707/summary#variant	TMPRSS2	7113	TMPRSS2-ERG			21	42879877	42879992			ENST00000398585.3	75	GRCh37	21	39751949	39817544	ENST00000398910.1	transcript_fusion	
708	https://civic.genome.wustl.edu/#/events/genes/7/summary/variants/708/summary#variant	BRCA2	675	TRUNCATING MUTATION																
709	https://civic.genome.wustl.edu/#/events/genes/6/summary/variants/709/summary#variant	BRCA1	672	TRUNCATING MUTATION																
711	https://civic.genome.wustl.edu/#/events/genes/32083/summary/variants/711/summary#variant	KLLN	100144748	PROMOTER METHYLATION																
712	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/712/summary#variant	EGFR	1956	D761Y			7	55242511	55242511	G	T	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.2281G>T,NM_005228.4:c.2281G>T,NP_005219.2:p.Asp761Tyr,NC_000007.13:g.55242511G>T
713	https://civic.genome.wustl.edu/#/events/genes/11761/summary/variants/713/summary#variant	CRBN	51185	MUTATION																
714	https://civic.genome.wustl.edu/#/events/genes/46/summary/variants/714/summary#variant	TSC1	7248	R1062W			9	135771933	135771933	G	A	ENST00000298552.3	75	GRCh37					missense_variant	NM_000368.3:c.3184C>T,NP_000359.1:p.Arg1062Trp,ENST00000298552.3:c.3184C>T,NC_000009.11:g.135771933G>A
715	https://civic.genome.wustl.edu/#/events/genes/5534/summary/variants/715/summary#variant	STK11	6794	MUTATION			19	1205740	1223074			ENST00000326873.7	75	GRCh37					gene_variant	
716	https://civic.genome.wustl.edu/#/events/genes/38/summary/variants/716/summary#variant	PDGFRA	5156	AMPLIFICATION			4	55095264	55164414			ENST00000257290.5	75	GRCh37					transcript_amplification	
717	https://civic.genome.wustl.edu/#/events/genes/1413/summary/variants/717/summary#variant	DDIT3	1649	EWSR1-DDIT3			22	29664307	29687588			ENST00000414183.2	75	GRCh37	12	57910376	57911536	ENST00000346473.3	transcript_fusion	
718	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/718/summary#variant	EGFR	1956	G719			7	55241707	55241708			ENST00000275493.2	75	GRCh37					protein_altering_variant	
719	https://civic.genome.wustl.edu/#/events/genes/9588/summary/variants/719/summary#variant	BRD4	23476	BRD4-NUTM1																
720	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/720/summary#variant	EGFR	1956	S720			7	55241710	55241711			ENST00000275493.2	75	GRCh37					protein_altering_variant	
721	https://civic.genome.wustl.edu/#/events/genes/1342/summary/variants/721/summary#variant	CYP2D6	1565	LOSS-OF-FUNCTION			22	42522501	42526908			ENST00000360608.5	75	GRCh37					loss_of_function_variant	
722	https://civic.genome.wustl.edu/#/events/genes/1413/summary/variants/722/summary#variant	DDIT3	1649	FUS-DDIT3																
723	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/723/summary#variant	EGFR	1956	K757R			7	55242500	55242500	A	G	ENST00000275493.2	75	GRCh37					missense_variant	
724	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/724/summary#variant	EGFR	1956	E746G			7	55242467	55242467	A	G	ENST00000275493.2	75	GRCh37					missense_variant	
725	https://civic.genome.wustl.edu/#/events/genes/3532/summary/variants/725/summary#variant	MLH1	4292	E13FS*3			3	37035075	37035075	G		ENST00000231790.2	75	GRCh37					frameshift_truncation	NM_000249.3:c.37delG,NP_000240.1:p.Glu13Argfs,ENST00000231790.2:c.37delG,NC_000003.11:g.37035075del
726	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/726/summary#variant	EGFR	1956	EXON 20 INSERTION			7	55248991	55249022			ENST00000275493.2	75	GRCh37					inframe_insertion	
727	https://civic.genome.wustl.edu/#/events/genes/3628/summary/variants/727/summary#variant	MSH2	4436	R383*			2	47656951	47656951	C	T	ENST00000233146.2	75	GRCh37					stop_gained	
728	https://civic.genome.wustl.edu/#/events/genes/3532/summary/variants/728/summary#variant	MLH1	4292	V534R			3	37081718	37081719	GT	AG	ENST00000231790.2	75	GRCh37					missense_variant	ENST00000231790.2:c.1600_1601delinsAG
729	https://civic.genome.wustl.edu/#/events/genes/12422/summary/variants/729/summary#variant	UGT1A1	54658	UGT1A1*28			2	234668881	234668882		TATATATATATATA	ENST00000305208.5	75	GRCh37					microsatellite	
730	https://civic.genome.wustl.edu/#/events/genes/3532/summary/variants/730/summary#variant	MLH1	4292	G606FS*2			3	37089094	37089095	GG		ENST00000231790.2	75	GRCh37					frameshift_truncation	ENST00000231790.2:c.1816_1817delGG,NC_000003.11:g.37089094_37089095del
731	https://civic.genome.wustl.edu/#/events/genes/3532/summary/variants/731/summary#variant	MLH1	4292	790+1G>A																
732	https://civic.genome.wustl.edu/#/events/genes/12422/summary/variants/732/summary#variant	UGT1A1	54658	UGT1A1*60																
733	https://civic.genome.wustl.edu/#/events/genes/3532/summary/variants/733/summary#variant	MLH1	4292	K618DEL			3	37089130	37089132	AAG		ENST00000231790.2	75	GRCh37					inframe_deletion	NC_000003.11:g.37089130_37089132del
734	https://civic.genome.wustl.edu/#/events/genes/3532/summary/variants/734/summary#variant	MLH1	4292	P138T																
735	https://civic.genome.wustl.edu/#/events/genes/3532/summary/variants/735/summary#variant	MLH1	4292	R687FS			3	37090464	37090464	C		ENST00000231790.2	75	GRCh37					frameshift_variant	
736	https://civic.genome.wustl.edu/#/events/genes/19/summary/variants/736/summary#variant	EGFR	1956	V769_770INSASV																
737	https://civic.genome.wustl.edu/#/events/genes/1526/summary/variants/737/summary#variant	DPYD	1806	DPYD*2A HOMOZYGOSITY			1	97915614	97915614	C	T	ENST00000370192.3	75	GRCh37					splice_donor_variant	
738	https://civic.genome.wustl.edu/#/events/genes/1526/summary/variants/738/summary#variant	DPYD	1806	DPYD*13 HOMOZYGOSITY			1	97981343	97981343	A	C	ENST00000370192.3	75	GRCh37					missense_variant	
739	https://civic.genome.wustl.edu/#/events/genes/1955/summary/variants/739/summary#variant	FOS	2353	FOS TRUNCATING FUSION																
740	https://civic.genome.wustl.edu/#/events/genes/1526/summary/variants/740/summary#variant	DPYD	1806	RS67376798 HOMOZYGOSITY																
741	https://civic.genome.wustl.edu/#/events/genes/3532/summary/variants/741/summary#variant	MLH1	4292	R100*			3	37042536	37042536	C	T	ENST00000231790.2	75	GRCh37					stop_gained	
742	https://civic.genome.wustl.edu/#/events/genes/9952/summary/variants/742/summary#variant	WWTR1	25937	WWTR1-CAMTA1			3	149235022	149290787			ENST00000465804.1	75	GRCh37	1	7721786	7829766	ENST00000303635.7	transcript_fusion	
743	https://civic.genome.wustl.edu/#/events/genes/3532/summary/variants/743/summary#variant	MLH1	4292	T117M			3	37045935	37045935	C	T	ENST00000231790.2	75	GRCh37					missense_variant	
744	https://civic.genome.wustl.edu/#/events/genes/3532/summary/variants/744/summary#variant	MLH1	4292	Q426FS			3	37067365	37067365	C		ENST00000231790.2	75	GRCh37					frameshift_truncation	
745	https://civic.genome.wustl.edu/#/events/genes/3532/summary/variants/745/summary#variant	MLH1	4292	V49A			3	37038139	37038139	T	C	ENST00000231790.2	75	GRCh37					missense_variant	
746	https://civic.genome.wustl.edu/#/events/genes/3532/summary/variants/746/summary#variant	MLH1	4292	D667FS			3	37090406	37090406	C		ENST00000231790.2	75	GRCh37						ENST00000231790.2:c.2001delC,NC_000003.11:g.37090406del
747	https://civic.genome.wustl.edu/#/events/genes/3532/summary/variants/747/summary#variant	MLH1	4292	M1L			3	37035039	37035039	A	T	ENST00000231790.2	75	GRCh37					missense_variant	NC_000003.11:g.37035039A>T
748	https://civic.genome.wustl.edu/#/events/genes/3532/summary/variants/748/summary#variant	MLH1	4292	*757L			3	37092143	37092143	A	T	ENST00000231790.2	75	GRCh37					stop_lost	ENST00000231790.2:c.2270A>T
749	https://civic.genome.wustl.edu/#/events/genes/3532/summary/variants/749/summary#variant	MLH1	4292	R265G			3	37058999	37058999	C	G	ENST00000231790.2	75	GRCh37					missense_variant	
750	https://civic.genome.wustl.edu/#/events/genes/3532/summary/variants/750/summary#variant	MLH1	4292	V213FS			3	37053551	37053551	T		ENST00000231790.2	75	GRCh37					frameshift_truncation	
751	https://civic.genome.wustl.edu/#/events/genes/3532/summary/variants/751/summary#variant	MLH1	4292	N551T			3	37081770	37081770	A	C	ENST00000231790.2	75	GRCh37					missense_variant	NM_000249.3:c.1652A>C,NP_000240.1:p.Asn551Thr,ENST00000231790.2:c.1652A>C
752	https://civic.genome.wustl.edu/#/events/genes/3532/summary/variants/752/summary#variant	MLH1	4292	A424T			3	37067359	37067359	G	A	ENST00000231790.2	75	GRCh37					missense_variant	NM_000249.3:c.1270G>A,NP_000240.1:p.Ala424Thr,ENST00000231790.2:c.1270G>A,NC_000003.11:g.37067359G>A
753	https://civic.genome.wustl.edu/#/events/genes/3532/summary/variants/753/summary#variant	MLH1	4292	Q149*			3	37048546	37048546	C	T	ENST00000231790.2	75	GRCh37					stop_gained	
754	https://civic.genome.wustl.edu/#/events/genes/3532/summary/variants/754/summary#variant	MLH1	4292	R226*			3	37053589	37053589	C	T	ENST00000231790.2	75	GRCh37					stop_gained	
755	https://civic.genome.wustl.edu/#/events/genes/2478/summary/variants/755/summary#variant	MSH6	2956	I972F																
756	https://civic.genome.wustl.edu/#/events/genes/3532/summary/variants/756/summary#variant	MLH1	4292	P536FS			3	37081726	37081726	T		ENST00000231790.2	75	GRCh37					frameshift_truncation	ENST00000231790.2:c.1608delT
757	https://civic.genome.wustl.edu/#/events/genes/3532/summary/variants/757/summary#variant	MLH1	4292	G67R			3	37038192	37038192	G	A	ENST00000231790.2	75	GRCh37					missense_variant	NC_000003.11:g.37038192G>A
758	https://civic.genome.wustl.edu/#/events/genes/3532/summary/variants/758/summary#variant	MLH1	4292	I68S			3	37038196	37038196	T	G	ENST00000231790.2	75	GRCh37					missense_variant	ENST00000231790.2:c.203T>G
759	https://civic.genome.wustl.edu/#/events/genes/3532/summary/variants/759/summary#variant	MLH1	4292	G65D			3	37038187	37038187	G	A	ENST00000231790.2	75	GRCh37					missense_variant	NM_000249.3:c.194G>A,NP_000240.1:p.Gly65Asp,ENST00000231790.2:c.194G>A
760	https://civic.genome.wustl.edu/#/events/genes/3532/summary/variants/760/summary#variant	MLH1	4292	A681V			3	37090447	37090447	C	T	ENST00000231790.2	75	GRCh37					missense_variant	NM_000249.3:c.2042C>T,NP_000240.1:p.Ala681Val,ENST00000231790.2:c.2042C>T,NC_000003.11:g.37090447C>T
761	https://civic.genome.wustl.edu/#/events/genes/2478/summary/variants/761/summary#variant	MSH6	2956	P138T			2	48018217	48018217	C	A	ENST00000234420.5	75	GRCh37					missense_variant	
762	https://civic.genome.wustl.edu/#/events/genes/3628/summary/variants/762/summary#variant	MSH2	4436	V273FS																
763	https://civic.genome.wustl.edu/#/events/genes/3628/summary/variants/763/summary#variant	MSH2	4436	E28FS			2	47630413	47630414		G	ENST00000233146.2	75	GRCh37					frameshift_elongation	
764	https://civic.genome.wustl.edu/#/events/genes/58/summary/variants/764/summary#variant	VHL	7428	E55fs (c.163_164delGA)			3	10183694	10183695	GA		ENST00000256474.2	75	GRCh37					frameshift_truncation	NP_000542.1:p.Glu55fs,NC_000003.11:g.10183694_10183695del
765	https://civic.genome.wustl.edu/#/events/genes/2478/summary/variants/765/summary#variant	MSH6	2956	I891FS			2	48027794	48027795	TC		ENST00000234420.5	75	GRCh37					frameshift_truncation	ENST00000234420.5:c.2672_2673delTC
766	https://civic.genome.wustl.edu/#/events/genes/58/summary/variants/766/summary#variant	VHL	7428	E55RfsTer11 (c.163delG)			3	10183694	10183694	G		ENST00000256474.2	75	GRCh37					frameshift_truncation	NP_000542.1:p.Glu55fs,NP_000542.1:p.Glu55ArgfsTer11,NM_000551.2:c.163delG,NC_000003.11:g.10183694del
767	https://civic.genome.wustl.edu/#/events/genes/2478/summary/variants/767/summary#variant	MSH6	2956	R1242H			2	48033421	48033421	G	A	ENST00000234420.5	75	GRCh37					missense_variant	
768	https://civic.genome.wustl.edu/#/events/genes/4371/summary/variants/768/summary#variant	PMS2	5395	R315*			7	6031649	6031649	G	A	ENST00000265849.7	75	GRCh37					stop_gained	NM_000535.6:c.943C>T,NP_000526.2:p.Arg315Ter
769	https://civic.genome.wustl.edu/#/events/genes/3532/summary/variants/769/summary#variant	MLH1	4292	M490T			3	37070334	37070334	T	C	ENST00000231790.2	75	GRCh37					missense_variant	ENST00000231790.2:c.1469T>C
770	https://civic.genome.wustl.edu/#/events/genes/3628/summary/variants/770/summary#variant	MSH2	4436	K172*																
771	https://civic.genome.wustl.edu/#/events/genes/58/summary/variants/771/summary#variant	VHL	7428	A56fs (c.164_165insG)			3	10183695	10183696		G	ENST00000256474.2	75	GRCh37					frameshift_truncation	NP_000542.1:p.Ala56fs,NP_000542.1:p.Ala56GlyfsTer74,NM_000551.2:c.164_165insG
772	https://civic.genome.wustl.edu/#/events/genes/8351/summary/variants/772/summary#variant	HOXB13	10481	G84E			17	46805705	46805705	C	T	ENST00000290295.7	75	GRCh37					missense_variant	
773	https://civic.genome.wustl.edu/#/events/genes/3628/summary/variants/773/summary#variant	MSH2	4436	E483G			2	47690231	47690231	A	G	ENST00000233146.2	75	GRCh37					missense_variant	
774	https://civic.genome.wustl.edu/#/events/genes/38/summary/variants/774/summary#variant	PDGFRA	5156	TNKS2-PDGFRA			10	93558069	93619405			ENST00000371627.4	75	GRCh37	4	55141008	55164414	ENST00000257290.5	transcript_fusion	
775	https://civic.genome.wustl.edu/#/events/genes/2478/summary/variants/775/summary#variant	MSH6	2956	V352I			2	48026176	48026176	G	A	ENST00000234420.5	75	GRCh37					missense_variant	
776	https://civic.genome.wustl.edu/#/events/genes/2478/summary/variants/776/summary#variant	MSH6	2956	R1242C			2	48033420	48033420	C	T	ENST00000234420.5	75	GRCh37					missense_variant	
777	https://civic.genome.wustl.edu/#/events/genes/8450/summary/variants/777/summary#variant	SLCO1B1	10599	RS4149056			12	21331549	21331549	T	C	ENST00000256958.2	75	GRCh37					missense_variant,polymorphic_sequence_variant	
778	https://civic.genome.wustl.edu/#/events/genes/8450/summary/variants/778/summary#variant	SLCO1B1	10599	RS2306283			12	21329738	21329738	A	G	ENST00000256958.2	75	GRCh37					missense_variant	
779	https://civic.genome.wustl.edu/#/events/genes/5971/summary/variants/779/summary#variant	TYMS	7298	RS34743033																
780	https://civic.genome.wustl.edu/#/events/genes/2279/summary/variants/780/summary#variant	GLI1	2735	ACTB-GLI1	Fusion of the hedgehog pathway component gene GLI1 to the -actin gene (ACTB)  has been described as a mechanism of GLI1,and by extension hedgehog pathway, activation. These fusions have been described in histologically distinctive soft tissue tumours showing a pericytic phenotype.  Gene fusions retain the DNA-binding zinc finger domains of GLI1 and it is likely that the replacement of the promoter region of GLI1with that of the ubiquitously expressed ACTB gene leads to deregulation of GLI expression and its downstream target genes.														gene_fusion	
781	https://civic.genome.wustl.edu/#/events/genes/1733/summary/variants/781/summary#variant	ERBB3	2065	V855A			12	56491672	56491672	T	C	ENST000000267101.3	75	GRCh37					missense_variant	
782	https://civic.genome.wustl.edu/#/events/genes/22/summary/variants/782/summary#variant	FGFR2	2263	FGFR2-BICC1																
783	https://civic.genome.wustl.edu/#/events/genes/22/summary/variants/783/summary#variant	FGFR2	2263	FGFR2-AHCYL1																
784	https://civic.genome.wustl.edu/#/events/genes/916/summary/variants/784/summary#variant	CDKN2B	1030	METHYLATION			9	22009121	22009172			ENST00000276925.6	75	GRCh37					N/A	
785	https://civic.genome.wustl.edu/#/events/genes/8950/summary/variants/785/summary#variant	CHEK2	11200	1100DELC																
787	https://civic.genome.wustl.edu/#/events/genes/8950/summary/variants/787/summary#variant	CHEK2	11200	I157T																
788	https://civic.genome.wustl.edu/#/events/genes/8950/summary/variants/788/summary#variant	CHEK2	11200	IVS2+1G>A																
792	https://civic.genome.wustl.edu/#/events/genes/4692/summary/variants/792/summary#variant	PTPRD	5789	V253I			9	8521481	8521481	C	T	ENST00000381196.4	75	GRCh37					missense_variant	
793	https://civic.genome.wustl.edu/#/events/genes/58/summary/variants/793/summary#variant	VHL	7428	A56fs (c.164_165insA)			3	10183695	10183696		A	ENST00000256474.2	75	GRCh37					frameshift_truncation	NP_000542.1:p.Ala56fs,NP_000542.1:p.Ala56GlyfsTer74,NM_000551.2:c.164_165insA
794	https://civic.genome.wustl.edu/#/events/genes/58/summary/variants/794/summary#variant	VHL	7428	E55E (c.165G>A)			3	10183696	10183696	G	A	ENST00000256474.2	75	GRCh37					silent_mutation	NM_000551.2:c.165G>A,NC_000003.11:g.10183696G>A
795	https://civic.genome.wustl.edu/#/events/genes/5051/summary/variants/795/summary#variant	RRM1	6240	OVEREXPRESSION																
796	https://civic.genome.wustl.edu/#/events/genes/5052/summary/variants/796/summary#variant	RRM2	6241	OVEREXPRESSION			2	10262455	10271545			ENST00000360566.2	75	GRCh37					N/A	
797	https://civic.genome.wustl.edu/#/events/genes/4386/summary/variants/797/summary#variant	POLE	5426	MUTATION			12	133202900	133256623			ENST00000320574.5	75	GRCh37					gene_variant	
798	https://civic.genome.wustl.edu/#/events/genes/52/summary/variants/798/summary#variant	MET	4233	D1228V			7	116423408	116423408	A	T	ENST00000397752.3	75	GRCh37					missense_variant	
799	https://civic.genome.wustl.edu/#/events/genes/4795/summary/variants/799/summary#variant	RB1	5925	MUTATION																
800	https://civic.genome.wustl.edu/#/events/genes/3983/summary/variants/800/summary#variant	NTRK1	4914	SQSTM1-NTRK1																
801	https://civic.genome.wustl.edu/#/events/genes/3985/summary/variants/801/summary#variant	NTRK3	4916	ETV6-NTRK3																
802	https://civic.genome.wustl.edu/#/events/genes/43/summary/variants/802/summary#variant	RUNX1	861	K83E			21	36259163	36259163	T	C	ENST00000344691.4	75	GRCh37					missense_variant	
803	https://civic.genome.wustl.edu/#/events/genes/43/summary/variants/803/summary#variant	RUNX1	861	Y260X																
804	https://civic.genome.wustl.edu/#/events/genes/43/summary/variants/804/summary#variant	RUNX1	861	R135FSX177																
805	https://civic.genome.wustl.edu/#/events/genes/3985/summary/variants/805/summary#variant	NTRK3	4916	ETV6-NTRK3 G623R			15	88476265	88476265	C	T	ENST00000394480.2	75	GRCh37					missense_variant,transcript_fusion	
806	https://civic.genome.wustl.edu/#/events/genes/43/summary/variants/806/summary#variant	RUNX1	861	D198Y			21	36231792	36231792	C	A	ENST00000300305.3	75	GRCh37					loss_of_function_variant,missense_variant	
807	https://civic.genome.wustl.edu/#/events/genes/43/summary/variants/807/summary#variant	RUNX1	861	A107P																
808	https://civic.genome.wustl.edu/#/events/genes/3628/summary/variants/808/summary#variant	MSH2	4436	LOSS			2	47630108	47710367			ENST00000233146.2	75	GRCh37					loss_of_function_variant	
809	https://civic.genome.wustl.edu/#/events/genes/2478/summary/variants/809/summary#variant	MSH6	2956	LOSS			2	48010221	48037240			ENST00000234420.5	75	GRCh37					loss_of_function_variant	
810	https://civic.genome.wustl.edu/#/events/genes/43/summary/variants/810/summary#variant	RUNX1	861	T148HFSX9			21	36252913	36252920	GCTGCGGT		ENST00000300305.3	75	GRCh37					frameshift_truncation	
811	https://civic.genome.wustl.edu/#/events/genes/1769/summary/variants/811/summary#variant	ETV6	2120	R399C			12	12038902	12038902	C	T	ENST00000396373.4	75	GRCh37					missense_variant	
812	https://civic.genome.wustl.edu/#/events/genes/1769/summary/variants/812/summary#variant	ETV6	2120	R369Q			12	12037475	12037475	G	A	ENST00000396373.4	75	GRCh37					missense_variant	
813	https://civic.genome.wustl.edu/#/events/genes/1769/summary/variants/813/summary#variant	ETV6	2120	P214L																
814	https://civic.genome.wustl.edu/#/events/genes/11932/summary/variants/814/summary#variant	DDX41	51428	R164W																
815	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/815/summary#variant	ERBB2	2064	Y772_A775DUP																
816	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/816/summary#variant	ERBB2	2064	G776L																
817	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/817/summary#variant	ERBB2	2064	G778_P780DUP																
818	https://civic.genome.wustl.edu/#/events/genes/20/summary/variants/818/summary#variant	ERBB2	2064	M774DELINSWLV																
819	https://civic.genome.wustl.edu/#/events/genes/4690/summary/variants/819/summary#variant	PTPRB	5787	LOSS-OF-FUNCTION			12	70910630	71031220			ENST00000334414.6	75	GRCh37					loss_of_function_variant	
820	https://civic.genome.wustl.edu/#/events/genes/58/summary/variants/820/summary#variant	VHL	7428	A149S (c.445G>T)			3	10188302	10188302	G	T	ENST00000256474.2	75	GRCh37					missense_variant	NP_000542.1:p.Ala149Ser,NM_000551.2:c.445G>T,ENST00000256474.2:c.445G>T,NC_000003.11:g.10188302G>T
821	https://civic.genome.wustl.edu/#/events/genes/2608/summary/variants/821/summary#variant	HLA-C	3107	COPY-NEUTRAL LOSS OF HETEROZYGOSITY																
822	https://civic.genome.wustl.edu/#/events/genes/3090/summary/variants/822/summary#variant	JAK1	3716	S703I			1	65311203	65311203	C	A	ENST00000342505.4	75	GRCh37					missense_variant	
823	https://civic.genome.wustl.edu/#/events/genes/3364/summary/variants/823/summary#variant	EPCAM	4072	3' EXON DELETION																
824	https://civic.genome.wustl.edu/#/events/genes/31/summary/variants/824/summary#variant	MAP2K1	5604	K57T																
825	https://civic.genome.wustl.edu/#/events/genes/3/summary/variants/825/summary#variant	ARAF	369	S490T																
826	https://civic.genome.wustl.edu/#/events/genes/2319/summary/variants/826/summary#variant	GNAS	2778	R201C																
827	https://civic.genome.wustl.edu/#/events/genes/23/summary/variants/827/summary#variant	FGFR3	2261	MUTATION																
828	https://civic.genome.wustl.edu/#/events/genes/22/summary/variants/828/summary#variant	FGFR2	2263	FUSION																
829	https://civic.genome.wustl.edu/#/events/genes/58/summary/variants/829/summary#variant	VHL	7428	M54Ifs (162_166DELGGAGG)			3	10183693	10183697	GGAGG		ENST00000256474.2	75	GRCh37					frameshift_truncation	NM_000551.2:c.162_166delGGAGG,NP_000542.1:p.Met54IlefsTer76,NC_000003.11:g.10183693_10183697del
830	https://civic.genome.wustl.edu/#/events/genes/23/summary/variants/830/summary#variant	FGFR3	2261	FGFR3-TACC3																
835	https://civic.genome.wustl.edu/#/events/genes/7936/summary/variants/835/summary#variant	AKT3	10000	UPREGULATION																
836	https://civic.genome.wustl.edu/#/events/genes/7936/summary/variants/836/summary#variant	AKT3	10000	DEPLETION																
837	https://civic.genome.wustl.edu/#/events/genes/5365/summary/variants/837/summary#variant	SMO	6608	W535L																
838	https://civic.genome.wustl.edu/#/events/genes/41/summary/variants/838/summary#variant	PTEN	5728	R173C			10	89711899	89711899	C	T	ENST00000371953.3	75	GRCh37					missense_variant	NM_000314.6:c.517C>T,NP_000305.3:p.Arg173Cys,ENST00000371953.3:c.517C>T,NC_000010.10:g.89711899C>T
